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Abstract 
Nanostructures for Plasmon Enhanced Fluorescence Sensing: 
From Photophysics to Biomedicine 
By 
Rizia Bardhan 
Metallic nanostructures exhibit unique plasmonic properties when optically excited, 
which includes modification of the spontaneous emission and lifetime of fluorophores in 
their vicinity. Here we utilize silica (SiC^) core encapsulated in gold (Au) shell 
nanoshells for emission enhancement of weak near-infrared (NIR) emitting fluorophores, 
including Indocyanine green (ICG) and IR800. The fluorescence enhancement of ICG 
molecules as a function of distance from the surface of nanoshells was studied. A 
maximum enhancement of 50X at a distance of 7 nm from the nanoshells surface, and 
minimum enhancement of 7X at 42 nm from nanoshells surface was achieved. 
Additionally, fluorescence enhancement of IR800 molecules induced by nanoshells was 
compared with that of Au nanorods. The quantum yield of IR800 was enhanced from 7% 
to 86% in the case of nanoshells and 74 % for nanorods. The native lifetime of IR800 
decreased from 564 ps to 121 ps when conjugated to nanorods and 68 ps for nanoshells. 
We then demonstrated a biomedical application of plasmon enhanced 
fluorescence sensing by utilizing nanoshell based complexes (nanocomplexes) for 
simultaneous fluorescence optical imaging as well as magnetic resonance imaging of 
cancer cells in vitro and in vivo. Nanocomplexes were fabricated by encapsulating 
nanoshells with a SiC>2 epilayer doped with iron oxide nanoparticles and ICG molecules, 
i 
which resulted in a high T2 relaxivity (390 mM"'sec"') and 45X fluorescence 
enhancement of ICG. The nanocomplexes were covalently conjugated with antibodies to 
enable active targeting in vitro and in vivo. In addition they were utilized for 
photothermal therapy of cancer cells in vitro. 
Furthermore, other plasmonic nanostructures relevant for biomedical applications 
were also synthesized in the sub-100 nm regime including Au/SiCVAu nanoshells and 
cuprous oxide core coated with Au shell nanoshells. Excellent agreement between their 
experimental and theoretical optical properties was achieved. Additionally, physical and 
chemical properties of mesostructures relevant for photonic devices including sub-
micrometer zinc oxide structures and Mesostars composed of a mixture of iron oxides and 
Au were also studied. 
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Chapter 1: Introduction 
Fluorescence sensing is a versatile technique widely applicable in many different 
disciplines from physiological imaging and clinical chemistry to environmental 
monitoring of gaseous molecules. In particular, fluorescence sensing and the subsequent 
use of clinically relevant fluorescent media have revolutionized the field of biomedical 
research for diagnosing disease markers in vitro and in vivo. In biological imaging the use 
of organic fluorophores, which emit in the near-infrared (NIR), has rapidly developed in 
the past few decades due to their low cost and biocompatibility when used in small doses. 
However, most organic fluorophores in the NIR have a relatively low quantum yield, 
they are susceptible to photobleaching and their excitation-emission profiles are often 
1 2 
prone to changes in local chemical environment such as pH, H2O, O2, and ions. ' There 
are several approaches to improving the properties of NIR organic fluorophores: (1) 
complex organic synthesis techniques to synthesize physiologically safe fluorescent 
molecules or (2) use metallic nanostructures to enhance the quantum efficiency of 
existing fluorescent molecules which have already been approved by U.S. Food and Drug 
Administration (FDA) for clinical applications. In this thesis, we have engineered a metal 
nanoparticle substrate to enhance the fluorescence of weak NIR fluorophores and 
subsequently employed these fluorescent nanoparticles for diagnosing and treating cancer 
at the cellular (in vitro) and molecular (in vivo) level. 
Since the pioneering work of Chance at al.3 and Drexhage4 it has been known that 
the emissive properties and lifetime of fluorophores are modified in the presence of 
metals. Metallic surfaces and nanostructures support surface plasmons, which are the 
1 
collective oscillations of the conduction electrons. Plasmon resonance when coupled to 
molecular fluorescence provides one of the most effective routes for enhancing the 
photostability and increasing the quantum yield of fluorophores. The metal/fluorophore 
interaction results from (i) the modification of the electromagnetic field and (ii) the 
photonic mode density in the vicinity of the fluorophores.5 For small metal/fluorophore 
distances (< 4 nm), the damping of dipole oscillation coupled to plasmon resonances 
leads to a strong quenching of fluorescence.6 This is also attributed to the increase in 
f\ 7 • • 
nonradiative decay rate for short fluorophore-metal distances ' because the nonradiative 
energy transfer rate depends on the inverse cube of the molecule-surface separation.6 
However, for larger metal/fluorophore distances, an increase in the fluorescence intensity 
results primarily from a combination of (i) increased absorption by the molecule due to 
interaction with the enhanced near-field, (ii) increased radiative decay rate of the 
molecule without significant changes in the nonradiative decay rates, and (iii) increased 
coupling efficiency of the fluorescent emission to the far-field. 
Beyond the quenching regime, the enhanced near-field persists for tens of 
nanometers which implies that an optimal distance d> 4 nm exists where the fluorescence 
enhancement is at a maximum.8 As the distance from the metal surface increases the 
near-field decays and consequently the fluorescence enhancement decreases. Due to the 
dipole-dipole interaction between the fluorophore and the metal, the radiative decay rate 
also reduces as the distance from the metal surface increases, contributing towards the 
diminishing fluorescence enhancement. 
2 
1.1 Plasmon Enhanced Fluorescence 
Fluorescence is defined as the emission of light from a singlet-excited electronic 
state to the ground state of a material. In excited singlet states, the electron in the excited 
orbital is paired to the second electron in the ground state orbital.4 As a result, return to 
ground state is spin-allowed and occurs by emission of a photon (Fig. 1.1). 
Excited higher 
energy states 
Si 
>» CT> 
o excitation 
c 
m 
fluorescence 
emission 
triplet 
states 
A phosphorescence 
0
 ground state 
Figure 1.1. Simple Jablosnki diagram describing the emission processes of a material. 
In a homogenous solution, fluorophores emit light into free space and are observed 
in the far field. The observed emission of the fluorophore in the absence of any 
quenching interactions is described in terms of its quantum yield (Q0) and lifetime (T0). 
The quantum yield, given by 
T 
Qo = r + t 0) 
is the fraction of the excited fluorophores which relaxes by radiative decay (.T) relative to 
the total relaxation rate (r+knr). The observed lifetime is simply the inverse of the total 
decay rate of the excited state: 
1 
= • 
r + k„ 
(2) 
3 
When a sample of molecules with molecular absorptivity e is excited with light of 
intensity Iexc, the total amount of energy absorbed by the molecules is simply Iexc -e.9 The 
quantum yield determines what portion of this energy is re-emitted as fluorescence; 
therefore, the observed emission intensity is 
I0 = IexcE-Qo- (3) 
In the presence of a metallic surface or nanoparticles, the enhanced local field will 
increase the amount of light absorbed by the molecule. In the case of spherical particles, 
the surface average of the near field intensity enhancement <|E|2> can be calculated 
directly using Mie theory, leading to a fluorescence emission which is (<|E| > I e x c ) l' Qo-
In addition, electromagnetic coupling occurs between the fluorophore and the 
nanoparticle plasmon, causing an increase in the radiative decay rate of the molecule at 
the emission wavelength by a factor yr. As a result the effective radiative decay rate is 
equivalent to yr-r.3' 4' 10 For spherical symmetrical systems, this can also be evaluated 
using Mie theory following the method in Gibson et al.n The modified quantum yield 
(QM) and lifetime (Tm) in the presence of the metallic surface are then given by: 
y r 
( 4 ) 
(5) 
yrr + k 
The observed emission of the fluorophore-metal system is therefore given by, 
IM=(<\E\2>IEXC)SQM. (6) 
The fluorescence enhancement can be evaluated by taking the ratio of the emission from 
the metal fluorophore system (7m) to the emission intensity of the fluorophore alone (70): 
Ll=I\^\QM.=/Myr(r+*J ( 7 ) 
h \ n / Q 0 \ ' yrr +knr ' 
The Jablonski diagram for metal enhanced fluorescence is shown in Figure 1.2. 
Free Space Metal enhanced 
Excited higher Excited higher 
energy states 
ground state ground state 
Figure 1.2. Jablonski diagram showing the fluorescence of a molecule in free space and 
in proximity to a metallic surface 
1.2 Nanoshell Background 
In this thesis, the metallic nanoparticle of choice for enhancing the fluorescence quantum 
yield of biologically relevant fluorophores is gold nanoshells. Nanoshells are symmetric 
spherical nanostructures consisting of dielectric silica (Si02) core uniformly coated with 
a thin gold (Au) shell.12 The plasmon resonance frequencies of nanoshells are dependent 
on the relative ratio of the core and shell dimensions, as well as the dielectric constant of 
the core, shell and medium. The size dependent properties of nanoshells have been 
explored for various technologies. Particularly, tunability of the nanoshell plasmon 
resonance in the NIR has enabled numerous diagnostic and therapeutic applications 
including NIR bioimaging13'14 and photothermal cancer therapy.15"17 Nanoshells are also 
interesting for biomedicine due to the inert, biocompatible Au layer which enables simple 
conjugation chemistry relevant for binding molecules as well as biopolymers such as 
antibodies, oligonucleotides, and peptides. The non-toxicity, stability in vivo, and 
5 
straightforward surface functionalization allows the use of nanoshells as a successful 
targeting, imaging, and therapeutic agent at the cellular and molecular level. 
1.2.1. Fabrication and Characterization of Nanoshells 
19 18 
The SiC^/Au nanoshell is fabricated following previously reported protocols. ' For the 
sake of this thesis, only the synthesis of nanoshells which are resonant in the NIR (~ 770 
-810 nm) are discussed. Briefly, monodisperse silica nanospheres of 120 ± 4 nm 
diameter are synthesized using the Stober method of particle growth.19 The Stober 
method involves the base catalyzed hydrolysis and condensation of tetraethylorthosilicate 
(TEOS, Sigma). Typically, ~ 4.5 mL of TEOS is mixed with —11.5 mL of NH4OH in the 
presence of 180 mL of 200 proof ethanol (Fisher) to yield silica nanospheres of the 
desired size regime. The silica nanospheres are then washed several times to remove 
excess TEOS and NH4OH and finally redispersed in 10 mL ethanol. Silica nanospheres 
are then functionalized with aminated silanes using 3-aminopropyltriethoxysilane 
(APTES, Sigma) overnight under vigorous stirring. The silane groups on the APTES 
molecule binds to the silica surface while the amine moiety is now available to attach to 
Au nanoparticles. Small gold nanoparticles ~2 nm in diameter are synthesized using 
tetrakis(hydroxymethyl)phosphonium chloride (THPC) as the reducing agent from the 
method reported by Duff, et al.20 The THPC reduced Au nanoparticles (THPC-Au) are 
attached to the surface of the silica nanospheres and used for metal shell growth. The 
amount of silica particles to THPC-Au is calculated from the total surface area of the 
silica particle solution, the concentration and physical cross-section of the THPC-Au, and 
assuming 25 - 30 % coverage of THPC-Au on the silica surface. The silica-Au precursor 
6 
particles are typically prepared by mixing 40 mL of THPC-Au aqueous solution with 
250-350 uL amine terminated silica nanospheres and 1 ml, 1 M NaCl. The salt increases 
the isoelectric point of the solution mixture by increaseing the ionic strength, thereby 
decreasing Columbic repulsion and increasing surface coverage of THPC-Au 
nanoparticles on the silica surface. 
Figure 1.3. Schematic diagram and corresponding TEM images showing nanoshell 
fabrication: (i) 2 nm Au particles attached to amine terminated silica nanospheres, (ii) 
gold reduction using electroless plating technique, and (iii) more gold reduction resulting 
in a complete Au shell 
Next, a plating solution is prepared for Au shell growth. Typically, 3 mL of 1 % 
HAuCl4 solution (which was aged for 14 days) is mixed with 50 mg K2CO3 in 200 mL of 
deionized H2O and aged for 24-72 hours. By varying the ratio of the silica-Au precursor 
particles' volume to the plating solution volume nanoshells with different Au shell 
thicknesses can be fabricated. The smooth Au shell on the silica-Au precursor particles is 
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obtained by either mixing formaldehyde as a reducing agent or by bubbling with CO. 
A schematic diagram and corresponding transmission electron microscopy (TEM) images 
of nanoshell fabrication (Fig. 1.3) and scanning electron microscopy (SEM) image of 
several nanoshells are shown (Fig. 1.4). 
II III 
7 
Figure 1.4. Low resolution SEM image of nanoshells [rj, r2] = [60, 74] nm in size with 
high resolution SEM image provided as inset. 
1.2.2. Optical Properties of Nanoshells and Plasmon Hybridization 
Wavelength (nm) 
Figure 1.5. Experimental extinction spectra of Au shell growth on 60 nm radius silica 
cores by varying the ratio of the precursor particles to the plating solution. 
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Figure 1.6. (A) Energy level diagram depicting plasmon hybridization in nanoshells 
resulting from interacting sphere and cavity plasmons. The two hybridized plasmon 
modes are an anti-symmetric plasmon resonance (co+) and a symmetric plasmon 
resonance (co-). (B) Energy diagrams illustrating the dependence of nanoshell plasmon 
energies on the strength of the interaction between the sphere and cavity plasmons, 
determined by the thickness of the Au shell. 
The nanoshell plasmon resonance shifts to longer wavelengths as the thickness of the Au 
shell decreases (Fig. 1.5). Experimentally this is achieved by simply decreasing the ratio 
of Au salt plating solution to the SiCh-Au precursor particles. Theoretically, this highly 
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tunable optical property of nanoshells can be explained in terms of the plasmon 
hybridization model of nanoshells. Plasmon hybridization theory is an electromagnetic 
analog of how atomic orbitals interact to form molecular orbitals in electronic structure 
theory.21 Plasmon hybridization theory principally deconstructs a complex nanostructure 
into more elementary shapes, and analyzes the interaction of the primitive plasmons 
supported by these elementary geometries with each other, to form the hybridized 
plasmons of the complex nanostructure. 
The geometry dependent plasmon resonance of nanoshells results from the 
interaction of two elementary geometries, a metallic sphere and a spherical cavity inside a 
bulk metal (Fig. 1.6A).22'23 From classical Mie theory the plasmon resonance of a metal 
sphere and a cavity are given by, 
I r i \
1/2 
coSJ = 0JB 2/ + 1 
(15) 
and 
' / + 1 f / i 1 V/2 0)c, = a B (16) 
.2/ + 1, 
where cob corresponds to the bulk plasma frequency of metal and I is the angular 
momentum. In a nanoshell, the deformation fields associated with the sphere and cavity 
plasmons introduce surface charges at both the inner and outer boundaries of the shell. 
These surface charges couple the sphere and cavity modes, resulting in hybridized 
plasmons. The hybridization of the cavity and the sphere plasmons depends on their 
interaction, which is determined by the thickness of the Au shell. The nanoshell plasmon 
hybridization gives rise to two hybridized plasmon modes |co+) and |a>_) for each / > 0. 
The frequencies of these modes are given by, 
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(of± = (On 1±-2/ + 1 
( \2M 
l + 4/(/ + l) 
\r2j 
1 / 2 
(17) 
where, \a)+) mode corresponds to antisymmetric or antiboding coupling between the 
sphere and cavity modes and the and \a>_) mode corresponds to symmetric or bonding 
coupling between the two modes. The lower energy co- plasmon interacts strongly with 
the incident optical field, while the to+ mode interacts weakly since the antisymmetric 
plasmon possesses a very weak net dipole moment. The interaction of the two plasmons 
is governed by the ratio ri/r2 (equation 17), from which the nanoshell plasmon derives its 
inherent tunability. The plasmon hybridization model of nanoshells also provides a 
simple explanation as to why the energy of the optically active plasmon resonance shifts 
to lower energies with decreasing shell thickness. A thinner shell leads to a stronger 
coupling between the sphere and cavity plasmons, increasing the splitting between the 
bonding and antibonding hybridized plasmons (Fig. 1,6B). 
1.2.3. Near Field and Far Field Properties of Nanoshells 
The nanoshell near field and far field properties can be best understood in terms of Mie 
scattering theory.24"26 Mie theory provides analytical solutions to Maxwell's equations for 
concentric spherical geometries by expressing electromagnetic waves as expansions of 
the vector spherical harmonic basis functions L, M, and N. The light scattering by 
nanoshells can be understood as a plane wave scattering off a spherical nanoshell. In the 
vector basis formalism the electric and magnetic fields associated with the incident plane 
wave, and the different layers of a nanoshell are written in terms of the spherical 
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harmonic functions. By satisfying Maxwell's equations at the interfaces between the core 
and shell and between the shell and embedding medium the scattering coefficients for the 
electric and magnetic fields can be determined. 
Figure 1.7. Schematic diagram showing nanoshell geometry with various parameters. 
The incident plane wave is assumed to be propagating along the z-axis and is 
linearly polarized in the x direction. The electromagnetic field can hence be expressed as 
linear combinations of the spherical vector basis function given by, 
E ^ X k i - M S V + ^ - N i i ! / } 
n=1 h<=JM; +1 (i8) 
V Mi h=i 
where the scattering coefficients a and b are given by, 
2n+\ 
am = bin= /n+1 2«(M+I) 
a-in = b.in = n(n+l)ain (19) 
For a nanoshell, the series expansion can be expressed in the 3 regions (Fig. 1.7): the 
dielectric core forms region 1, with radius Ri and dielectric constant ei, the Au shell forms 
region2 with radius R2 and dielectric constant 82 and the embedding medium forms 
region3 with dielectric constant 83. The electric fields in the three regions are given by, 
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E1 = Z {a±l« M±l« + b±lnN±ln } 
F _ V L(2)JM(2)J l(2);N(2)J amhM{2)h L(2)An(2)A ) 
00 
(20) 
and the magnetic fields are given by, 
V n=l 
H
 2 ^ n ™
 + M | \ Ml 
(21) 
V >^3 n=l 
where the subscripts represent the individual regions (Fig. 1.7). It is noteworthy that 
region 1 only has radial contributions from the spherical Bessel functions (/'), region3 
contain only the Hankel functions of the first kind (h) and region2 has contributions from 
both types of functions. Assuming that the materials are nonmagnetic so that the relative 
permeability |a=l simplifies the above equations. Then solving these equations by 
continuity equation at the boundaries, coefficients a and b can be determined. 
The local near field at the nanoshell surface is calculated as E3 from eq. 20. The 
nanoshell near field can be evaluated at appropriate distances from the surface by 
calculating the average of the field at 2500 different points on the nanoshell surface (50 
different 0 and 50 different 9 angles). For example, for a nanoshell with dimensions [ri, 
r2] = [60, 76] nm, the surface average near field calculated at 2, 7, 13, 21, 30 and 42 nm 
from the nanoshell surface is shown in Figure 1.8A. The near field decays off with 
increasing distance from the nanoshell surface. A pictorial depiction of nanoshell near 
field (Fig. 1.8B), where the k vector is perpendicular to the E-field, clearly demonstrates 
highest field are generated near the nanoshell surface. 
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Figure 1.8. (A) The near field of nanoshells with dimensions [ri, r2] = [60, 76] nm 
plotted as a function of distance from the surface and (B) Pictorial depiction of nanoshell 
near field. 
The far field properties of nanoshells including its absorption, scattering and 
extinction cross-sections can be straightforwardly determined from a and b coefficients 
and the wave vector k evaluated in region 3. The cross-sections are given by, 
£ n=1 
,(3 )h 
In + ef ) 
2 K 
<Jext = ~ R ^ ( 2 n + l ) (a^ h + (22) 
n=1 
^abs ~ aext °sea 
1.2.4. Photothermal Properties of Nanoshells 
Nanoshells have been extensively used in therapeutic applications including 
photothermal cancer therapy27 and light assisted gene therapy.28 In this thesis, nanoshells 
have been utilized for cancer therapy (chapter 4, 5). It is therefore important to 
understand the physical process attributing to the photothermal properties of nanoshells. 
Upon illumination with resonant light, the plasmon resonance in metal 
nanostructures either decays radiatively resulting in light scattering, a phenomenon 
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highly useful in biological sensing and bioimaging, or the plasmon decays nonradiatively 
resulting in light absorption.26 As absorbers, metallic nanostructures efficiently convert 
light to heat. The absorption and scattering characteristics of a nanoparticle is a function 
of its size: small nanoparticles absorb strongly, while with increasing size the absorption 
to scattering ratio decreases, and ultimately larger particles are better scatters. 
The fundamental principle underlying the photothermal response of nanoshells has 
been studied with ultrafast laser spectroscopic studies.24 The photoexcitation of the 
electrons by an ultrashort laser pulse leads to a perturbation of the electron distribution in 
the metal, which is given by its Fermi distribution. This is followed by relaxation with 
electron-electron scattering which results in rapid increase in surface temperature 
(subpicosecond timescale). This initial rapid heating is followed by cooling back to 
equilibrium by energy exchange between the electrons and the lattice via electron-phonon 
coupling (few picosecond timescale). At very fast rates of energy dissipation relative to 
lattice cooling, the photothermal heating can result in the melting or reshaping of the 
nanostructure changing its optical absorption characteristics irreversibly. However, at 
slower rates (on the order of several hundred picoseconds), the lattice cools via phonon-
phonon coupling resulting in heating of the medium surrounding the nanostructure, 
which can be used in cancer therapy to induce photothermal cell death. If nanostructures 
are immersed in a medium, following illumination, a non-equilibrium condition will exist 
between the hot nanoparticle and the cooler surrounding medium resulting in large 
temperature increases in the surrounding medium. The characteristics of the surrounding 
medium strongly influence the cooling dynamics of the hot electrons in the 
nanostructures. The relaxation time (electron-phonon and phonon-phonon) decreases 
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when the thermal contact between the nanostructures and the surrounding medium 
reduces or when the thermal conductivity of the medium is decreased, implying that the 
cooling dynamics would be fastest in aqueous media.29 Nanoshells, due to their large 
absorption cross-section, are efficient light-to-heat converters. Even at low illumination 
intensities, specifically of interest in biomedical applications, photothermal response of 
nanoshells results in heating of the surrounding tissue inducing hyperthermia and 
subsequent tumor cell death. 
1.3 Frequency Domain Fluorescence Lifetime 
A steady-state measurement of fluorescence only provides an averaged 
measurement of a fluorophores absorption and resulting emission of light. To effectively 
characterize the fluorophore-nanoshell complexes and determine the changes in the 
emissive properties of the fluorophore due to the presence of the metal, fluorescence 
lifetime measurements are employed. The behavior of a material's fluorescence as a 
function of time, can systematically explain the fluorophore's environment, 
intermolecular distances, and many other molecular parameters. When a fluorophore is 
excited with an infinitely sharp pulse of light, it results in an initial population (no) of 
fluorophores in the excited state.33 The excited state population then decays with a rate (T 
+ knr) according to, 
M > = _( r
 + * „ > ( , ) (8) 
at 
where, n(t) is the number of excited molecules in time t following excitation. So the 
exponential decay of the excited state population can be understood by, 
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nit) = n0e T ^ 
where x = ( r + knr)'x. However, when fluorescence emission is measured, the no. of 
excited molecules is not observed, rather a fluorescence intensity is measured given by, 
-i 
I(t) = I0e~. (10) 
This time dependent intensity is the expression for a single exponential (SE) decay. 
Decay profiles for most exogenous fluorophores employed for biomedical applications 
can be explained with SE kinetics. A multi exponential (ME) model, however, describes 
the fractional contribution of decay time for each component present in a heterogeneous 
sample. The ME model for analyzing the intensity decay is given by 
-i 
7(0 = (11) 
i 
where r, are observed lifetimes with amplitude or molecular fraction a h and ^ a i = 1. 
i 
The amplitude-weighted lifetime is then 
M = 0 2 ) 
/ 
Fluorescence lifetime can be measured in the time domain or in the frequency domain as 
shown in Figure 1.9. This thesis will focus on the frequency domain technique. In the 
frequency domain technique, lifetime measurements are obtained by exciting the 
fluorescent sample with intensity-modulated light at a high frequency comparable to 
of the sample.9 Subsequent to excitation, the fluorescence emission of the sample follows 
the same modulation frequency as the excitation, but it is delayed in time relative to the 
17 
excitation. The time delay is measured as a phase shift (O) from which the lifetime (t®) is 
determined given by 
r 0 = —tan(o), 
CO 
where co is angular frequency. 
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Figure 1.9. Schematic showing the two different fluorescence lifetime measurement 
techniques 
The finite time response of the sample also results in demodulation of the 
emission by a factor defined as modulation (m). As the frequency increases the lifetime 
of the excited state results in a decrease in the amplitude of the modulated emission. The 
modulation decreases because a fraction of the fluorophores excited at the peak of the 
excitation continue to emit even when the excitation is at a minimum. The extent to 
which modulation decreases depends on the frequency and also the intrinsic lifetime of 
the fluorophore. The lifetime can also be calculated from the modulation given by, 
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The difference between time domain and frequency domain is simply that in the 
time domain technique, the sample is excited with a pulse of light (instead of modulated 
light) which is much shorter than the decay time x of the sample (Fig. 1.9). The time 
dependent intensity is measured following the excitation pulse and the decay time x is 
9 33 
calculated from the slope of the plot of log I(t) versus t, so slope = - 1/ x. ' 
1.4 Non-Invasive Biological Imaging Techniques 
The plasmon enhanced nanoshell-fluorophore complexes are utilized in an exciting 
biomedical application: diagnosing cancer using dual modal non-invasive imaging 
modalities including fluorescence optical imaging (FOI) and magnetic resonance imaging 
(MRI). The development of non-invasive imaging techniques that diagnose cancer at its 
earliest stages is vital to cancer therapy and patient survival rate. Non-invasive imaging 
techniques are benign and safe as they do not involve physical incision into the body. 
Powerful non-invasive imaging techniques are necessary to precisely identify tumor 
location, tumor size, whether tumor has spread to lymph nodes, tumor treatment stage, 
and to assess therapeutic strategies in real time.34 An overview of different non-invasive 
imaging modalities commonly utilized in clinic are shown in Table 1.1.34 The 
conventional anatomical imaging methods currently a mainstay in the clinic include 
computed x-ray tomography (CT), MRI, and ultrasound (US). These imaging 
technologies allow for non-invasive visualization of the body based on different forms of 
energy interacting with tissues including physical (absorption, scattering, relaxation 
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rates), metabolic, and physiologic characteristics of tissue.35 While these traditional 
imaging methods have high spatial resolution, they are inadequate in acquiring complete 
physiological information due to lack of sensitivity, specificity, and inefficiency in 
identifying specific molecular events responsible for diseases.2 
Table 1.1 Overview of different non-invasive imaging modalities adapted from Ref. 34 
Technique Resolution 
Magnetic resonance 10- too fim 
imaging (MRI) 
X-ray computed 50 nm 
tomography (CT) 
imaging 
Ultrasound imaging: 50 pm 
Positron emission 1-2 mm 
tomography 
(PET) imaging 
Single photon 1-2 mm 
emission tomography 
(SPEC!) imaging 
Fluorescence 1-2 mm 
reflectance imaging 
(FRI) 
Fluorescence- 1-2 mm 
mediated 
tomography (FMT) 
Depth Time Imaging agents Cost 
No fimEt Min/hours Gadoinium, sss 
dysprosium, 
iron oxide particles 
No imit Min 
mm Min 
Iodine $$ 
Microbubbles SS 
No Smit Min 
No limit Min 
1 cm Sec/min 
< 10 cm Sec/min 
®F, "C, ,50 
" r e , 1 "In SS 
Fluorescent S 
proteins 
MIR fluorocfrromes 
NIRfluorochromes SS 
Biotumhesoence 
imaging }BLI) 
Intravital microscopy 1 jirn 
(confocal, mulophoton) 
Several mm cm (Win 
< 400 nm Sec/min 
Luclerin $$ 
Fluorescent proteins, SSS 
photoproteins, 
ffciorochrornes 
Primary use 
Best all-round 
imaging system with 
high contrast; used in 
phenotyping. 
physiological imaging 
and cell tracking 
Lung and bone-
tumour imaging 
Vascular and 
interventional 
imaging 
Imaging metabolism 
of molecules, such as 
glucose, thymidine 
and so on 
Imaging of probes 
such as 
antibodies, peptides 
and so on 
Rapid screening of 
molecular events in 
surface-based 
tumours 
Quantitative imaging 
of targeted or 'smart' 
ftuorochrome 
reporters in deep 
tumours 
Gene expression, cell 
tracking 
All of the above at 
higher resolutions but 
at limited depths and 
coverage 
Cost of system: $ « 100 K; $ $ 100-300 K; $$$: > 300 K. C, carbon; F, fiuorine; In, M u m ; MIR, near infrared; O, oxygen; «*Tc, 
tecfineUjm metastabte. 
Molecular imaging, a rapidly emerging technique, effectively integrates biology, 
chemistry, medical physics, and pharmacology with novel technologies to overcome 
• 36 
some of the challenges involved in the conventional imaging methods. It is primarily 
defined as the "visual representation, characterization, and quantification of biological 
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processes at the cellular and sub-cellular levels within intact living organisms". 
Molecular imaging techniques can be classified under two categories, (i) nuclear imaging 
which include positron emission tomography (PET) and single photon emission 
tomography (SPECT), and (ii) optical imaging which includes fluorescence optical 
imaging (FOI), and fluorescence mediated tomography. MRI and ultrasound can be used 
for molecular imaging as well using appropriate contras agents such as gadolinium and 
iron oxide based agents for MRI and microbubbles for ultrasound. 
Molecular imaging provides routes for obtaining rapid, reproducible, high 
resolution images with high sensitivity which are lacking in the conventional imaging 
methods. In combination with innovative probes, targeting ligands and novel tools, 
molecular imaging can thus provide earlier detection of disease and evaluation of 
treatment long before phenotypic changes occur. Additionally, developing imaging 
probes which incorporate the advantages of molecular imaging techniques with 
conventional imaging methodologies into a single platform can potentially modify the 
way in which cancer is clinically diagnosed and treated. This dissertation will focus on 
two non-invasive molecular imaging modalities: FOI and MRI, by employing receptor 
targeted fluorescence and MR contrast agents. 
1.4.1 Fluorescence Optical Imaging (FOI) 
Among the many known optical imaging techniques, FOI is the most inexpensive and 
rapid way of imaging at the cellular and molecular level. FOI in tissues is employed 
mainly via two strategies: (i) detection of endogenous fluorescence (fluorescent proteins, 
luciferase bioluminescence system), and (iii) detection of exogenous fluorescence 
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(organic dyes, lanthanide compounds, quantum dots, inorganic nanoparticles) that is 
either untargeted, or targeted via antibodies, peptides, or other biopolymers. Exogenous 
contrast agents are more popular today among scientists and clinicians for molecular 
imaging. FOI specifically in vitro and in vivo entails injecting a fluorescent agent into 
cells or the body, which emits photons upon activation with excitation light. The emitted 
photons are then detected externally either by image intensifying cameras or other 
sensitive detectors. 
Wavelength (nm) 
Figure 1.10. The NIR water window showing minimal light absorption by hemoglobin 
and water, adapted from ref 38. 
The fundamental obstacles to FOI of tissue are high absorption, scattering and 
autofluorescence by hemoglobin in the visible region of the spectrum. The use of NIR 
light is particularly advantageous due to the large penetration depth of NIR light in soft 
tissue.1 NIR light has been reported to penetrate ~10 cm through breast tissue, and 4 cm 
TO 
of brain tissue using microwatt laser sources. Moreover, excitation and emission in this 
physiologically relevant "water window" (680-900 nm) is crucial to obtaining functional 
images since hemoglobin and water have their lowest absorption coefficient here (Fig. 
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1.10). Autofluorescence of tissues and Rayleigh scattering are also minimal in the NIR 
water window. 
An effective fluorescent agent should have the following attributes: (i) 
biocompatibility and non toxicity, (ii) stability in vitro and in vivo, (ii) high quantum 
yield, (iii) resistance to rapid metabolic disintegration, (iv) resistance to photobleaching, 
and (v) availability of bioconjugation and targeting sites. While quantum dots combine a 
number of the desired properties listed above, the difficulty in sample preparation and 
toxicity poses a major challenge for them. The excitation of quantum dots are also limited 
to the UV and visible region of the spectrum where tissue absorbs maximally and UV 
light causes irreversible damage to tissue. Moreover, the penetration of excitation light is 
limited at UV and visible wavelengths, making quantum dots unsuitable for imaging 
deeper tissue. This thesis thus focuses on the use of NIR organic fluorophores for FOI 
and a simple approach to achieving enhanced stability. By enhancing their quantum yield 
using plasmonic nanostructures, lower concentrations of the fluorophore can be used, 
which is clinically safe and non-toxic. 
1.4.2 Magnetic Resonance Imaging (MRI) 
MRI is based on the fundamental principles of nuclear magnetic resonance, 
commonly known as NMR. When an external magnetic field B0 is applied to a system, 
each proton rotates around its axis with an angular frequency coo, which is proportional to 
the applied magnetic field strength. This is given by the Larmor equation: too = yB0 where 
y is the gyromagnetic ratio. The net magnetization vector, M, is described by its 3 
components: Mz is the component parallel to Bo defined as longitudinal magnetization. At 
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equilibrium, Mz is maximal and termed as equilibrium magnetization, Mo, where Mo -
Mz. Mxy is the component perpendicular to Bo known as transverse magnetization. At 
equilibrium, Mxy = 0 since the vector components of the spins are randomly oriented 
about 360 ° in the x-y plane and cancel each other. 
In MRI, radiofrequency (rf) energy is applied synchronized (or in "resonance") to 
the coo of the protons causing displacement of the tissue magnetic moment from 
equilibrium conditions. Return to equilibrium results in emission of MR signals 
proportional to the number of excited protons in the sample as shown in Figure 1.11. The 
MR signal strength also depends on the characteristics of the tissues. Ti relaxation, also 
known as spin-lattice relaxation, is the loss of energy from the excited state (spin) to its 
surrounding tissue (lattice), mostly exhibited by gadolinium based contrast agents. Since 
this thesis discusses iron oxide based agents, which are T2 contrast agents, only T2 
relaxation will be elaborated in details. 
Figure 1.11. Schematic diagram explaining the relaxation processes in MRI. 
T2 or transverse relaxation is an exponential decay which represents the spin-spin 
interactions of processing nuclei resulting in the loss of phase coherence. This arises from 
the intrinsic magnetic properties of the sample. After the rf sequence is applied, the 90° rf 
pulse produces phase coherence of the individual protons and generates the maximum 
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Mxy. As Mxy rotates with the coo, the receiver antenna coil is induced by magnetic 
induction to produce a damped sinusoidal electronic signal, known as free induction 
decay (FID). FID arises due to loss of phase coherence of the individual spins caused by 
magnetic field variations. The T2 decay constant is generally expressed as: 
Mxy(t)=M0e("tAr2). (15) 
There are three terms which essentially explain T2 relaxation process: echo, spin 
echo sequence, and time of echo (TE). An echo is the emission of energy in form of an 
electromagnetic resonance signal of nuclei after its excitation. Spin echo sequence 
describes a sequence of events: the excitation of the magnetized protons in a sample with 
an RF pulse, FID production, followed by a 2nd RF pulse to produce an echo. The spin 
echo sequence starts with a 90° pulse and produces a FID that decays according to T2 
relaxation. A 180° pulse inverts the spins that reestablishes the phase coherence and 
produces an echo at a time equivalent to TE (Fig. 1.12). In other words the time 
difference between the 90 0 pulse and the maximum in the echo is TE. 
Figure 1.12. Schematic explaining TE in a spin echo sequence adapted from ref 39. 
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The T2 values are distinct for each tissue in the body which results in the contrast 
between tissues of various types. Due to the low sensitivity of MRI, tumors are difficult 
to distinguish from normal tissues in the body using an MR image. Therefore patients are 
often injected with contrast agents, such as iron oxide particles that selectively highlight 
the tumors. Effective MRI contrast agents significantly change the Ti and/or T2 values of 
the protons in the vicinity of the agent and generate image contrast (bright/dark) for 
diagnosis. In the case of T2 contrast, the presence of iron oxide based agents leads to 
inhomogeneities in the external magnetic field resulting in a rapid dephasing of spins and 
T2 shortening which generates strong contrast. Depending on the concentration of the 
contrast agent, either fast relaxation occurs producing strong contrast or slow relaxation 
occurs resulting in weak contrast (Fig. 1.13). 
weak 
Figure 1.13. Schematic representation of iron oxide interaction with H2O molecule 
1.6 Cancer Biology and Therapy 
Cancer is one of the most lethal diseases known to human kind and the second most 
common cause of death in the U.S., exceeded only by heart disease. In 2009, ~ 1.5 
million new cases of cancer were reported in the U.S. with an estimated death of 38 %. 40 
Since this thesis will discuss the diagnosis and therapy of breast and ovarian cancer, an 
understanding of the cause and implications of cancer is important. Among the many 
contrast 
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known types of cancer in women, breast cancer is the most frequently diagnosed with a 
mortality rate of 21% in 2009.40 While fewer cases of ovarian cancer are reported 
compared to breast cancer, most are at advanced stages of the disease and has a 68 % 
mortality rate. An estimate of cancer cases and death in 2009 are shown (Table 1.2). 
While cancer not only represents significant threat to human health, it also incurs 
tremendous costs in diagnosis, treatment and loss to economy. The National institutes of 
health (NIH) estimates overall costs of cancer in 2008 at $228.1 billion: $93.2 billion for 
direct medical costs, $18.8 billion for indirect cost of lost productivity due to illness and 
$116.1 billion for indirect mortality costs attributed to lost productivity due to premature 
death. Due to this enormous human and economic cost, improved diagnostic and 
therapeutic strategies are imperative for early detection and treatment of cancer. 
Table 1.2. Overview of cancer cases and deaths in 2009 adapted from Ref. 40 
Leading Sites of New Cancer Cases and Deaths - 2009 Estimates 
Estimated New Cases* Estimated E*eatfis 
Male Female Male Female 
P.tb stale B'east Lung & brorcr.us Lung S DrarithtK 
192,28C ;2i%) is,s:o c3o%:i 70.433 (26%j 
Ling S bromhus Lung brcnchus- Prostate are Est 
116,030(1 s%:< 103,350 4%'; 27,3SC (3V.: 40,* 70 (15%) 
Ccton & rectun Co'.cn & wctm Co s1- it rectun Cchn & recturr 
75,550(10%) 7t,38C 2S,2£C 12 24,sac CS%< 
Urinary Bladder Uterine 'iDrous Pancreas Psrttress 
32.8107%] i2,t60 13,030 16%: 17.21C [£%! 
Vs anerra of the skin Non-Hoigk i m^e'roma Leukemia Cvary 
sg.oae 20^ 30 12,590 14%: 14.6CC 
Nci-hodgkin lymphrcns Welarana of lie skin Lwa- & intiahepeti: t ife due \cr-r-:cgk. iympha.TK 
3S.93C 15%; •;£%) 12,090 (4%J 9.S7D 
Kidney & rena! pelvis Thjrcid Esoohsgus Lsi terra 
3SX3C :BV.: 17,203 yCfc? 1U3C !4<K: 9.253 
Lsuserr-a Kicney St rera: pete Urinary oIkds- Uterine carp .is 
is,sic m: 22,3300%) 1C.18C0K: 7.75:><:3%;i 
Z-i\ tavty S 3ha-v>: Ovary Nc.'-rotckj n iympho.-ns . vs- a intra-! spatic fc :« duct 
2S.24C ' 9,53:' f3%:« 6.07-3 
PsrcfeK Pancess * a -en* pefvi: Irain & oths- He-rais syst&r 21.OX 21.420-3*) E.tSI' ,3%;. 
M si-.es A: 3 tS2 Ali sites Ali sites 
7ss,t3s >:i-m:. 7! 5.22C 2S9.s:o i im; 
•l*:u.-Js tasaiara sqianais ssi sen onrrsaKirt sxararona Esspt urrcrj Daaosr. 
•SIZZ'3, A r e i a t CstH- v.<ire. i j a u i i a r c s ar3 i-testr. 
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1.6.2 Cancer Biology 
Cancer is the unremitting and uncontrolled cell proliferation in the body forming a tumor. 
The underlying cause for neoplastic progression (cancer) is either due to deregulated cell 
proliferation or suppressed apoptosis, both of which can lead to pathological disorders. 
Cancer genes are categorized into two groups: (1) oncogenes, mutations of which result 
in suppressed apoptosis, uncontrolled cell growth and incorrect differentiation, and (2) 
tumor suppressor genes or anti-oncogenes, which when mutated results in aberrant cell 
proliferation.41 In the case of breast and ovarian cancer, the human epidermal growth 
factor receptor 2 (HER2) proto-oncogene (normal gene), becomes oncogenic due to 
overexpression of the gene leading to tumorigenesis.42' 43 The processes that drive the 
progression of normal human cells into malignant cells can be summarized into six 
genetic alterations, termed as the "hallmarks of cancer": self-sufficiency in growth 
signals, insensitivity to growth-inhibitory (anti-growth) signals, evasion of programmed 
cell death (apoptosis), limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis (Fig. 1.14).41 Independent of how these genetic pathways are 
acquired by normal cells to become malignant, the biological endpoints that are 
ultimately reached is shared by almost all tumor types. 
Tumors pose a less threat when they are localized and can either be surgically 
removed or successfully treated with radiotherapy. The major cause of mortality is not 
due to these localized tumors but due to metastasis, which is spread of tumor cells from 
primary site to form secondary tumors at other locations in the body 44 Metastasis occurs 
by a complex multi-step process: (1) cancer cells separation from the primary tumor site, 
(2) penetration through basement membrane of blood vessels, (3) migration of tumor 
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cells through stroma, (4) disruption of lymphatic vasculature and circulation, (5) 
extravasation through blood vessels into tissues of a different location and (6) secondary 
tumor formation and metastatic growth.44 While it is difficult to predict the location of 
metastatic spread for a specific tumor, carcinomas (cancers of the epithelial or endothelial 
cells) mainly spread to lymph nodes. Metastasis in lung, liver, and bone is usually 
common due to the presence of small blood vessels where tumor cells often get 
Figure 1.14. Hallmarks of cancer adapted from Ref. 41 describing the genetic alterations 
which characterize the progression of malignant cells. 
There is a general consensus that blood vessels in tumors have structural 
irregularity, heterogeneity and leaky endothelium.45"47 The endothelial cells are 
disorganized, irregularly shaped, have loose interconnections and intercellular openings 
as large as 4.7 |im 45 It is due to this leakiness of the tumor vessels that allow flow of 
tumor cells into the bloodstream and formation of metastasis. There are multiple factors 
that influence the leakiness of blood vessels: luminal surface area, permeability of the 
trapped. 41,44 
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vessel wall, concentration and driving forces (hydrostatic and osmotic) across the 
endothelium and blood flow.45 In addition to abnormal blood vessel structures, the rapid 
growth of tumors often does not allow lymphatic drainage to be well developed. 
However, the combination of leaky blood vessels and poor drainage has also led to the 
enhanced permeability and retention (EPR) effect which is vital for the accumulation of 
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many diagnostic and therapeutic agents in tumor cells. 
While nanoparticles and other therapeutic agents < 400 nm may be delivered by 
the EPR effect (passive targeting),45"47 targeting proteins that are preferentially expressed 
on specific tumor types (active targeting) is more effective. Among the many known 
potential targets on tumor vessels, antibody targeting against phosphatidylserine are 
effective and non-toxic. Phosphatidylserine are expressed on the cytoplasmic surface but 
flips to external surface in tumor vessels due to hypoxic conditions. Antibodies can be 
conjugated with therapeutic agents to target the vasculature of tumors as well as destroy 
the tumors. This thesis focuses on the use of anti-HER2 antibodies for targeting breast 
and ovary cancer cells in vitro and in vivo. 
1.6.3 Cancer Therapy Strategies 
The leading cancer therapy strategies being followed in clinic are chemotherapy, which is 
systemically toxic, and radiation therapy, which has serious side effects such as radiation 
induced necrosis of surrounding healthy tissue. Surgical oncology, a highly invasive 
approach, is usually the treatment of choice for primary tumors and metastasis in 
locations other than brain. However, several non-invasive and less-toxic strategies have 
also been developed for cancer treatment such as antibody based therapies, which are 
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directed at reducing systemic toxicity, the overexpression of a tumor receptor is down 
regulated by directly binding a monoclonal antibody to the receptor. For example, 
Herceptin was developed for down regulating overexpression of HER2, which is found in 
majority of human breast and ovarian cancer cases.49 Aptamer based therapies, which are 
short chain of nucleotides developed from DNA and RNA, have also proven effective 
since aptamers are resistant to degradation in tissue, allowing longer circulation time. 
Aptamers can selectively identify internalized surface markers, thus be imported into 
cells and used as a delivery vehicle for transporting therapeutic cargoes to cancer cells.50 
These therapeutic strategies are, however, limited to only a single functionality. As 
cancer continues to aggressively take human lives, novel agents which can detect and 
treat the disease in one setting is impending. 
In the past decade various nanoparticles have been explored for diagnosis and 
therapy of cancer including polymeric nanoparticles, liposomes, iron oxide agents and 
gold nanostructures. Polymeric nanoparticles are designed by incorporating 
biodegradable polymers such as polylactic acid (PLA), polyethylene glycol (PEG) or 
polylactic-co-glycolic acid and encapsulating chemotherapeutic drugs or photosensitizers 
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within the polymeric capsules. ' These nanoparticles can be engineered to release drug 
based on pH, temperature, diffusion through polymer surface and diffusion due to 
polymer swelling. Liposomes are spherical micellar structures formed by one or several 
lipid bilayers with an aqueous phase inside and between the lipid bilayers. They can 
entrap hydrophilic agents within the internal compartment and hydrophobic agents into 
the membrane. These nanocarriers can be labeled with immunoglobulin and probes for 
targeting and imaging or incorporated with DNA, proteins, peptides and drugs for 
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therapeutics.53,54 Nonetheless, both liposomes and polymeric nanoparticles are restricted 
due to their larger size, and in some cases inability to perform multiple functionalities. 
Iron oxide nanoparticles have been traditionally used as MRI contrast agents. When 
exposed to alternating magnetic fields (AMFs), magnetic particles can generate heat by 
hysteresis loss resulting in hyperthermia and tumor ablation, a process referred as 
magnetodynamic therapy. Heat generation in the range of 100-1000 W/g has been 
reported using AMFs at physiologically safe frequencies and magnetic field strengths.55 
Additionally, magnetic fields in the KHz to MHz frequencies can easily penetrate tissues 
up to several centimeters, making the magnetodynamic therapy a promising strategy for 
tumor treatment. However, a high dosage of iron oxide particles is necessary for inducing 
hyperthermia which may have severe toxic effects. 
Gold nanostructures, both solid and in a core-shell geometry, of different shapes 
and sizes have been explored extensively as therapeutic agents due to their photothermal 
properties. When illuminated with resonant light, gold nanostructures efficiently convert 
light to heat causing high local temperatures on the surface which result in hyperthermia 
and tumor cell death. Unlike magnetic nanoparticles, these noble metal heat-generators 
only require pico-molar concentrations for inducing hyperthermia. Gold colloids resonant 
in the visible,56 and NIR resonant structures including nanorods57 nanocages,58 and 
nanoshells are the commonly used particles for cancer therapy. Gold nanostructures 
synergistically combine a biocompatible surface which can be straightforwardly 
conjugated with PEG for stealth character,59 or antibodies for active targeting.16' 57 
Nanostructures with large scattering cross-sections, for example nanoshells, can be used 
as optical contrast agents,14 or in combination with iron oxide particles they can be used 
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for MRI and photothermal therapy.60' 61 Recently, a promising new paradigm termed as 
"Theranostic", which entails the efficient integration of therapeutic and diagnostic 
moieties into a single agent, is rapidly emerging as an imminent alternative to traditional 
drugs and imaging agents. The ability to controllably manipulate the properties of gold 
nanostructures for targeting, imaging and therapy, hence provides a full theranostic 
spectrum of capabilities in a single nanostructure. 
1.7 Thesis Outline 
The research covered in this thesis may be categorized into four aspects: (1) nanoshells 
for plasmon enhanced fluorescence sensing in the NIR, (2) plasmon enhanced fluorescent 
nanoshell complexes for dual modal imaging, antibody targeting in vitro and in vivo, and 
for photothermal therapy in vitro, (3) novel plasmonic nanoparticles for biomedicine and 
(4) photonic nanostructures developed via electrolytically induced assembly and wet 
chemical synthesis. 
Chapter 2 discusses plasmon enhanced fluorescence of weak NIR fluorophore, 
Indocyanine green, as a function of distance from the nanoshell surface. The distance 
between the fluorophore and the nanoshell surface was controlled by growing silica 
epilayers of varying thicknesses. In Chapter 3, the fluorescence enhancement efficiency 
of nanoshells has been compared with gold nanorods for NIR fluorophore IR800, to 
understand the detailed photophysics and analyze the factors contributing towards 
fluorescence enhancement. In Chapter 4 and 5, the plasmon enhanced fluorescent 
nanoshells incorporated with iron oxide nanoparticles were demonstrated in an exciting 
biomedical application: in vitro diagnostics and therapeutics of breast and ovarian cancer 
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cells respectively. The antibody conjugated nanoshells targeted the cancer cells, 
diagnosed via multimodal imaging using MRI and FOI and finally treated the cells using 
photothermal hyperthermia. Chapter 6 extends the in vitro studies to targeting, 
multimodal imaging and biodistribution of nanocomplexes in vivo in breast cancer 
xenograft mouse models. In Chapter 7, novel Au/SiCVAu plasmonic nanostructures were 
fabricated in the sub-150 and sub-100 nm size regime to expand the therapeutic 
possibilities of nanoshells to diseases where smaller nanoparticles are necessary. Plasmon 
hybridization was used to analyze and assign the optical modes observed for these 
complex layered nanostructures. Chapter 8 discusses the fabrication and plasmonic 
properties of a high refractive index semiconductor core, CU2O (n=7), coated with Au 
shell nanoshells. The CU2O/AU nanoshells were fabricated in the sub-100 nm size regime 
by a straightforward wet-chemistry approach and are highly promising for biomedical 
applications where smaller sizes are needed. Their optical properties were explored 
experimentally and theoretically. Chapter 9 describes the electrolytically induced 
formation, growth mechanism and optical properties of mesostars formed from Fe2C>3-
core/Au-shell nanorice structures. Chapter 10 illustrates the fabrication, growth 
mechanism and photoluminescence studies of ZnO submicrometer particles relevant for 
photonic applications. 
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Chapter 2: Nanoscale Control of Near-Infrared Fluorescence 
Enhancement Using Au Nanoshells 
2.1 Introduction 
Metal enhanced fluorescence is highly relevant for understanding the fundamental 
physical phenomena contributing towards emission enhancement as well as for 
developing technologies based on these nanoparticle-fluorophore assemblies. Metal-
fluorophore interaction is a sensitive function of the distance between them. While at 
short distances (< 4 nm) fluorescence quenching is inevitable, at an optimum distance 
from the nanoparticle surface strong plasmon-enhanced fluorescence can be observed.3'4' 
10
 The enhancement will decrease as the fluorophore-metal distance continues to increase 
until the metal's optical field does not affect the fluorophore emission properties. In this 
chapter, we have qualitatively measured the fluorescence of NIR fluorophore, 
Indocyanine Green (ICG), as a function of distance from the Au nanoshell surface and 
determined the optimum distance where a maximum enhancement of 5 OX is achieved. 
Beyond the optimal distance from the nanoshell surface, the emission and hence the 
quantum yield decreases. All nanoparticle synthesis, characterization and experimental 
fluorescence spectra were obtained by Rizia Bardhan and Nathaniel K. Grady contributed 
towards theoretical analysis and discussion. Reproduced with permission from Rizia 
Bardhan, Nathaniel K. Grady, Naomi J. Halas, Small, 2008, 4, 1716-1722. Copyright 
2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. 
Water-soluble and biocompatible NIR emitting fluorescent molecules have 
provided an important new tool for biomedical imaging and for the detection of disease 
markers in vivo. The relatively large penetration depth of NIR light in most biological 
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media offers the potential for imaging deeply into the organs and soft tissues of living 
systems. This property is aided by the use of NIR-excitable fluorescent molecules as 
agents for contrast enhancement.64 The goal of designing and synthesizing NIR 
fluorescent molecules with large absorption coefficients and high quantum yields that are 
also safe for physiological environments is quite challenging, due at least in part to the 
complex synthetic routes required for these large, complex molecules.65' 66 A highly 
promising alternative approach is to enhance the emission of currently available NIR 
fluorescent molecules by combining them with appropriately designed metallic 
"nanoantennas". For example, ICG, currently the only FDA-approved, commercially 
available NIR emitting dye, is used extensively as an exogenous fluorescent marker in 
clinical imaging applications such as the diagnosis of cardiac and hepatic function, 
69 70 71 72 
measurement of plasma volume, ' ophthalmic scanning laser angiography ' and 
optical tomography.73 However, ICG is a relatively weak fluorophore with a quantum 
yield of only 1.3 %,74 and toxicity limits the maximum concentration appropriate for 
clinical use. Enhancing the quantum efficiency of ICG significantly without 
compromising its biocompatibility will lead to significant improvements in the detection 
limits of NIR fluorescence-based imaging, enabling, for example, the detection of 
significantly smaller tumor volumes than is currently possible. Recently, we have shown 
that the fluorescence of ICG can be significantly enhanced when the fluorescent 
molecules are positioned near Au nanoshells, when the plasmon resonance of the 
nanoshell is tuned to the emission wavelength of the fluorophore.75 Fluorescence 
enhancements as large as 50 were achieved, for a nanoshell designed with a significant 
scattering cross section at that wavelength. In this system the ICG molecules act like 
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local sources that feed the optical "nanoantenna", which then transmits their light 
efficiently into the nanoparticle far field. 
Noble metal nanoparticles and nanostructures exhibit unique, remarkably vivid 
optical properties due to excitation of their surface plasmons by incident light. Plasmon 
excitation results in significantly enhanced local fields at the nanoparticle surfaces, which 
give rise to fundamentally interesting phenomena and technologically important 
•5 nr 70 . 
applications. ' " Noble metal nanoparticles are known to significantly enhance the 
emission rates of vicinal fluorophores by decreasing their radiative lifetime, thereby 
increasing their quantum yield.7' 10' 79 The photostability of fluorophores can also be 
increased in this manner. Enhancing the emission of molecular fluorophores is a highly 
useful strategy for improving detection sensitivity and selectivity in many emerging 
applications such as DNA screening80 and single molecule detection,81 in addition to 
image enhancement.82 Consequently, designing and developing nanoparticle-molecule 
complexes to enhance molecular fluorescence is of broad interest and general importance. 
The influence of metallic surfaces (and subsequently metal nanoparticles) on 
fluorescence emission and molecular excited-state lifetimes has been a topic of interest 
since the pioneering work of Drexhage.3,4 The lifetime of a molecular excited state varies 
as a function of distance from the surface of a noble metal due to a modification of the 
enhanced absorption (due to the near field), radiative decay rate (due to the modified 
photon density of states near the metal surface) and nonradiative decay channels (due to 
01 QA 
energy dissipation). ' While fluorescence from a molecule directly adsorbed onto a 
metal surface or nanoparticle is quenched, for a molecule positioned a few nanometers 
from the metal, it can be strongly enhanced. As the fluorophore-metal distance is 
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increased, longer-range interactions between the molecule and the metal can lead to 
oscillatory enhancement and quenching behavior as a function of separation distance for 
bulk metals. For large separation distances from a bulk metal or metallic nanoparticle, the 
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molecular fluorescence returns to its unperturbed value. ' 
In this study, we have investigated the fluorescence enhancement of ICG 
molecules as a function of distance from the surface of Au nanoshells (NS). The distance 
between ICG molecules and the NS surface is controlled by varying the thickness of 
silica shell spacer layers grown on the nanoshell surface. We observe a fluorescence 
enhancement of 50 when ICG molecules are spaced 7 nm from the Au nanoshell surface, 
which decreases with increasing distance of the molecule from the nanoshell surface. Au 
nanoshells are excellent plasmonic nanostructures for these experiments for several 
reasons. First, their plasmon resonances can be controllably tuned across the visible and 
12 87 infrared region of the spectrum by modification of their core and shell dimensions. ' 
Their relative absorption and scattering cross sections can also be controlled by varying 
88 80 • /> total nanoparticle size. ' The spherical symmetry provides a highly uniform geometry 
for studying phenomena requiring a systematic variation of molecule-metal nanoparticle 
distance. Growing a silica shell spacer layer around the Au nanoshell core, then binding 
molecules onto the silica layer, is a controllable and reproducible technique for 
positioning fluorophores at well controlled, nanometer-scale distances from the 
nanoparticle surface over the length scales appropriate for modifying molecular 
fluorescence. The chemistry also imparts a robust, chemically inert, and biocompatible 
surface for the nanoparticle.90 This approach allows us to measure the spatial extent of 
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the fluorophore - nanoparticle interaction quantitatively over a length scale relevant to 
fluorescence enhancement. 
2.2 Fabrication of Nanoshell-ICG Conjugates 
NSfSlSiO? fabrication: Au nanoshells [ri, r2] = [60, 76] nm were fabricated as described 
in Chapter 1. The NS were then coated with a thin layer of silica to facilitate a 
biocompatible surface as well as to bind the fluorophore on the silica layer. NS@SiC>2 
nanoparticles were fabricated by slight modification of a previously reported protocol.91 4 
mL of the NS (2 x 109 particles/mL) were added to 40 mL of 200 proof fresh ethanol, 
followed by adding 500 uL of 28% NH4OH (Fisher). Subsequently, 6 - 70 \iL of fresh 
TEOS was quickly added to the reaction mixture under vigorous stirring. The vessel was 
immediately sealed and vigorously stirred for 45 minutes. Note: A new bottle of ethanol 
should be opened every time this synthesis is done. The volume ratio between NS and 
ethanol should be between 1:7-1:10. The amount of NH4OH depends on how it is, 400 
|iL is sufficient for fresh ammonia, more should be added if not fresh. The NS@Si02 
nanoparticles were stored in the refrigerator at 4 °C overnight without agitation. After 24 
hours the particles were centrifuged twice and re-dispersed in 20 mL ethanol. 
ICG Binding to NSfajSiO? Nanoparticles: ICG molecules were adsorbed onto the 
NS@Si02 by a two step procedure. (1) 1 mg ICG was mixed with 500 p.L degassed 200 
proof ethanol and 100 |aL APTES was subsequently added and the mixture was stirred 
for 8 hrs at room temperature. (2) The APTES-ICG mixture was added to the NS@Si02 
nanoparticles dispersed in ethanol and stirred for 24 hours at room temperature. The ICG 
bound nanoparticles were centrifuged in microcentrifuge tubes in small aliquots of 1 mL 
for 5 minutes at 280 rcf to remove unbound ICG molecules. Absorbance of the 
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supernatant was monitored to account for unbound dye and we determined that ~ 400 nM 
ICG molecules were bound to the NS@SiC>2 nanoparticles. ICG molecules were bound to 
silica nanospheres similarly and ~ 400 nM ICG were attached to the silica nanospheres as 
well. The final nanoparticle solutions were redispersed in water and stored at 4 °C. 
Fluorescence measurements of ICG molecules adsorbed on NS@SiC>2 nanoparticles and 
silica nanospheres were obtained in solution with 107 particles/ mL. 
2.3 Characterization of Nanoshell-ICG Conjugates 
i i i i i 
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Figure 2.1. Absorption-emission spectra (X . m a x _ A b = 780 nm and X . m a x -Em = 820 nm) and 
chemical structure (inset) of ICG. 
The nanoparticles were characterized by obtaining transmission electron 
microscope (TEM) images using a JEOL JEM-2010 TEM, and absorption measurements 
using a Varian Cary 5000 UV-Vis-NIR spectrometer. Fluorescence emission spectra 
were obtained using Jobin Yvon Spex Fluorolog 3 and the samples were excited at 785 
nm. The absorption-emission spectrum and chemical structure of ICG (Fig. 2.1), shows 
40 
that ICG, a negatively charged tricarbocyanine dye, strongly absorbs at 780 nm and emits 
at 820 nm. The presence of the charged sulfonate groups increases the solubility of ICG 
in aqueous media and minimizes significant ground-state aggregation, a phenomenon 
09 
commonly observed in carbocyanine-type dyes. 
Figure 2.2. (A) Schematic diagram of fabrication procedure, and TEM micrographs (B -
F) of NS coated with varying thicknesses of silica epilayers (B) 7 ± 2 nm (C) 13 ± 2 nm 
(D) 21 ± 3 nm (E) 30 ± 3 nm (F) 42 ± 3 nm. Scale bar is 50 nm for all TEM images. 
The fabrication procedure of NS@Si02 nanoparticles is illustrated in Figure 2.2A. TEM 
micrographs of NS coated with different thicknesses of SiC>2 are shown in Figure 2.2B -
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2F, where the thickness of the silica shell was varied from 7 - 4 2 nm. The NS@SiC>2 
nanoparticles range from 166 ± 3 nm in diameter to 236 ± 4 nm where the silica thickness 
was controlled by concentration of tetraethylorthosilicate (TEOS) after alkaline initiation. 
Thickness of Silica Epilayer [nm] 
Figure 2.3. Observed shift in the plasmon resonance peak with increasing thickness of 
silica layer surrounding the NS. (•) Experimental, and ( ) calculated values for NS 
[ri, r2] = [60, 76] nm and NS@Si02 nanoparticles, with 7 ± 2 nm, 13 ± 2 nm, 21 ± 3 nm, 
30 ± 3 nm, 42 ± 3 nm, 61 ± 4 nm, and 90 ± 4 nm thick silica epilayers are shown. 
The plasmon resonance of the NS nanoparticles shifts to longer wavelengths as 
the silica layer thickness is increased. The experimentally obtained plasmon resonance 
frequencies as a function of silica layer thickness are compared directly to theoretical 
values calculated using Mie Theory for a concentric, three-layer, Si02-Au-Si02 spherical 
nanoparticle (Fig. 2.3). The plasmon redshift occurs due to the presence of the silica layer 
because of the higher refractive index of silica relative to water. The increasing thickness 
of the silica epilayer surrounding the NS screens the electron oscillation in the metal, 
Q-J 
decreasing the plasmon energy. A redshift in the plasmon resonance peak from 790 nm 
(without silica shell layer) to 834 nm (with 60 nm silica shell layer) is observed, with the 
plasmon shift remaining constant for the thicker silica shell layers. This behavior 
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indicates that changes to the local dielectric environment beyond a certain distance from 
the surface do not apparently affect the surface plasmons of the NS nanoparticles.91 
However, the silica layer thicknesses used in this experiment do not extend to the longer 
length scale where oscillatory behavior of the SPR shift with increasing dielectric layer 
thickness has been reported.94 The experimentally obtained values of the plasmon 
resonance wavelength shown in Figure 2.3 correlate very well with the theoretically 
obtained values. The linewidth of the plasmon peak of these nanostructures allows good 
overlap with the ICG absorption-emission profile for all the NS@SiC>2 nanoparticles 
synthesized for this experiment. 
2.4 Experimental Fluorescence Enhancement 
A schematic of ICG adsorption on the NS@SiC>2 nanoparticles through APTES 
surface functionalization, and subsequent fluorescence emission, is illustrated in Figure 
2.4A. The ICG molecules are adsorbed onto the silica surface of the nanoparticle 
electrostatically. To quantify the fluorescence enhancement due to the silica coated 
nanoshells, ICG bound in the same manner to silica nanospheres (radius 60 ± 2 nm) was 
used as a control sample. Comparison of the fluorescence of ICG adsorbed to silica-
coated nanoshells vs. ICG on silica nanoparticles, rather than ICG in solution, allows us 
to examine the fluorescence enhancement process for molecules in equivalent chemical 
environments. The fluorescence spectra of ICG bound to silica (Xmax = 810 nm) at varying 
distances from NS surface, as determined by the silica spacer layer, is shown (Fig. 2.4B). 
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Figure 2.4. (A) Schematic diagram of ICG conjugation on NS@SiC>2 nanoparticles, 
excitation and observed emission. (B) Fluorescence spectra of ICG conjugated at various 
distances from the NS surface. (——) Emission spectrum of control, ICG deposited on 
silica nanospheres is also included. (C) Fluorescence enhancement factor of ICG 
conjugated on NS@SiC>2 nanoparticles relative to silica nanospheres is shown as a 
function of thickness of silica layer surrounding the NS (color coordinated with reference 
to figure 4B). 
The fluorescence spectra were collected under identical excitation and detection 
conditions, allowing direct comparison of the various nanoparticle-ICG complexes. The 
concentration of ICG molecules was maintained at ~ 400 nM in each of the nanoshell and 
silica nanoparticle solutions used in the deposition of ICG onto the nanoparticle surfaces. 
Based on our deposition protocol, near-saturation coverage of ICG on the nanoparticle 
surfaces is likely, corresponding to nominally 103 ICG molecules per nanoparticle, 
increasing as nanoparticle size (and therefore surface area) is increased. A maximum 
enhancement of 50X is achieved relative to ICG molecules adsorbed on silica 
nanospheres for a silica spacer layer of 7 ± 2 nm on the nanoshell surface. As the 
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thickness of the silica spacer layer (13 ± 2 nm, 21 ± 3 nm, 30 ± 3 nm, 42 ± 3 nm) was 
increased, the fluorescence enhancement decreased, with the lowest enhancement factor 
of 7 observed for the largest spacer layer. This distance-dependent decay of the 
fluorescence enhancement is shown in Figure 2.4C as a function of silica layer thickness. 
2.5 Calculated Fluorescence Enhancement 
The Au nanoshells influence ICG emission by a combination of two processes: 
absorption enhancement via the high intensity nanoparticle near field, and radiative rate 
enhancement, which increases its quantum yield.75 Since the nanoparticle complexes used 
in this study have spherical symmetry, their properties can be calculated quite 
straightforwardly using Mie theory. In particular, both the near field enhancement and the 
radiative rate enhancement of molecules near the nanoshell surface can be calculated for 
this spherical geometry.11 To obtain the near field enhancement, the electromagnetic 
fields around and within the particle are expressed in terms of a spherical harmonic basis 
set and the scattering is obtained in response to an incident plane wave.95 To evaluate the 
radiative rate enhancement, a similar procedure is followed, except that the plane wave 
excitation is replaced with a point dipole adjacent to the nanoparticle. The far-field 
Poynting vector is then integrated over all angles and compared directly to the amount of 
energy radiated by the same dipole in free space. This theoretical model agrees very well 
with the distance dependence of the fluorescence enhancement we have observed (Fig. 
2.5A). We will now examine the relative contribution of these processes in more detail. 
Emission from a fluorophore is experimentally quantified in terms of its quantum 
yield (Q0) and lifetime (T). Intrinsically, these processes are best described in terms of the 
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radiative emission rate (P) and non-radiative decay rate (knr) as discussed in chapter 1. 
For most dye molecules, including ICG, these parameters are highly dependent on local 
environment.96 For ICG adsorbed onto silica-coated NS and ICG on solid silica 
nanospheres, we can assume that the intrinsic radiative and non-radiative decay rates of 
ICG are the same for these equivalent environments. The emission intensity of reference, 
ICG adsorbed on silica, is I0 = hxc'e Qo where s is molecular adsoprtivity and Iexc is 
intensity of excitation source. In the presence of the metal, the quantum yield increases 
and lifetime decreases. Because the chemical environment is unchanged from the 
reference sample and quenching is not observed, we assume that knr is unaffected by the 
presence of the metal shell inside the silica coating. The observed emission of the ICG-
NS system is therefore INS = (<121 >IEXC).£. QNS where <|E| > is the surface average near 
field enhancement of nanoshells. The fluorescence enhancement is evaluated following 
the same procedure as for the experiment, by taking the ratio of the emission from the 
ICG-NS (INS) to the reference ICG on the silica nanosphere (70): 
i y L
 = / | e | 2 \ ^ = / i E i 2 U r ( r + U 
h \ ' Qo \ ' Zrr + knr ' ^ 
where both the dye concentration and excitation intensity are taken to be the same in both 
cases. Xr is the factor by which the radiative decay rate of the molecules increases due to 
electromagnetic coupling. From this expression, one can see that the observed 
enhancement can be separated into the effect of the field enhancement (<|E| >) and the 
quantum yield enhancement (QNS/QO)• This expression indicates that fluorescence 
enhancement depends on the properties of the nanoparticle, and also the dye molecule, 
via r and knr. A third effect should come into play when the molecule is very close to the 
metal surface, where the fluorescence is quenched by an increase in the nonradiative 
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decay rate. In the experimental regime studied here, no evidence of quenching is 
observed and is therefore not included in this analysis. We performed a control 
experiment with ICG molecules bound to nanoshells without any silica layer, and 
observed fluorophore quenching, shown in Figure 2.5. However, direct comparison of the 
fluorescence enhancement factor of ICG molecules bound to NS@Si02 nanoparticles 
relative to ICG adsorbed on NS surface would not be quantitative since the chemical 
environment of the fluorophore is different in each solution. 
Figure 2.5. Fluorescence enhancement factor of ICG molecules adsorbed on NS without 
any silica layer ( • ) is represented showing strong quenching of ICG molecules. ICG 
molecules bound to NS@SiC>2 nanoparticles relative to silica nanospheres is also shown 
as a function of silica layer thickness surrounding the NS. The data points representing 
ICG-NS@Si02 nanoparticles are color coordinated with ref. to Figure 2.4B and 2.4C. 
The theoretical model we have used yields excellent agreement with the observed 
fluorescence enhancement as a function of distance (Fig. 2.6A). To obtain this fit, we first 
calculated the surface-averaged near field intensity enhancement <|E| > as a function of 
distance from the nanoshell surface using Mie theory (Fig. 2.6B). This term appears quite 
similar to the observed distance-dependent fluorescence enhancement. However, it was 
shown previously that near field enhancement alone does not explain the fluorescence 
enhancement as a function of plasmon energy for ICG at a fixed distance from the 
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nanoparticle surface.75 Therefore we need to investigate to what extent the properties of 
the molecule affect the fluorescence enhancement. We also calculate the radiative rate 
enhancement factory (Fig. 2.6C). 
Silica Spacer Thickness [nm] Silica Spacer Thickness [nm] 
Silica Spacer Thickness [nm] Silica Spacer Thickness [nm] 
Figure 2.6. (A) ( • ) Experimental, and ( ) calculated values of fluorescence 
enhancement factor of ICG conjugated to NS@SiC>2 nanoparticles relative to ICG bound 
to silica nanospheres. (B)-(D) Calculated values of distance dependent fluorescence of 
ICG as a function of silica spacer thickness surrounding the NS. (B) Calculated surface 
average field enhancements, (C) Calculated radiative rate enhancements, (D) Calculated 
Q.E. enhancement of ICG conjugated to NS@SiC>2 nanoparticles relative to that of silica 
nanospheres. 
To calculate the quantum yield enhancement QNS/QO, R and knr for ICG in a silica 
environment are required. To determine these parameters, the total fluorescence 
enhancement (Eqn. 1) was fit to the experimental data with f\ knr, and a scale factor 
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(interpreted as molecular orientation) as free parameters, using a generalized reduced 
gradient minimization algorithm. The initial values of r and k„r, were chosen based on 
the rates previously reported.42 From this approach, values of r= 0.19 ns"1, knr = 2.1 ns"1, 
and a scale factor of 0.53, yielding values of T0 = 0.44 ns and Q0 = 8.6 % for the ICG-on-
silica-nanoparticle control sample, were obtained. The increase in quantum yield for ICG 
from nominally 1.3% for the molecule in solution to 8.6% for ICG adsorbed on silica 
nanoparticles is quite reasonable and consistent with several aspects of the molecule's 
new environment: stabilization of the polymethine chain due to adsorption on the silica 
surface, and the reduction in polarity and free oxygen exposure relative to an aqueous 
phase environment.96 The resulting fit, i.e. the product of Figures 2.6B, 2.6D, and a scale 
factor on the order of 0.5, is shown in Figure 2.6A. The scale factor is justifiable due to 
the random orientation of ICG on the nanoparticle surface. The agreement between our 
analysis and the experimental data shown in Figure 6A demonstrates that this modeling 
approach does an excellent job describing the system, and also confirms that the sample 
uniformity is quite good. Due to the tractability of this system, this approach is highly 
promising for further experimental studies and analysis of fluorescence modification on 
nanoshell-based structures. 
2.6 Calculated Quantum Yield and Lifetime 
Examining the contribution from the near field enhancement (Fig. 2.6B) and quantum 
yield enhancement (Fig. 2.6D), it can be seen that the radiative rate enhancement is 
actually more important than the near field enhancement at all distances studied here, and 
decreases quite slowly with distance. This is quite an important point to consider, since a 
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fluorophore with intrinsically high quantum yield can only be enhanced due to <|E|2>, 
and would therefore experience much weaker enhancement. The effective quantum yield 
and lifetime of the ICG-NS system can be calculated using these obtained parameters and 
Equations 4 and 5 from chapter 1, and is shown in Figure 2.7. From Figure 2.7A it can 
be seen that the quantum yield is strongly enhanced, approaching unity, relative to the 
unenhanced 8.6% quantum yield without the presence of the nanoshell. In this analysis, 
the quantum yield enhancement (Fig. 2.6D) is relatively flat for thin spacer layers. The 
lifetime of the dye decreases significantly as the silica layer is decreased (Fig. 2.7B), 
resulting in an increased quantum yield. Further studies to test this model using direct 
lifetime measurements are currently underway. 
Figure 2.7. Calculated values of distance dependent fluorescence of ICG as a function of 
silica spacer thickness surrounding the Au-NS (a) quantum yield and (b) lifetime. 
2.7 Conclusions 
In conclusion, we have shown that fabrication of silica epilayers surrounding NS 
nanoparticles of controlled thicknesses allows us to examine the distance-dependent 
fluorescence enhancement of the low quantum yield molecular fluorophore ICG in a 
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quantifiable manner. A maximum fluorescence enhancement of 50 is achieved at a 
distance of ~ 7 nm from the NS surface, and even for the thickest silica layer fabricated 
on the NS (~ 42 nm) a 7 fold enhancement is still observed. The quantum yield of ICG 
molecules decrease with increasing distance from the NS surface due to a decrease in the 
NS near field at the excitation wavelength and a decrease in coupling of the fluorophore 
to the NS plasmon at the emission wavelength. The strongly enhanced fluorescent 
emission of ICG in this nanoparticle configuration is potentially very valuable in 
biomedical imaging and clinical diagnostic applications. This strategy for enhancing the 
emission of low-quantum-yield fluorescent emitters can be straightforwardly generalized 
to other types of fluorescent emitters and media. 
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Chapter 3: Fluorescence Enhancement by Au nanostructures: 
Nanoshells and Nanorods 
3.1 Introduction 
Plasmonic fluorescence enhancement is not only critically dependent on the 
distance between the metal surface and the fluorophores, but also on the geometry, 
dimensions and corresponding near-field and far-field properties of the nanoparticles. In 
this chapter, we have studied in details the fundamental photophysics contributing to 
wards plasmon enhanced fluorescence of molecular systems. We have examined the 
enhancement of NIR fluorophore, IR800-NHS ester (IR800), with Au nanoshells and 
compared that with Au nanorods and experimentally determined the quantum yield and 
lifetime of the fluorophore. All nanoparticle synthesis, characterization, fluorescence, 
lifetime and experimental angular scattering measurements were obtained by Rizia 
Bardhan. Nathaniel K. Grady contributed in building the angular scattering set-up, data 
interpretation and discussion. Reproduced with permission from Rizia Bardhan, 
Nathaniel K. Grady, Joseph R. Cole, Amit Joshi, Naomi J. Halas, ACS Nano, 2009, 3, 
744-752. Copyright 2009 American Chemical Society. 
Fluorescence imaging has seen widespread use in clinical diagnosis and 
• 07 
monitoring processes in biological systems. The development of contrast agents, such 
as fluorescent probes with engineered biomarker functionalities, has become integral to 
08 • • 
the advancement of new bioimaging technologies. Fluorescent molecules emitting at 
wavelengths in the physiologically relevant "water window" (700 nm - 900 nm), are of 
particular interest due to the large penetration depth of near infrared (NIR) light in most 
biological media, and offer the potential for imaging at significant depths in living 
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tissues.38 However, achieving bright fluorescent emission with photostable and 
biocompatible NIR fluorophores has proven to be extremely difficult. It has long been 
known that in the proximity of a metallic surface, fluorescence emission of molecules can 
be enhanced; this is also the case for metallic nanostructures and nanoparticles adjacent 
c 
to a fluorophore. " The presence of a nearby metallic nanoparticle can not only enhance 
the quantum yield but also stabilize adjacent fluorophores against photobleaching, further 
enhancing their practical use in bioimaging applications.10 In new and emerging light-
assisted therapeutic applications such as photothermal cancer therapy, the addition of 
bright NIR fluorescence to a therapeutic nanostructure complex could provide addition 
diagnostic imaging capabilities for this treatment strategy that could facilitate clinical use. 
Understanding precisely how metallic nanostructures enhance molecular fluorescence is 
of general fundamental interest, and may ultimately provide practical routes to enhancing 
light emission from a variety of materials systems and devices far beyond the specific 
application of bioimaging. 
Metal nanostructures exhibit remarkable optical properties due to excitation of 
their surface plasmons by incident light, which results in a significant enhancement of the 
electromagnetic field at the nanoparticle surface. This enhanced near field can be used to 
design highly sensitive chemical and biosensors with specific plasmon resonances 
tailored by the nanoparticle geometry.99' 100 Metallic nanoparticles have been shown to 
enhance the fluorescence emission and decrease the molecular excited-state lifetimes of 
vicinal fluorophores. The fluorescence enhancement is attributable to a combination of 
processes including enhanced absorption by the molecule, modification of the radiative 
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decay rate of the molecule, and enhanced coupling efficiency of the fluorescent emission 
to the far field.3,10 
The plasmon resonant properties of metallic nanoparticles can be controlled by 
optimizing the nanoparticle topology, dimensions, and composition.56' 101"103 When 
plasmonic nanoparticles are much smaller than a wavelength of light they are absorbers, 
much like molecules. Nanoparticles larger than a few tens of nanometers both absorb 
and scatter light. While both the absorption and scattering cross sections of a plasmon 
resonant nanoparticle increase with increasing particle size, scattering begins to dominate 
in this larger-size regime.89 Au nanorods (NRs) and Au nanoshells (NSs) are both 
particularly useful for biological applications since their near field and far field optical 
properties can be tuned controllably throughout the NIR water window by varying their 
geometry. For NRs, the aspect ratio defines two distinct plasmon resonance frequencies 
associated with the longitudinal and transverse dimensions of the nanostructure. 104 For 
NSs, symmetric spherical nanoparticles consisting of a dielectric core and a metal shell, 
the plasmon resonances are determined by the relative size of the core and the metal shell 
layer.87 NSs can be fabricated both in a small size regime (d~50 nm) using AU2S/AU and 
sizes up to a micron in silica/Au core/shell structures, accessing NIR resonances over a 
QQ 
large size range. NRs tuned to the same NIR plasmon resonance frequency as silica/Au 
NSs are significantly smaller in size than the corresponding nanoshell, resulting in a 
much smaller contribution of scattering to the overall extinction cross section. Studying 
fluorescence enhancement by these two types of structures allows us to examine how the 
properties of both nanostructures contribute to this effect. 
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We have recently shown that the fluorescence of NIR fluorophores can be 
significantly enhanced when the molecules are in close proximity to NSs.75' 105 
Fluorescence enhancements as large as 50 were obtained when the plasmon resonance of 
the nanoshell was tuned to the emission wavelength of the fluorophore, for a nanoshell 
designed with a significant scattering cross section at that wavelength. In the study we 
report here, we compare the fluorescence enhancement of IR800 positioned a small, 
controlled distance from NSs and NRs. We quantified the fluorescence enhancement of 
IR800 experimentally by measuring the angle resolved scattering intensities, frequency 
domain fluorescence decay, and quantum yield of IR800 before and after binding to the 
nanoparticles. We also calculated the scattering cross sections of NSs and NRs to 
determine the scattering intensities of the nanoparticles and relative contribution of 
nanoparticle scattering towards molecular fluorescence enhancement. 
When a fluorophore is adsorbed directly onto a metal surface, its fluorescence is 
quenched. However, at a distance of a few nanometers from the nanoparticle surface, the 
fluorescence can be strongly enhanced.106 IR800 molecules were placed in close proximity 
of NS and NR surfaces by coating the nanoparticles with a 5-11 nm layer of human 
serum albumin (HSA) in order to prevent quenching of IR800. Serum albumin, a large 
multi-domain protein relevant to many physiological functions,107 has been conjugated to 
Au nanoparticles extensively for cell-targeting applications.108' 109 It binds to Au by 
electrostatic attraction between the amine groups of the protein and the negative charge 
on the gold surface, or, alternatively, by covalent attachment between the Au surface and 
amino acid functional groups present in the protein. 110 In this study HSA acts as both a 
spacer layer as well as a linker of the fluorophore to the nanoparticle. It contains an 
abundance of a-amines at N-terminals and s-amines on lysine side chains, which 
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covalently bind to IR800 via the N-hydroxysuccinimide (NHS) ester group to form a 
stable protein-dye complex.111 The NHS ester group facilitates protein conjugation, and 
the presence of the negatively charged sulfonate groups makes IR800 soluble in aqueous 
media. While these properties make IR800 a suitable dye for bioimaging,64 it is limited 
by low quantum efficiency compared to commonly used visible dyes such as Boron 
Dipyrromethene (BODIPY) and Fluorescein isothiocyanate (FITC). Therefore, by 
binding IR800 to metal nanoparticles with a suitably determined spacer layer, the 
quantum yield can be significantly enhanced. 
3.2 Fabrication of Nanoparticle-Fluorophore Conjugates 
Section-I. Nanoparticle Fabrication: All chemicals were purchased from Sigma Aldrich 
and IR800 NHS ester was purchased from Licor Biosceinces. Au nanoshells (NSs) [ri, 
= [63, 78] nm were fabricated as described in Chapter 1. The fabricated NSs were 
centrifuged several times and finally redispersed in phosphate buffer (Na3P04, pH ~ 8.0). 
Au nanorods (NRs) [w, 1] = [11, 46] nm were fabricated by the method reported 
by Murphy and co workers.112 Briefly, the seed solution was prepared by gently mixing 
7.5 mL of 0.1 M Cetyl trimethylammonium bromide (CTAB) with 0.25 mL of 0.01 M 
HAuCU. 0.6 mL of ice-cold 0.01 M NaBH4 was injected into the solution and mixed 
rapidly. The solution turns from a golden yellow color to pale brown color. It is essential 
that the temperature of NaBH4 is maintained at ~ 0 °C prior to mixing with CTAB and 
HAuCU for proper growth of nanorods. The seed solution was then stored at 27 °C until 
further use. The growth solution was prepared by gently mixing 47.5 mL of 0.1 M 
CTAB, 2 mL of 0.01 M HAUC14, 0.3 mL of 0.01 M AgN03 and 0.32 mL of 0.1 M 
Ascorbic Acid in the order mentioned. Addition of ascorbic acid turns the solution from 
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golden yellow to colorless. 0.25 mL of the seed solution was added to the growth solution 
and mixed gently and then the solution was stored at 27 °C for 3 hours without agitation. 
Within 20 minutes the solution changes from colorless to pink and eventually changes to 
dark pinkish brown after 3 hours. The NRs were washed twice at 8000 rpm to remove 
excess CTAB and finally redispersed in 10 mL Na3PC>4 buffer. 
Section-II. Protein and Fluorophore Conjugation: HSA was conjugated to IR800 by 
mixing equal volumes of 5 (iM HSA aqueous solutions in Na3PC>4 buffer and 30 |a,M 
IR800 aqueous solution at room temperature for 5 hours, in the dark. The protein-
flurophore complex was then dialyzed in Na3PC>4 buffer for 24 hours at room temperature 
protected from light, in a 3500 MW dialysis bag (MW of HSA is 67 kDA and MW of 
IR800 is 1166 g/mol) to remove excess dye. Absorbance peaks of the protein-dye 
complex (km^ = 782 nm) and protein (Xmax = 280 nm) were monitored to account for free-
dye removal. After sufficient removal of unbound dye, the ratio of fluorophore to protein 
concentration (NIRSOONHSA) of the complex is determined by utilizing the absorbance of 
fluorophore at 782 nm (AIRBOO), molar extinction coefficient of IR800 (SIRBOO), absorbance 
of HSA at 280 nm (AHSA), molar extinction coefficient of HSA (SHSA) given by: 
NIRSOO / N H S A = [AIR8()()/SLR800] / [AHSA/SHSA] 
where EIR8OO = 240,000 IVr'cm"1 and SHSA = 42,864 IVf'cm"1. The final protein 
concentration was calculated using the molecular weight (M.W.HSA) and dilution factor 
(d. f.) of original solution given by: 
NRSA = [AHSA/SHSA] x M.W.HSA X d. f . 
The final protein concentration was ~ 4 pM and fluorophore concentration was ~ 10 (iM. 
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Section-Ill. Protein-Fluorophore Complex Binding to Nanoparticles: The protein-
fluorophore complex obtained was conjugated to the nanoparticles by adding 1 mL of 
HSA-IR800 solution in Na3PC>4 buffer to 10 ml nanoshells, and 10 ml nanorods dispersed 
in Na3PC>4 buffer respectively under constant stirring. After 7 hours conjugation at room 
temperature, in the dark, the nanoparticles were centrifuged in small aliquots of 500 |jL to 
remove excess dye and resuspended in Na3P04 buffer and we closely monitored the 
absorbance of the supernatant to account for unbound fluorophore concentration in the 
supernatant (9.55 - 9.65 (iM). The concentration of the supernatant was then subtracted 
from the initial concentration of HSA-IR800 which was added to the nanoparticles to 
calculate the amount of HSA-IR800 on the nanoparticles. The final NSs concentration 
o 
after resuspension in buffer was at ~ 10 particles/mL and final NRs concentration was at 
~ 109 particles/mL. The surface area available for the HSA-IR800 complex to bind to the 
nanoparticles was normalized (see below) and hence the concentration of fluorophore 
was equivalent for both the NSs-HSA-IR800 and NRs-HSA-IR800, ~ 400 ± 50 nM. 
Section-IV. Calculation of surface area available for HSA-IR800 to bind to nanoparticles 
The amount of protein and fluorophore bound to the nanoparticles were quantified by 
assuming that IR800 binds to HSA similarly for both nanoshells and nanorods. The 
available surface area for fluorophore binding is kept equivalent for both nanoparticle 
solutions. The concentration (CNS) and extinction co-efficient (CNS) for NSs were 
calculated utilizing Mie theory: 
GNS = 9.6072 x 10"10cm2 for NSs [n, r2] = [63, 78] nm 
CNS = ln(10) x Absorbance / o x cuvette path length 
= 2.303 x 0.052 / 9.6072 x 10"10 cm2 x 1 cm 
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= 1.25 x 10 particles/ mL 
The Surface Area of one NS (SANS) = 4ji [r22 - r,2] = 2.855 x 10"14 m2. 
The Surface Area of NSs solution = (SANs) x CNS = 3.568 x 10"6 m2/mL 
The extinction coefficient (CTNR) for NRs [w, 1] = [11, 46] nm resonant at ~ 800 
nm have been reported previously as GNR ~ 4 x 10"11 cm2.41 The concentration of NRs 
(CNR) were calculated utilizing Gan's theory, 
CNR = 2 x Absorbance / a x cuvette path length 
= 2 x 0.043 / 4 x 10"ncm2x 1cm 
= 2.154 x 109 particles/ mL 
The Surface Area of one NR (SANR) = 2n r2 + 2ml = 1.727 x 10"15 m2. 
The Surface Area of NRs solution = (SANR) x C N R= 3.719 x 10"6 m2/mL. 
However, experimentally the available nanoparticle surface area for fluorophore binding 
would vary slightly due to non-uniform size distribution of nanoparticles in solution. 
Section V. Calculation of no. of HSA-IR800 molecules bound to the nanoparticles 
The diameter of a HSA molecule is approximately ~ 8 ± 3 nm and we assume the 
diameter of a IR800 molecule is roughly ~ 2 nm, resulting in a hydrodynamic diameter of 
~ 12 nm for the protein-fluorophore complex. We have determined the number of 
fluorophore molecules per protein molecule by taking a ratio of their surface area: 
The surface area of one HSA molecule (SAHSA) = 4;ir2 = An (4 x 10"9)2 = 2.011 x 10"16 m2 
The surface area of one IR800 molecule (SAIR8OO) = 4TI (1 X 10"9)2= 1.256 x 10"17 m2 
The no. of IR800 molecules per HSA molecule = SAHSA/ SAIRSOO 
= 16 dye molecules 
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We have also calculated the number of molecules of protein-fluorophore complex per 
nanoparticle, for both NSs as well as NRs: 
The surface area of one HSA-IR800 molecule (SAHSA-IRSOO) = 4TI (6 X 10"9)2 
= 4.523 x 10"16m2 
The no. of HSA-IR800 molecule per N S = S A N S / SAHSA-IRSOO 
= 2.855x 10"14 m2 / 4.523 x 10"16 m2 
» 63 HSA-IR800 molecules 
The no. of HSA-IR800 molecule per NR = S A N S / SAHSA-IRSOO 
= 1.727 x 10'15m2/4.523 x 10"16m2 
» 4 HSA-IR800 molecules 
However, as described above the surface area available for HSA-IR800 complex to bind 
to NSs and NRs have been normalized by adjusting the nanoparticle concentration. This 
provides almost equivalent amounts of protein-dye molecules to bind to each 
nanoparticle suspension. 
3.3 Characterization of Nanoparticle-Fluorophore Conjugates 
The nanoparticles were characterized by obtaining transmission electron microscope 
(TEM) images using a JEOL JEM-2010 TEM, and absorbance measurements using a 
Varian Cary 5000 UV-Vis-NIR spectrometer. Fluorescence emission spectra and 
frequency domain lifetime measurements were obtained using Jobin Yvon Fluorolog 3 
and the samples were excited at 780 nm. The dynamic range of the Fluorolog 3 for 
lifetime measurements is 0 - 300 MHz. The absorption-emission profile of IR800 
conjugated to HSA in sodium phosphate buffer (Na3PC>4, pH ~ 8.0) is shown in Figure 
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3.1a. The absorbance maximum of the protein-fluorophore complex is observed at 782 
nm, and the fluorescence emission maximum at 804 nm. The IR800 molecules were 
conjugated to HSA to form the HSA-IR800 complex, which was then bound to NSs 
(NSs-HSA-IR800) and NRs (NRs-HSA-IR800) as demonstrated in Figure 3.1b. 
500 600 700 800 900 1000 
b W a v e l e n g t h ( n m ) 
NSs NSs-HSA-IR800 
HSA-IR800 
NRs NRS-HSA-IR800 
Figure 3.1. (a) Absorption - emission profile (Xmax-Ab ~ 782 nm and A,max-Em ~ 804 nm) of 
IR800 conjugated with HSA. Chemical structure of IR800 is provided as inset, (b) 
Schematic diagram illustrating the conjugation of HSA-IR800 protein-fluorophore 
complex to Nanoshells (NSs) and Nanorods (NRs) to form NSs-HSA-IR800 and NRs-
HSA-IR800 respectively. The blue curved line represents HSA and red dots represent 
IR800 dye. 
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HSA-IR800 conjugation was performed at room temperature, and the protein-
fluorophore complex was dialyzed for 24 hours to remove excess dye (see 3.2 section II). 
It was determined that approximately 16 molecules of IR800 were bound to each HSA 
molecule (see 3.2 section V). The bioconjugation of the HSA-IR800 complex to the 
nanoparticles was performed in Na3PC>4 buffer at room temperature and protected from 
light, and excess protein-fluorophore mixture was removed by centrifuging the 
nanoparticle conjugates in small aliquots (see 3.2 section III). We determined that ~ 63 
HSA-IR800 complexes were conjugated to each NS and ~ 4 HSA-IR800 complexes were 
bound to each NR (see 3.2 section V). However, the total number of HSA-IR800 
complexes bound to NSs or NRs was kept constant by adjusting the nanoparticle 
concentration, such that the total surface area available for conjugation was equivalent for 
both NSs and NRs (see 3.2 section IV). 
The geometry of the nanoparticles coated with HSA-IR800 was characterized with 
transmission electron microscopy (TEM). TEM micrographs of NSs with dimensions [rj, 
r2] = [63, 78] nm, where ri is the radius of the silica core and r2 is the radius of the Au 
shell, are shown in Figure 3.2a. NRs, [w, 1] = [11, 46] nm, where w is the width and 1 is 
the length, are shown in Figure 3.2c. The NSs and NRs coated with a uniform 8 ± 3 nm 
layer of HSA are shown in Figure 3.2b and 3.2d, respectively. 
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Figure 3.2. TEM micrographs of (a) NSs [rj, r2] = [63, 78] nm, (b) NSs coated with 8 ± 3 
nm HSA-IR800, (c) NRs [w, 1] = [11, 46] nm, and d) NRs coated with 8 ± 3 nm HSA-
IR800. 
Wavelength (nm) Wavelength (nm) 
Figure 3.3. Surface plasmon resonance shift when nanoparticles are conjugated with 
HSA-IR800 (a) NSs (solid red), W ~ 800 nm and NSs coated with HSA-IR800 (dash), 
m^ax ~ 805 nm, and (b) NRs (solid blue), l m m ~ 796 nm and NRs coated with HSA-IR800 
(dash), Xmax ~ 804 nm. The peak at 280 nm is protein absorbance peak. 
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3.4 Experimental Fluorescence Enhancement 
Wavelength (nm) Wavelength (nm) 
Figure 3.4. (a) Extinction spectra of (i) NSs-HSA-IR800, plasmon maximum at ~ 805 
nm, and (ii) NRs-HSA-IR800, plasmon maximum at ~ 804 nm are shown. Spectra are 
offset for clarity, (b) Fluorescence (FL) spectra, X a^* ~ 804 nm of (i) NSs-HSA-IR800, 
(ii) NRs-HSA-IR800, and (iii) control sample HSA-IR800 are shown. 
The plasmon resonance of NSs and NRs shifts to longer wavelengths by 5 - 8 nm when 
HSA-IR800 is adsorbed, due to the higher refractive index of HSA than H20113 '114 shown 
in Figure 3.3. The plasmon resonances of the nanoparticles were tuned to the emission 
wavelength of the fluorophore-protein complex to maximize the fluorescence 
enhancement.75 The extinction maximum of NSs-HSA-IR800 was observed at ~ 805 nm, 
and that of NRs-HSA-IR800 was observed at ~ 804 nm, as shown in Figure 3.4a. The 
corresponding emission spectra of HSA-IR800 conjugated to the nanoparticles are shown 
in Figure 3.4b. HSA-IR800 was used as the control sample rather than IR800 in aqueous 
solution to ensure that the fluorophore was in essentially the same chemical environment 
in all measurements. The emission spectra of nanoshells coated with HSA without IR800 
and nanorods coated with HSA without IR800 are also provided in Figure 3.5. The 
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nanoparticles exhibited no fluorescence in the near-infrared without the fluorophore. The 
reference sample as well as the nanoparticle-conjugates was excited at 780 nm and the 
fluorescence spectra were collected in solution under identical excitation and detection 
conditions, allowing direct comparison of the various nanoparticle-fluorophore 
complexes. A maximum fluorescence enhancement of ~ 40 was measured for NSs-HSA-
IR800 relative to the control sample, and an enhancement of ~ 9 was found for NRs-
HSA-IR800. 
Wavelength (nm) 
Figure 3.5. Emission spectra of control, HSA-IR800 (black), nanoshells coated with 
HSA without IR800 (red), and nanorods coated with HSA without IR800 (blue) are 
shown. Fluorescence is not observed from the nanoparticles without the fluorophore. 
3.5 Calculated and Experimental Scattering Efficiency of Nanostructures 
Since the nanoparticles used in this experiment vary in size, their relative scattering 
cross sections also differ significantly, which directly affects their fluorescence 
enhancement efficiency. We determined the scattering intensities of the NSs and NRs by 
calculating their scattering cross sections using experimentally obtained nanoparticle 
sizes. The calculated scattering intensities for NSs [ri, x{\ = [63, 78] nm in aqueous 
medium were obtained using Mie theory, and the maximum plasmon resonance peak was 
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observed at 800 nm. The theoretical scattering intensity of NRs was calculated by using 
the finite element method (FEM) (as implemented by COMSOL Multiphysics). The 
nanorods were modeled as cylindrical objects with hemispherical end-caps in H2O, 
estimating size obtained from TEM [w, 1] = [11, 46] nm. The dielectric function used for 
Au was obtained from literature values.115 The calculated longitudinal plasmon mode of 
NRs, showed a maximum at a wavelength of 824 nm in water. The experimentally 
observed longitudinal plasmon resonance of NRs (804 nm) differs from that calculated 
theoretically because the energy of the longitudinal mode depends strongly on the end 
cap geometry.116 Nonetheless, the calculated scattering spectra shown in Figure 3.6 
indicate that NSs scatter more efficiently than NRs for the sizes of nanoparticles studied. 
Wavelength (nm) 
Figure 3.6. Calculated scattering spectra of (i) NSs [ri, r2] = [63, 78] nm, A,max — 805 nm 
and (ii) NRs [w, 1] = [11, 46] nm, Xmax= 824 nm. 
The scattering measurements were also obtained experimentally by utilizing 
solutions with similar concentrations of NSs and NRs (Fig. 3.7A). The nanoparticle 
solutions were positioned in a 6.25 mm path length cylindrical cuvette and placed on a 
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goniometer which rotated the collection point around the sample while keeping the angle 
of the sample fixed. A 785 nm diode laser was used as the excitation source, along with 
appropriate combination of filters and linear polarizers for light propagation and 
detection. The scattered light from the nanoparticles was detected by a CCD array 
connected to a spectrograph. The scattering intensities of the nanoparticles were then 
determined by obtaining the scattered light intensity as a function of polar angle. The 
measurements range from 0° to 360°, however measurements between 130° - 180° were 
not obtained due to constraints in the experimental set-up. The spectra are not completely 
symmetric for rotation over 90° attributable to a small misalignment in the apparatus. We 
observe that NSs scatter by a factor of ~ 34 more than NRs. (Fig. 3.7B) The larger 
scattering efficiency of NSs relative to NRs studied here correlates with the larger 
fluorescence enhancement observed for IR800 by NSs. 
Figure 3.7. (a) Schematic diagram representing angle-resolved fluorescence emission 
apparatus. Ml: Mirrorl, M2: Mirror 2, PI: Polarizerl, P2: Polarizer2, A/2: Half-
wavelength plate, Fl: Laser selection filter, F2: Long pass filter, RM: Rotating mount 
with knob to control the angle of the sample relative to the excitation light (Red circle). 
Black solid line indicates laser light path, (b) Experimental angle-resolved scattering 
spectra of NSs (red circles) and NRs (blue circles). Spectra are normalized by 
concentration of nanoparticles. The radial axis ranges from 0 - 4 . 
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3.6 Frequency Domain Lifetime Decay 
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Figure 3.8. Frequency domain fluorescence decay of (a) IR800 (x ~ 564 ps), (b) HSA-
IR800 (x ~ 427 ps), (c) NRs-HSA-IR800 (x ~ 121 ps), and (d) NSs-HSA-IR800 (x ~ 68 
ps). The curves referring to phase and modulation are shown with arrows. 
In addition to the scattering characteristics of the nanoparticles, increasing the radiative 
decay rate of the fluorophore also contributes substantially to fluorescence enhancement. 
The change in radiative lifetime for IR800 conjugated to NSs and NRs via HSA was 
determined experimentally by monitoring the frequency domain fluorescence decay in 
aqueous solution. The lifetime spectra of IR800, HSA-IR800, NRs-HSA-IR800, and 
NSs-HSA-IR800 are shown in Figure 3.8. The intrinsic lifetime of the fluorophore was 
measured to be ~ 564 ps, which corresponds well to the previously reported value.64 The 
lifetime decreased to 427 ps when IR800 molecules were bound to HSA (Fig. 3.8b). This 
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is due to a small enhancement in quantum yield of the fluorophore when conjugated to 
the protein, attributable to an increased steric stabilization of IR800 bound to HSA. This 
reduces the mobility of the fluorophore in aqueous solution, resulting in higher stability 
and a decreased lifetime.117 The lifetime of IR800 bound to the nanoparticles via HSA 
was reduced significantly to 121 ps for NRs-HSA-IR800 and 68 ps for NSs-HSA-IR800. 
These measured lifetimes confirm the theoretical prediction of enhanced quantum yield 
and diminished lifetime of fluorophores near metallic surfaces. 105 
The fluorescence lifetime data can be evaluated in terms of a single exponential 
(SE) model or a multi exponential (ME) model. A SE model is appropriate for samples 
consisting of a single fluorophore in a homogenous environment, while a ME model 
describes the fractional contribution of decay time for each component present in a 
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sample mixture. The results of fitting to a ME decay analysis are represented in Table 
3.1. The decay rate for IR800 in aqueous media, in the absence of any other component 
in the solution, fits a SE decay model. However, the HSA-IR800 complex required a ME 
decay model, demonstrating that two different environments are available to the 
fluorophore with distinct lifetimes in each individual environment. About 90 % of the 
IR800 molecules were covalently attached to HSA with a fluorescence decay of 418 ps. 
The lifetime of the remaining fraction was similar to that observed for free IR800 in 
aqueous media, suggesting that a small fraction of unbound fluorophores remain in the 
HSA-IR800 solution. The ME analysis of the fluorescence decay of IR800 conjugated to 
nanoparticles indicates three distinct environments, which we interpret as IR800 
molecules conjugated to the nanoparticle-HSA, IR800 molecules bound to HSA only, 
and the free fluorophore in solution. Most of the fluorophores in these samples exhibited 
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a significantly reduced lifetime, indicating that nearly all of the dye molecules were 
attached to the nanoparticles via the HSA layer. This analysis reveals that both 
nanoparticle samples had less than 2% of unbound HSA-IR800 complex and less than 
1% of free fluorophore in the solution mixture. This is attributable to the high affinity of 
the protein for Au nanoparticle surface as well as the use of a fluorophore with a 
chemical linker which can covalently attach to the protein. Therefore, the nanoparticle-
HSA-IR800 system provides a useful complex for determining individual lifetime 
components. The %2R values shown in the last column of Table 3.1 are the goodness of fit 
parameter, obtained by fitting calculated values to experimentally obtained parameters by 
a nonlinear least-squares deconvulation method. The % R values represented here are 
1 1 R 
within 5-10% of the random deviations in the data. 
Table 3.1. Multiexponential analysis of intensity decay of IR800 with nanoparticles 
showing molecular fraction (a), observed lifetime (ij, ns), amplitude weighted lifetime 
(<X>, ns), and goodness of fit parameter (X2R)-
Sample a i Tj < T > 5C2R 
IR800 
1 0.564 
0.564 1.57 
HSA-IR800 
0.076 
0.924 
0.547 
0.418 0.427 1.54 
NRs-HSA-IR800 
0.008 
0.019 
0.973 
0.550 
0.419 
0.112 
0.121 1.42 
NSs-HSA-IR800 
0.005 
0.01 
0.985 
0.568 
0.421 
0.065 
0.068 1.39 
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3.7 Experimental Quantification of Quantum Yield 
In order to determine the radiative rate enhancement from the experimentally measured 
changes in lifetime, the nonradiative decay rate must be known. By combining and 
rearranging quantum yield, Q0=17 F+ knr and lifetime z0= 1/ T+ knr equations (chapter 1), 
the radiative and nonradiative decay rate can be experimentally obtained: 
r = (1) 
knr = ~
 r
" (2) 
The quantum yield of IR800 (Q) was determined experimentally using Indocyanine green 
(ICG) as a reference sample with a known quantum yield (QR) of ~ 1% in aqueous 
media.96 The NIR excitation-emission profile of ICG (excitation: 780 nm, emission: 820 
nm) is similar to that of IR800 and is therefore ideal as a reference sample for quantum 
yield determination. The quantum yield was computed by measuring the optical density 
of solutions with equivalent concentrations of IR800 (OD) and ICG (ODR) and by 
calculating the integrated fluorescence intensity of IR800 (7) and ICG (/«): 
IR ODr TJR 
where t] is the refractive index of sample medium and r\R is the refractive index of the 
reference medium, which are equivalent in this experiment (rj = rjR = rjH2o = 1.33). By 
using Eqn. (3), the quantum yield of IR800 was determined to be 7% in H2O, and that of 
the HSA-IR800 complex was determined to be 11%. Using the quantum yield and 
lifetime measured independently, Eqns. 1 and 2 allow determination of the radiative and 
nonradiative decay rates of the fluorophore as shown in Table 3.2. The quantum yield 
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values obtained for IR800 in aqueous media as well as HSA-IR800 are comparable to 
those reported in the literature.119 
Table 3.2. Quantum yield (Q.Y.), radiative decay rate (T) and nonradiative decay rate 
(knr) of IR800, HSA-IR800 and HSA-IR800 with nanoparticles. 
Sample Q.Y. r Kr 
IR800 0.07 1.241 x 108 1.648 x 109 
HSA-IR800 0.11 2 . 5 7 6 x 1 0 8 2.084 x 109 
NRS-HSA-IR800 0.74 6.180 x 109 2.084 x 109 
NSs-HSA-IR800 0.86 1.262 x 1010 2.084 x 109 
The radiative rate enhancement of IR800 induced by NSs and NRs and the 
improved quantum yields can now be calculated by rearranging the modified quantum 
yield QM= yrTI(yrY+ knr) and lifetime TM = M{yrT+ k„r) near metallic surfaces (chapter 1): 
rrr = —— k„r (4) 
QM = Yr r^M > (5) 
where TM is obtained from Table 3.1, and knr is the non-radiative decay rate for HSA-
IR800. We assume that knr is unaltered from HSA-IR800 for both NS-HSA-IR800 and 
NR-HSA-IR800 complexes because no fluorescence quenching was observable and the 
chemical environment of the fluorophore was equivalent in all cases. The nonradiative 
decay rate does increase when the chemical environment of the fluorophore is changed 6 
from solution phase to being bound to HSA. Table 3.2 shows that the knr increases when 
IR800 is bound to HSA compared to the free fluorophore in solution. On a metallic 
surface, the nonradiative decay rate also increases for short fluorophore-metal distances, 
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< 4 nm,7 '49 '120 since the nonradiative energy transfer rate depends on the inverse cube of 
the molecule-surface separation.35 However, in our nanostructure complexes, HSA 
provides a spacer layer of ~ 8 nm between the fluorophore and the metal nanoparticle 
surface. For this significantly larger metal-molecule distance, a significant increase in k„r 
due to the metal nanoparticle surface is not anticipated.75'105 Therefore we assume that k„r 
is essentially the same for HSA-IR800 in solution and for HSA-IR800 adsorbed 
sequentially onto a nanoshell or nanorod surface. The radiative decay rates of NRs-HSA-
IR800 and NSs-HSA-IR800 and the quantum efficiencies are also shown in Table 3.2. 
The high quantum yield of 86% for NSs-HSA-IR800 demonstrates that plasmonic 
enhancement can be used to create NIR-fluorescent species with similar intensities as 
visible dyes. Although the NRs achieve a lower quantum yield of 74% due to the lower 
scattering efficiency of the particles, this is still a very high value for a NIR fluorophore, 
and these structures would certainly also be useful as markers in fluorescence-based 
bioimaging where the smaller physical size of the NR-based nanoparticle complex would 
be desired. 
The precise relative contribution of each process responsible for IR800 
fluorescence enhancement, including absorption enhancement, scattering enhancement, 
and radiative decay rate enhancement, is difficult to determine since these processes are 
interdependent. Nevertheless, for the experimental parameters and nanoparticle 
geometries discussed here, the scattering efficiency of a nanoparticle appears to provide 
the most important mechanism for improving the quantum yield of a fluorophore. NRs 
predominantly enhance the emission of the fluorophore by absorption enhancement, 
owing to the high-intensity near field resulting from the longitudinal plasmon resonance. 
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However, due to the significant difference in scattering cross sections of NSs and NRs it 
is apparent that NSs increase the coupling efficiency of the fluorescence emission to the 
far field more efficiently than NRs. This explains the 40-fold fluorescence enhancement 
observed for IR800 bound to NSs compared to the 9-fold enhancement for IR800 bound 
to NRs. The radiative decay rate enhancement of the fluorophore is dependent on both 
the scattering efficiency as well as the absorption efficiency of nanoparticles. This 
explains why NRs enhance the quantum yield of IR800 by 74% as well as decrease the 
fluorophore's lifetime considerably. 
3.8 Conclusions 
In conclusion, we have examined the fluorescence enhancement of IR800 conjugated to 
NSs and NRs, and we have shown that both NS and NR lead to large increases in 
quantum yield relative to the isolated fluorophore. We have observed that nanoshells are 
more efficient in improving the emissive properties of a fluorophore due to their 
significant scattering cross section at the emission wavelength of the fluorophore. 
Additionally, the near-field response of NSs gives rise to a considerable enhancement in 
the absorption, and the radiative decay rate of IR800, resulting in 40 fold enhancement 
and 86% quantum yield. IR800 molecules bound to NRs demonstrate a 9-fold emission 
enhancement and a 74% quantum yield, attributable to the high local field enhancement 
at the longitudinal plasmon wavelength. Utilizing Au nanoparticles with appropriate 
geometry and dimensions for emission enhancement is a useful strategy for enhancing the 
detection sensitivity of low-quantum-yield fluorescent emitters. This approach is also 
potentially valuable in biomedical imaging, and moreover can be conveniently 
generalized to enhance other fluorescent media. 
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Chapter 4: Nanoshells for Simultaneous Magnetic and Optical 
Imaging and Photothermal Therapeutic Response 
4.1 Introduction 
Fluorescence spectroscopy is a widely used research tool in molecular and 
translational biology which has enabled significant progress in medical diagnostics. In 
this chapter, we show an exciting biomedical application of plasmon enhanced Au 
nanoshell-ICG molecular conjugates for NIR fluorescence optical imaging (FOI) at the 
cellular level. Iron oxide nanoparticles were also integrated on the Au nanoshell surface 
to simultaneously enable MRI in addition to FOI. These novel nanoshell complexes are 
not only effective diagnostic probes but also enable photothermal tumor ablation when 
illuminated with resonant light. The design and development of the nanoshell complexes, 
their characterization, MRI data analysis, FOI and photothermal cancer therapy in vitro 
was performed by Rizia Bardhan. Wenxue Chen performed the cell culture and 
contributed in FOI, MRI and cancer therapy in vitro. Carlos Perez-Torres obtained MR 
images of nanoshell complexes and MRI in vitro. Reproduced with permission from 
Rizia Bardhan*, Wenxue Chen*, Carlos Perez-Torres, Marc Bartels, Ryan M. Huschka, 
Liang L. Zhao, Emilia Morosan, Robia G. Pautler, Amit Joshi and Naomi J. Halas, Adv. 
Func. Mater. 2009, 19, 3901-3909 (*equal contribution). Copyright 2009 Wiley-VCH 
Verlag GmbH & Co. KGaA, Weinheim. 
The rapid development of noninvasive diagnostic imaging modalities such as MRI 
and FOI has revolutionized biomedical research and practice. " Each imaging 
technique has its own merits and drawbacks in terms of sensitivity, resolution, data 
acquisition time, and complexity. While numerous contrast agents for biological image 
75 
enhancement have been developed in the past decade, they have most often been limited 
to the enhancement of a single modality.124' 125 Contrast agents that enhance more than 
one imaging method provide a very important advance, enabling the use of multiple 
modalities to probe the same system, yielding more information than any single imaging 
1 1 97 
method alone. ' For example, multimodal contrast agents that simultaneously 
enhance MRI and FOI would combine the high sensitivity of FOI with the high spatial 198 
resolution of MRI. In practice, such a dual-modality contrast agent could be used in a 
single clinical procedure, for pre- and post-operative MRI, then for intraoperative FOI, 
• • 126 129 
providing enhanced imaging before, during, and after the procedure. ' The addition 
of antibody targeting, so that the nanocomplex can bind to the surface receptors of 
specific cell types in the case of cancer, along with a therapeutic function, such as 
photothermal heating to induce cell death, would provide a full theranostic spectrum of 
capabilities in a single, practical nanocomplex. The availability of multiple diagnostic 
and therapeutic modalities in a single agent will streamline the regulatory processed in 
the pharamaceutical drug development pipeline, and thus significantly reduce the cost 
and complexity involved in translating novel therapies from in vitro and in vivo settings 
to human applications. 
Here we report the design and demonstration of Au nanoshell-based, targeted, 
multimodality contrast agents in the NIR for MRI and FOI which also possess an 
effective photothermal therapeutic response. Nanoshells, consisting of a spherical 
dielectric core coated with a thin metallic shell, are ideal nanostructures for fabrication of 
these multifunctional probes. Their plasmon-derived optical resonance can be easily 
tuned to the NIR region of the spectrum, where tissue is maximally transparent, by 
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modification of their core and shell dimensions.12 This enables a broad range of 
diagnostic and therapeutic applications including optical imaging and photothermal 
cancer therapy. ' The plasmonic properties of nanoshells can also provide a significant 
fluorescence enhancement of NIR fluorescent ICG molecules when they are positioned at 
an appropriate distance 10 nm) from the nanoshell surface. This can be accomplished 
by growing a dielectric layer around the nanoparticle to serve as a spacer between the 
fluorophore and the metallic nanoparticle surface.75 ICG, although extensively used for 
contrast enhancement in molecular imaging, is limited by a low quantum yield of ~ 1% in 
aqueous media.105 Recently, we have shown that the emission of weak NIR fluorophores 
such as ICG can be dramatically enhanced to ~ 80% for a weak fluorophore in proximity 
to nanoshells designed with a significant scattering cross section at the emission 
wavelength of the fluorophore.105'130 The enhancement is attributable to a combination of 
several processes including enhanced absorption, enhanced coupling efficiency of the 
fluorescence emission to the far-field, and enhanced radiative decay rate of the 
fluorophores which increases the quantum yield. 
In this geometry, the spacer layer that separates the fluorophores from the metallic 
nanoparticle surface can also incorporate Fe304 nanoparticles for MRI enhancement. This 
minor modification in the chemical structure of the nanoparticle complex enables it to 
provide simultaneous MR and fluorescence enhancement integrated naturally into the 
same nanostructure. It is relatively straightforward to incorporate Fe3C>4 nanoparticles at a 
sufficient density to promote increased magnetic interaction between neighboring Fe3C>4 
nanoparticles, resulting in efficient MR contrast. Binding the Fe304 nanoparticles to the 
nanoshell surface, rather than encapsulating them within the Au shell, preserves their 
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large magnetic moment and superparamagnetic behavior.132 Au coatings on iron oxide 
nanoparticles have been known to compromise the magnetic properties of iron oxide due 
1 ^  
to the large diamagnetic mass of Au. 
The tunability of these nanocomplexes in the NIR region (700-900 nm) is highly 
advantageous since NIR light has been reported to penetrate deep into soft tissue, nearly 
• 35 38 
~ 10 cm through breast and 4 cm through brain tissue using microwatt laser sources. ' ' 
134
 The therapeutic response of nanoshells results from their ability to absorb NIR light IS 17 
resonant with the nanoshell plasmon energy and convert the light to heat. ' The heat 
generated by the nanoshells raises the local temperature of tissues resulting in thermal 
ablation of cancer cells. Unlike current cancer treatment strategies such as chemotherapy 
and radiation therapy, whose toxicity leads to deleterious side effects, these benign, 
nontoxic nanoshell-based complexes are far less likely to induce side effects in clinical 
applications. 
Molecular targeting of the nanocomplexes to cancer cells via antibodies against cell 
surface markers will selectively accumulate these agents in tumors, retard their clearance, 
and enable extended periods of imaging as well as photoinduced thermal ablation 
therapy.16' 135 Among the many known cell surface markers for targeting breast tumor, 
human epidermal growth factor receptor (HER2) has been identified as a promising target 
for antibody-based therapy. HER2 is expressed on healthy cells at ~ 104 receptors per 
cells; however, in tumors overexpressing this marker, roughly 106 HER2 receptors per 
cell may be present.136'137 HER2 has been used to target breast cancer cells because of its 
stable overexpression on -30% of breast cancers: it is currently considered to be the best 
138 • prognostic marker for breast cancer. Here, the nanocomplexes are conjugated with 
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anti-HER2 to target HER2-expressing breast carcinoma cells in vitro, imaged via MRI 
and FOI, and used for photothermal therapy. 
4.2 Experimental Methods 
FejC>4 Nanoparticles Fabrication: The 10 ± 3 nm magnetic Fe304 nanoparticles were 
1 "50 > 
fabricated by following a procedure previously reported. Briefly, 0.85 mL of 12.1 N 
HC1 (Fisher Scientific) and 25 mL of deionized, deoxygenated H2O (bubbled with N2 for 
30 mins) were mixed together. Subsequently, 5.2 g of anhydrous FeC^ (Sigma) and 2 g 
of FeCb (Sigma) are added in the solution under vigorous stirring. The brownish yellow 
solution is then added drop wise into 250 mL of 1.5 M NaOH solution under vigorous 
stirring. This step generated an instant black precipitate which was isolated in the 
magnetic field and the supernatant was removed by decantation. The precipitate was 
purified with deionized, deoxygenated H2O and centrifuged at 1000 rcf several times and 
the final precipitate was stored in a N2 environment for further characterization. 
Nanocomplexes Fabrication: Au nanoshells (NS) [ri, r2] = [60, 74] nm were fabricated as 
described in Chapter 1. The Fe304 nanoparticles were functionalized with APTES 
overnight under mild stirring. After 24 hours of stirring, the nanoparticles were 
centrifuged twice at 1000 rcf and re-dispersed in H2O. The amine terminated Fe304 
nanoparticles were then added to the NS (2xl09particles/mL) drop-wise under vigorous 
stirring and left overnight. The NS coated with the Fe304 nanoparticles (NS@Fe304) 
were washed to remove excess APTES and unbound Fe304 nanoparticles. NS@Fe304 
nanoparticles were then coated with a thin layer of silica to facilitate a biocompatible 
surface as well as to trap the fluorophore within the silica layer. The dye doped silica 
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layer was grown around the NS@Fe3C>4 nanoparticles by slight modification of a 
previously reported protocol.105 Briefly, NS@Fe3C>4 (2x109 particles/mL) were mixed 
with 200 proof ethanol and 28% NH4OH (Fisher) was subsequently added. Fresh TEOS 
was immediately added to the solution mixture under vigorous stirring followed by 500 
uL of an ethanolic solution of ICG-APTES mixture. The vessel was sealed and 
vigorously stirred for 45 minutes. The nanocomplexes were stored in the refrigerator at 4 
°C overnight protected from light. After 24 hours the particles were centrifuged and 
redispersed in ethanol. The absorbance of the supernatant was monitored to account for 
unbound fluorophore concentration in the supernatant. The concentration of the 
supernatant was then subtracted from the initial concentration of ICG which was added to 
the nanoparticles to calculate the amount of ICG doped within the silica layer of the 
nanocomplexes. The final nanocomplexes concentration after resuspension in ethanol 
was at ~ 109 particles/mL and the ICG concentration was ~ 500 ± 50 nM. The control 
sample, 180 nm SiC>2 nanospheres doped with ICG molecules was prepared similarly and 
contained almost equivalent amount of ICG. 
Anti-HER2 conjugation to nanocomplexes:The antibody conjugation is a three-step 
process; (i) anti-HER2 is biotinylated, (ii) nanocomplexes are coated with streptavidin 
and (iii) biotinylated antibodies are added to the streptavidin conjugated nanocomplexes. 
A. Anti-HER2 Biotinylation: A 1 mM solution of Sulfo-NHS-Biotin (Pierce) reagent 
was added to the antibody solution, anti-HER2 (c-erbB-2 / HER-2 / neu epitope specific 
rabbit antibody 200 |j.g/mL, Thermo Scientific). The biotin-antibody conjugate is 
incubated at 4 °C for 3 hours followed by dialysis in PBS (phosphate buffered saline, pH 
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7.4) to remove excess biotin. The ratio of biotin/antibody was determined with an HABA 
colorimetric assay and the measured concentration was 5-7 biotins per antibody. 
B. Streptavidin binding to nanocomplexes: The nanocomplexes were conjugated to 
streptavidin by initially functionalizing the nanocomplexes with (3-mercaptopropyl) 
triethoxysilane (MPTES, Sigma) to generate thiol terminated nanoparticles. These thiol 
terminated nanoparticles were re-dispersed in phosphate buffer at pH 7.5. Subsequently, a 
solution of streptavidin maleimide (Sigma) was added to the nanocomplexes and mildly 
stirred for 4 hours at 4 °C. The nanoparticles were centrifuged and resuspended in 5 mL 
phosphate buffer. 
C. Biotinylated anti-HER2 binding to Streptavidin conjugated nanocomplexes: The 
antibody-biotin conjugate prepared in part B is added to the streptavidin conjugated 
nanocomplexes and incubated overnight at 4 °C. The nanoparticles are centrifuged at 
300g for 5 mins in to remove unbound antibody and redispered in phosphate buffer. 
D. Number of antibodies per nanocomplexes: The number of antibodies per nanocomplex 
was quantified by utilizing ELISA. The nanocomplexes-anti-HER2 conjugates were 
incubated with horseradish peroxidase-labeled Anti-Rabbit IgG (HRP-AR, Sigma 
A0545) for 1 hour after non specific reaction sites were blocked with 3 % solution of 
bovine serum albumin (BSA, Sigma). The HRP bound nanocomplexes were developed 
with 3,3',5,5'-tetramethylbenzidine (TMB, Sigma) and compared with a HRP anti-rabbit 
IgG standard curve ranging from 0.02-0.0003125 |ig/ml. Results were analyzed using a 
spectrophotometer. 
Cell culture for FOI: SKBR3 Breast Adenocarcinoma Human (Homo sapiens) cells were 
grown in DMEM/F-12 50/50 IX (Dulbecco's Mod. of Eagle's Medium/Ham's F-12 
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50/50 mix with L-glutamine), 1% antibiotics and 10% fetal bovine serum (FBS). Cells 
were incubated at 37 °C in a 5% CO2 environment and were detached from culture with 
trypsin (0.05%) and EDTA(0.02%) and re-suspended in media for passaging to wells. 
The control cell line, MDA-MB-231 Breast Adenocarcinoma Human (Homo sapiens) 
cells were grown similarly at 37 °C in a 5% CO2 environment and were detached from 
culture with trypsin and EDTA and re-suspended in media for passaging to wells. 3xl05 
cells of SKBR3 and MDA-MB-231 were plated in each well of 4 well plates respectively, 
and allowed to incubate. Subsequently, cells were washed with IX PBS twice and fixed 
with PFA (3.7% paraformaldehyde in PBS). Cells were then quenched with Lysine-
periodate and permeabilized with 0.2 % triton, following which they were washed twice 
with PBS. Normal goat serum solution is PBS was added to each well plate and incubated 
for 15 mins, following which excess NGS was removed and the cells were incubated with 
nanocomplexes conjugated with anti-HER2 and control, unconjugated nanocomplexes at 
particle concentration 2xl09 particles/mL for 2 hrs at 4 °C. After 2 hours, the cells were 
washed with PBS to remove unbound nanocomplexes, and subsequently the secondary 
antibody, Goat Anti-rabbit IgG-Alexa Fluor 488 (Invitrogen) was added to the wells and 
incubated for 1 hr at 4 °C. The cells were again washed with PBS while protected from 
light and excess secondary antibody was removed. The cell plates were then mounted on 
slides with mounting media containing DAPI and prepared for fluorescence imaging. 
Cell Culture for MRI: lxl06 cells of SKBR3 and MDA-MB-231 were plated in each well 
of 6 well plates respectively, and allowed to incubate. A similar procedure was followed 
as described in section V. After removing excess normal goat serum, the cells were 
incubated with nanocomplexes conjugated with anti-HER2, and unconjugated 
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nanocomplexes at particle concentration 2xl09 particles/mL with - 0 . 1 8 mM Fe for 2 hrs 
at 4°C. After 2 hours, the cells were washed with PBS to remove unbound 
nanocomplexes. Subsequently, the cells were scraped from the bottom of the petridish, 
dispersed in 500 uL PBS, and centrifuged at 1100 rpm for 5 mins. The supernatant was 
then removed leaving ~ 100 uL cells containing nanocomplexes conjugated with anti-
HER2 and unconjugated nanocomplexes respectively in the eppendorf tubes. 400 uL of 
0.5% agarose gel was added to each tube and the samples were left at 4 °C for 10 mins to 
allow the agarose to solidify. The tubes containing the solidified agarose gel with the 
nanocomplexes bound to cells suspended within the gel were directly utilized for MRI. 
Cell Culture and Photothermal Therapy: lxl06 cells of SKBR3 and MDA-MB-231 were 
plated in each well of 6 well plates respectively, and allowed to incubate. 
Nanocomplexes-anti-HER2 conjugates as well as unconjugated nanocomplexes were 
dispersed in media (without FBS) at a concentration of 2 x 109 particles/mL and allowed 
to incubate with the SKBR3 cells and MDA-MB-231 cells for 2 hours. Following 
incubation, the cells were gently rinsed with PBS 3 times to remove unbound 
nanocomplexes and resuspended in media. The cells were then treated with a 200 mW 
laser diode with a wavelength of 808 nm at a power density of 3.72 W/cm2 and spot size 
of ~1 mm diameter for 10 minutes each. After laser irradiation the cells were incubated 
with media for 4 hrs. Subsequently, the cells were rinsed with PBS 3 times and then cell 
viability was assessed. Calcein-AM and propidium iodide (PI) was purchased from 
Sigma Aldrich. A 2 mM solution of calcein was prepared in anhydrous DMSO (Sigma) 
and stored at -20 °C. Calcein-AM in extremely sensitive to moisture and hydrolyses 
rapidly. Immediately before use, a solution mixture with 2 [iM calcein and 3 PI in 
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PBS was prepared and the cells were incubated with the dye mixture for 30 minutes. The 
cell plates were then mounted on slides and directly used for imaging without rinsing. 
Instrumentation: The nanocomplexes were characterized using scanning electron 
microscope (SEM). Images were obtained on a FEI Quanta 400 environmental SEM at an 
accelerating voltage of 25 kV. Extinction spectra were obtained using a Cary 5000 
UV/Vis/NIR spectrophotometer. X-ray diffraction (XRD) patterns were obtained using a 
Rigaku Ultima II vertical 0-9 powder diffractometer (CuKa, X = 1.5418 A). 
Magnetization measurements as a function of applied field were performed in a Quantum 
Design Magnetic Properties Measurement System (MPMS) superconducting quantum 
interference device (SQUID) magnetometer (Hmax = 70 kOe). The ICP-OES analysis 
were done using a Perkin Elmer inductively coupled plasma optical emission 
spectrometer the spectral range of 165-800 nm. Fluorescence emission spectra were 
obtained using Jobin Yvon Fluorolog 3 and the samples were excited at 780 nm. 
Fluorescence images were obtained on a Leica fluorescence microscope. The images 
were obtained using cutoff filters with appropriate excitation and emission wavelengths: 
Dye Excitation (nm) Emission (nm) 
DAPI 360 470 
Alexa Fluor 488 480 530 
ICG 720 820 
Calcein 480 530 
PI 520 620 
4.3 Characterization of Nanocomplexes 
A schematic representing the fabrication procedure of the nanocomplexes is shown in 
Figure 4.1 A. Water soluble Fe3C>4 nanoparticles were synthesized as previously 
reported139 and functionalized with (3-aminopropyl) triethoxysilane (APTES) molecules. 
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NS were then coated with amine terminated Fe3C>4 nanoparticles (NS@Fe304) and 
subsequently surrounded with a thin silica epilayer with the fluorophore, ICG, doped 
within the silica layer, forming the nanocomplexes. The SiC>2 layer not only traps the 
fluorophore but also encapsulates the Fe3C>4 nanoparticles, providing a chemically inert 
and biocompatible surface. ICG is stabilized within the protective silica shell which 
decreases photobleaching of the fluorophore due to interaction with aqueous media.90 The 
silica shell also allows straightforward conjugation of antibodies and other biomolecules 
for in vitro applications. 
Figure 4.1. (A) Schematic diagram illustrating fabrication of nanocomplexes for imaging 
and therapy. Au Nanoshells (NS) were coated with Fe3C>4 and SiC>2 with the fluorophore, 
ICG, doped within the Si02 layer. Low resolution SEM images of (B) NS [ri, r2] = [60, 
74] nm, (C) NS@Fe3C>4, where the Fe304 nanoparticles are 10 ± 3 nm in diameter, and 
(D) Nanocomplexes, where the SiC>2 layer is 10 ± 4 nm. Corresponding high resolution 
SEM images of (E) NS, (F) NS@Fe304, and (G) Nanocomplexes. 
Low resolution scanning electron microscopy (SEM) images of NS with 
dimensions [ri, r2] = [60, 74] nm, where ri is the radius of the silica core and r2 is the 
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radius of the Au shell, is shown in Figure 4.IB. A low resolution SEM image of NS 
coated with 10 ± 3 nm Fe3C>4 nanoparticles is shown in Figure 4.1C and nanocomplexes 
with a 10 ± 4 nm SiC>2 layer is shown in Figure 4.ID. The corresponding high resolution 
SEM images of the NS, NS@Fe3C>4, and nanocomplexes are shown in Figure 4.1E-G. 
Crystallographic studies of the nanocomplexes using powder X-ray diffraction (XRD) 
show strong Au peaks as well as Fe3C>4 peaks (Fig. 4.2A). The diffraction from Au 
dominates the pattern and the Fe304 peaks are relatively weaker, due to the heavy atom 
effect of Au. The Au peaks represent a cubic phase with cell parameters a = c = 4.0786 A 
and space group Fm3m (225) (JCPDS card no. 98-000-0230). The Fe3C>4 peaks observed 
in the XRD spectrum indicate a highly crystalline cubic phase of Fe304 with cell 
parameters a = c = 8.3969 A and space group Fd-3m (227) (JCPDS card no. 98-000-
0294). The corresponding XRD intensity profile of Au and Fe3C>4 from the powder 
diffraction database is also included for reference. Transmission electron microscope 
image and XRD spectrum of the Fe3C>4 nanoparticles is provided in Figure 4.3. 
The extinction spectra of NS, NS@Fe304, and the nanocomplexes are shown in 
Figure 4.2B. The plasmon resonances of the nanocomplexes are tuned to match the 
emission wavelength of the fluorophore to maximize the fluorescence enhancement of 
ICG.105 The NS have a plasmon resonance at 770 nm, which redshifts to 815 nm when 
coated with Fe304. This significant redshift is due to the higher refractive index of Fe3C>4 
QT 
(n=3) relative to H2O (n=1.33). The extinction spectrum shifts to 822 nm when the 
NS@Fe3C>4 nanoparticles are coated with additional silica. The corresponding emission 
spectrum of ICG doped within the silica layer of nanocomplexes is shown in Figure 
4.2C-i. The fluorescence maximum was observed at 820 nm. 
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Figure 4.2. (A) Powder XRD patterns of nanocomplexes and corresponding XRD 
intensity profile of Au and Fe304 from powder diffraction database. (B) Extinction 
spectra of (i) NS, Xmax ~ 770 nm, (ii) NS@Fe304, Xmax ~ 815 nm, and (iii) 
nanocomplexes, ^max ~ 822 nm. (C) Fluorescence (FL) spectra of (i) ICG doped within 
the silica layer of nanocomplexes, A,max-Em ~ 820 nm, and (ii) control, ICG doped within 
SiC>2 nanospheres. Optical image of nanocomplexes dispersed in aqueous media and with 
magnet (shown with arrow) is provided as inset. Magnetization as a function of applied 
magnetic field of nanocomplexes at (C) 5 K, (D) 300 K, and (E) 300 K where external 
magnetic field is cycled between -70 kOe to 70 kOe. 
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ICG doped within 180 nm diameter silica nanospheres, following a similar procedure as 
the nanocomplexes, was used as a reference sample rather than ICG in aqueous solution, 
to ensure the molecules are in similar chemical environments for fluorescence 
quantification. The fluorescence spectra were collected in solution under identical 
excitation and detection conditions, allowing direct comparison of the nanocomplexes 
with the reference sample. Additionally, excess dye was removed by centrifuging both 
sample types, and the supernatant was monitored to quantify the concentration of 
fluorophore present. A maximum fluorescence enhancement of ~ 45X is achieved for ~ 
500 ± 50 nM ICG doped within the silica layer of nanocomplexes relative to the 
reference sample. The enhancement of ICG by nanoshells observed in these complexes is 
comparable to that reported previously.105 
An optical image of the nanocomplexes dispersed in aqueous media is shown as 
an inset in Figure 4.2C. Upon placement of an Nd2Fel4B magnet next to the vial, the 
nanocomplexes collect near the magnet within ~2 hrs resulting in a transparent solution 
(shown in the adjacent optical image). The slower magnet-induced movement of the 
nanocomplexes compared to the as-fabricated Fe3C>4 nanoparticles (30 minute collection 
time) is expected due to relatively large diamagnetic mass of Au present on the 
nanocomplexes. 
In addition to their high quantum efficiency NIR fluorescence, the nanocomplexes 
also possess robust magnetic properties. The magnetization as a function of applied 
magnetic field at 5 K and 300 K is shown in Figure 4.2D-F. At 5 K, the thermal energy is 
insufficient to induce magnetic moment randomization, thus the nanoparticles show 
typical ferromagnetic hysteresis loops with remanence of 4.2 emug"1 and coercivity of 
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385 ± 10.2 Oe. However, at 300K the thermal energy is enough to randomize the 
magnetic moments, leading to a decrease in magnetization, thus the nanoparticles show 
no remanence or coercivity. 
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Figure 4.3. (A) TEM image of 10 ± 3 nm diameter Fe3C>4 nanoparticles. Scale bar is 100 
nm. (B) Powder X-ray diffraction patterns of Fe3C>4 nanoparticles and corresponding 
XRD intensity profile of Fe3C>4 from powder diffraction database. Magnetization as a 
function of applied magnetic field of Fe3C>4 nanoparticles at (C) 5 K, (D) 300 K, and (E) 
300 K where external magnetic field is cycled between -70 kOe to 70 kOe. At 5K the 
Fe3<D4 nanoparticles show a remanence of 18.3 emug"1 and coercivity of 424.2 ±1.6 Oe. 
At 300 K there is no remanence or coercivity which is typical superparamagnetic 
behavior. The saturation magnetization of the Fe304 nanoparticles is 58.2 emug"1. 
To evaluate the response of the nanocomplexes to an external magnetic field, the 
magnetization was measured at 300 K by cycling the field between -70 kOe and 70 kOe 
(Fig. 4.2F). The saturation magnetization, |asat, was determined to be 17.98 emug"1 at 70 
kOe, which is significantly higher than the pSat values reported for other Au-Fe304 or Au-
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y Fe2C>3 systems.60' 61' 140 The saturation magnetization of the nanocomplexes was 
observed to be lower than that of the Fe3C>4 nanoparticles, 58.2 emug"1, (Fig. 4.3), which 
is possibly due to the large diamagnetic mass of Au contributing to the total mass of the 
nanocomplexes. Additionally, the presence of canted or noncollinear surface spins, which 
has been observed in ferromagnetic materials with substituted diamagnetic neighbor 
cations, may also contribute to a decrease in saturation magnetization, since saturation of 
these spins usually requires a higher magnetic field.133'141'142 
4.4 Magnetic Resonance Analysis and Relaxivity 
MRI experiments were performed on a Bruker Avance Biospec, 9.4 T 
spectrometer, 21 cm bore horizontal imaging system (Bruker Biospin, Billerica, MA) 
with a 35 mm volume resonator. Two types of imaging experiments were carried out on 
the nanocomplexes dispersed in aqueous media with Fe3C>4 concentration ranging from 0 
mM to 0.2 mM. For each sample, a quantitative T2 measurement scan was conducted 
which consisted of a spin echo sequence with 8 echoes and TR/TE/IE equal to 
1000/10.29/10.29 ms with a Field of View (FOV) of 30x30 mm, slice thickness of 2 mm 
and an acquisition matrix of 256x256 yielding an in plane resolution of 120x120 (im. 
Additionally, a T2 weighted image was acquired for all samples at the same position. The 
T2 weighted scan had a spin echo sequence with a TR/TE equal to 2000/20 ms with 2 
averages. Acquisition was same as above with a FOV of 30x30 mm, slice thickness of 2 
mm and an acquisition matrix of 256x256 yielding an in plane resolution of 120x120 (im. 
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Figure 4.4. (A) T2-weighted MR images of nanocomplexes in aqueous media at various 
concentrations. The [Fe] concentration (mM) in each sample is provided at the bottom of 
the respective images. (B) MR image intensity as a function of echo time of 
nanocomplexes in aqueous media at various concentrations. (C) Spin-Spin relaxation rate 
( T 2 " 1 ) as a function of Fe concentration of nanocomplexes (color coordinated with 
reference to Figure 4.4B). r2 is the relaxivity obtained from the slope. 
Magnetic resonance (MR) images of the nanocomplexes were obtained at 9.4 
Tesla and 400 MHz. From the MR images the value of T2, the transverse, or spin-spin 
relaxation, was evaluated. The T2-weighted MR images (echo time = 20 msec) of the 
nanocomplexes in aqueous media with Fe concentrations ranging from 0 mM - 0.2 mM 
were obtained (Fig. 4.4A). The Fe concentrations in our nanocomplexes were determined 
by inductively coupled plasma optical emission spectrometry (ICP-OES). As the Fe 
concentration increases, the signal intensity of the MR images decreases, as expected for 
T2 contrast agents. T2 is determined from the slope of the normalized image intensity as a 
function of echo time (Fig. 4.4B). The increasing Fe concentration leads to a significant 
decrease in image intensity due to a shortening of the spin-spin relaxation time of water 
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(Fig. 4.4A, B). The specific relaxivity, r2, a measure of the change in spin-spin relaxation 
rate (T2_1) per unit concentration, was determined to be 390 mivr'sec"1 for the 
nanocomplexes (Fig. 4.4C). This high r2 could be due to the large external magnetic field 
(9.4 T) applied to the nanocomplexes, as well as their magnetic properties. Based on the 
SEM images and the amine functionalization protocol, a nearly saturated coverage of the 
NS surface with Fe3C>4 nanoparticles is estimated. Thus the interparticle distance between 
the Fe3C>4 nanoparticles bound to the nanoshell surface is probably extremely small, 
resulting in an increased magnetic interaction among the nanoparticles and an enhanced 
specific relaxivity. Some aggregation of Fe304 nanoparticles on the nanoshell surface 
may have occurred which would contribute in enhancing the relaxivity. Additionally, the 
porous silica shell present on the nanocomplexes may increase the molecular motion of 
H 20 within the pores and enhance the proton relaxation rate. Enhanced proton relaxation 
rates within porous silica matrices have been previously reported.143'144 These combined 
reasons could result in increased T2 shortening and a consequent increase in specific 
relaxivity. The MR images and r2 for the as-synthesized Fe304 nanoparticles is provided 
in Figure 4.5. 
The r2 values with increasing magnetic field strengths for superparamagnetic iron 
oxide (SPIO) and ultrasmall superparamagnetic iron oxide (USPIO) -based MRI contrast 
agents of various sizes is provided in Table 4.1 for comparision.145"150 It is worth noting 
that at high magnetic field strengths the two contrast agents approved by the US Food 
and Drug Administration (FDA), AMI-25 and Resovist, have a considerably lower r2 than 
the nanocomplexes we have synthesized. Some single modality contrast agents including 
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AMNP and USPIO (serial no.l) have been reported with relaxivities comparable to our 
nanocomplexes. 
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Figure 4.5. (A) T2-weighted MR images of Fe304 nanoparticles in aqueous media at 
various concentrations. The [Fe] concentration in each sample is provided at the bottom 
of the respective images. (B) MR image intensity as a function of echo time of Fe3C>4 
nanoparticles in aqueous media at various concentrations. (C) Spin - Spin relaxation rate 
(T2_1) as a function of Fe concentration (color coordinated with Fig. 4.5B). 
Table 4.1. Comparison of size and T2 relaxivity of nanocomplexes with various USPIO / 
SPIO agents at increasing magnetic field strengths 
Serial No. Agent Particle Size (nm) r2 Field (T) Ref. 
1 USPIO 20-100 410 mM'V 4.7 145 
2 AMI-25 (FDA) 120-180 132 mivr's"1 7 146 
3 USPIO 30 106 m M V 7 147 
4 SPIO 50 247 mM"'s"' 7 148 
5 AMNP 35 350 mM"'s"' 7 149 
6 Resovist (FDA) 62 280 mM-'s"1 9.4 150 
7 Nanocomplexes 185 390 mM-'s1 9.4 
93 
4.5 Antibody Conjugation and Quantification of number of Antibodies 
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Figure 4.6. (A) Schematic diagram showing anti-HER2 conjugation to nanocomplexes 
via streptavidin-biotin binding. (B) ELISA results showing number of biotinylated-anti 
HER2 antibodies bound per nanocomplexes which are functionalized with streptavidin, 
relative to the control sample, nanocomplexes without streptavidin. 
The efficacy of the nanocomplexes was also visualized in vitro by the molecular 
targeting of HER2+ breast cancer cells and performing MRI and FOI. As represented in 
the schematic diagram (Fig. 4.6A), the silica surface was terminated with thiols using a 
thiolated silane coupling agent, 3(mercaptopropyl) triethoxysilane, followed by covalent 
attachment of streptavidin maleimide. The maleimide group forms a thioester bond with 
the thiol on the silica surface. Anti-HER2 was initially biotinylated and then bound to the 
streptavidin conjugated nanocomplexes at physiological pH and 4 °C. The extraordinary 
affinity of avidin for biotin, (Ka =1015 M"1) the strongest known noncovalent interaction 
of a protein and ligand, is a practical and widely used nanoparticle bioconjugation 
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protocol. The number of antibodies attached to the nanocomplexes was quantified by 
enzyme-linked immunosorbent assay (ELISA) shown in Figure 4.6B. 
4.6 In vitro Magnetic Resonance Imaging 
The nanocomplex-anti-HER2 conjugates and the control, unconjugated nanocomplexes, 
were incubated with HER2+ cells, SKBR3, at a concentration of 2x109 particles/mL, 
containing 0.18 mM Fe nanoparticles (determined by ICP-OES). MDA-MB-231 cells, 
which have been reported to have very low HER2 expression,151 was also incubated with 
nanocomplex-anti-HER2 conjugates and unconjugated nanocomplexes. MR images of 
the incubated SKBR3 cells embedded in 0.5% agarose gel, in a microcentrifuge tube, are 
shown in Figure 4.7Ai-ii. High resolution in vitro images were obtained on eppendorf 0.5 
mL microcentrifuge tubes with cells suspended in 0.5% agarose using a 3D RARE (rapid 
acquisition with relaxation enhancement) sequence with a TR/TE equal to 2000/20 ms 
with a RARE factor of 8 leading to an effective TE of 60 ms. FOV was 20x20x10 mm 
with an acquisition matrix of 128x128x64 yielding an isotropic 156 |im resolution. 
The cells labeled with nanocomplexes clearly appear as hypointense spots, 
indicated that the nanocomplex-anti-HER2 conjugates were bound to SKBR3 cells (Fig. 
4.7Ai). Very few of the unconjugated nanocomplexes appeared to be bound to SKBR3 
cells (Fig. 4.7Aii). MR images of the nanocomplex-anti-HER2 conjugates and the 
unconjugated nanocomplexes incubated with MDA-MB-231 cells showed significantly 
less MR contrast, as expected (Fig. 4.7Aiii-iv). Since the outer silica shell of the 
nanocomplexes possesses an overall negative charge it may permit nonspecific binding of 
the unconjugated complex to the positively charged proteins present in cells. This level of 
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nonspecific binding could be ameliorated by refinement of the surface chemistry of the 
nanocomplex. 
Figure 4.7. (A) MR image of HER2 positive SKBR3 cells suspended in 0.5% agarose 
after incubating with (i) nanocomplexes-anti-HER2 conjugates with ~ 0.18 mM Fe3C>4 
and (ii) control, unconjugated nanocomplexes. MR images of HER2 negative MDA-MB-
231 cells suspended in 0.5% agarose after incubating with (iii) nanocomplexes-anti-
HER2 conjugates, and (iv) control. (B) Maximum intensity projection of 64x128x64 
pixel threshold T2 maps of the images corresponding to part B. (i) SKBR3 cells with 
nanocomplexes-anti-HER2 conjugates and (ii) control, (iii) MDA-MB-231 cells with 
nanocomplexes-anti-HER2 conjugates and (iv) control. The hypointense signals observed 
in parts B and C are the cells labeled with the nanocomplexes. 
The maximum intensity projections (MIP) of 64x128x64 pixel threshold T2 maps 
where each pixel represents the cubic volume of 156x156x156 |im are shown in Figure 
4.7Bi-iv. The MIP were created from the 3D MRI data using a threshold segmentation 
approach in MATLAB® (2008a, The Mathworks, Natick, MA). The threshold was set at 
the average minus twice the standard deviation of the sample. Pixels under this value 
were considered to be hypointense and are labeled as black in the image. The surrounding 
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normointense agarose is labeled as a transparent pink. The hypointense pixels represent 
the nanocomplex-labeled cells and the normointense pixels represent agarose. Each 
hypointense pixel should contain a cluster of labeled cells since the scan resolution is 
insufficient to identify individual cells. The number of hypointense pixels was quantified 
to determine the specificity and selectivity of the nanocomplex-anti-HER2 conjugates in 
targeting HER2+ carcinoma cells. Both the MDA-MB-231 and SKBR3 cells that had 
been incubated with the unconjugated nanocomplexes showed approximately equal 
counts of hypointense pixels. The MDA-MB-231 cells incubated with nanocomplex-anti-
HER2 had 6.5X the number of hypointense pixels relative to the cell samples incubated 
with unconjugated nanocomplexes. In contrast, SKBR3 cells incubated with 
nanocomplex-anti-HER2 conjugates had 26X the number of hypointense pixels relative 
to SKBR3 cells incubated with the unconjugated nanocomplexes. SKBR3 cells incubated 
with nanocomplex-anti-HER2 conjugates also had 4X the number of hypointense pixels 
as the MDA-MB-231 cells incubated with the nanocomplex-anti-HER2 conjugates. 
4.7 In vitro Fluorescence Optical Imaging 
The targeting of the multimodality nanocomplex-antibody conjugates to tumor cells in 
vitro was further confirmed by fluorescence optical imaging. Fluorescence images of 
SKBR3 cells and MDA-MB-231 cells incubated with nanocomplex-anti-HER2 
conjugates and unconjugated nanocomplexes were obtained, as shown in Figure 4.8. An 
image of the DAPI-stained nuclei of SKBR3 cells is shown in Figure 4.8A (blue). The 
cytoplasm marker, a secondary antibody conjugated with visible dye (Goat Anti-rabbit 
IgG-Alexa Fluor 488) is shown in Figure 4.8B (green), and the NIR fluorescence image 
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of the nanocomplex-anti-HER2 conjugate sample, is shown in Figure 4.8C (red). After 2 
hour incubation with SKBR3 cells, the nanocomplexes appear to be specifically bound to 
the cell membrane, as observed in the merged fluorescence image (Fig. 4.8). 
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Figure 4.8. Fluorescence images of SKBR3 cells showing (A) nuclei stained with DAPI 
(blue) (B) cytoplasm stained with secondary antibody-Alexa-fluor 488 (green), (C) NIR 
fluorescence by ICG doped in silica layer of nanocomplexes-anti-HER2 conjugates (red), 
and (D) A, B, C merged together showing the nanocomplexes binding outside the cells. 
(E) Control, unconjugated nanocomplexes. Some non-specific binding was observed for 
the control. Fluorescence images of HER2 negative MDA-MB-231 cells showing (F) 
nanocomplexes-anti-HER2 conjugates and (G) control. Some non-specific binding to the 
extracellular matrix was observed for both nanocomplexes-anti-HER2 conjugates and 
control. 
A small amount of the unconjugated nanocomplexes also appeared to be attached 
to the SKBR3 cells (Fig. 4.8E). In this case, with the absence of the primary antibody 
(anti-HER2), the secondary antibody does not bind as well, resulting in no observable 
signal from the Alexa Fluor 488. Nanocomplex-anti-HER2 conjugates were also 
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incubated with MDA-MB-231 cells (Fig. 4.8F). In this case, only a small fraction of 
nanocomplex-anti-HER2 conjugates were observed to associate with the extracellular 
matrix, resulting in a very weak NIR signal. Again, without the presence of the primary 
antibody the secondary antibody did not bind significantly, resulting in a low Alexa Fluor 
488 signal. The unconjugated nanocomplex incubated with MDA-MB-231 cells also did 
not associate appreciably with the cell membrane (Fig. 4.8G). This sequence of control 
experiments demonstrates that the nanocomplex-anti-HER2 conjugates target HER2+ 
cells with significant specificity. 
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4.8 In vitro Photothermal Therapy 
Figure 4.9. Photothermal ablation and live/dead stain of SKBR3 cells incubated with (A) 
nanocomplexes-anti-HER2 conjugates and (B) control, unconjugated nanocomplexes and 
treated with NIR laser at 808 nm for 10 minutes at a power density of 3.72 W/cm2 and 
spot size of ~ 1 mm diameter. Live cells are stained green with calcein and dead cells are 
stained red with propidium iodide. Similar staining procedure for MDA-MB-231 cells 
incubated with (C) nanocomplexes-anti-HER2 conjugates and (D) control, and treated 
with NIR laser as well. 
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In addition to HER2-specific targeting, MRI and fluorescence enhancement, the 
nanocomplexes also demonstrated the therapeutic function of photothermally induced 
ablation in vitro. SKBR3 cells and MDA-MB-231 cells were incubated with 
nanocomplex-anti-HER2 conjugates and the unconjugated nanocomplex for 2 hours. The 
nanocomplexes were suspended in media appropriate for the cell line prior to incubation 
at a concentration of 2xl09 particles/mL. Photothermal therapy was performed using a 
200 mW laser diode with a wavelength of 808 nm at a power density of 3.72 W/cm2 and 
a spot size of ~ 1 mm for 10 minutes. 
The cells were incubated with a solution mixture of calcein AM (live cell stain) 
and propidium iodide (PI) (dead cell stain) for 30 minutes prior to imaging. Calcein AM 
is a cell-permeant, non-fluorescent compound which enters the cells and is hydrolyzed by 
intracellular esterases in live cells into the green fluorescent calcein. PI is membrane 
impermeant for live cells and binds to the DNA (and nucleic acids) of dead cells by 
intrabase intercalation, generating red fluorescence. The cells stained with Calcein/PI 
after treatment with NIR laser are shown in Figure 4.9. The nanocomplex-anti-HER2 
conjugates were specifically bound to the cell membrane of the SKBR3 cells; upon laser 
irradiation the nanocomplexes produced hyperthermia, resulting in cell death. The 
increased PI uptake by the dead cells within the laser spot is clearly observed (Fig. 4.9A). 
MDA-MB-231 cells incubated with nanocomplex-anti-HER2 conjugates were also 
exposed to the same NIR laser treatment for 10 minutes, and showed minimal cell death 
(Fig. 4.9C). A nominal amount of the unconjugated nanocomplex was nonspecifically 
bound to both the SKBR3 cells as well as the MDA-MB-231 cells, and resulted in some 
cell death after laser treatment (Fig. 4.9B, D). Nanocomplexes by themselves, without 
100 
photothermal ablation, were observed to be innocuous to cells and no cell cytotoxicity 
was observed (data not shown). 
4.9 Conclusions 
In conclusion, we have designed a multimodal theranostic with bright NIR fluorescence 
for fluorescence image enhancement, MR contrast enhancement, antibody targeting of 
HER+2 cells, and photothermal therapy of breast cancer cells in vitro. The NS enhance 
the fluorescence of ICG while efficiently integrating Fe3C>4 nanoparticles into the 
requisite silica spacer layer between the metallic shell layer and the ICG fluorophore, 
resulting in a contrast agent with high fluorescence quantum yield as well as high specific 
relaxivity. These properties may potentially allow the use of lower nanoparticle doses for 
contrast enhancement both in vitro and in vivo. The high relaxivity observed for this 
nanocomplex may also be valuable for cell trafficking studies as well as detection of 
single magnetically labeled cells. Nanoparticles in the size range of 20-200 nm have been 
also shown to accumulate preferentially at tumor sites through an enhanced permeability 
and retention effect.152 Therefore these nanocomplexes may be practical prospects for 
theranostics of small tumor volumes in vivo. The bioconjugation techniques utilized in 
this study are straightforward and can be conveniently generalized to bind other 
antibodies and peptides which may be useful for targeting different cancer cell lines. 
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Chapter 5: A Molecularly Targeted Theranostic Probe for 
Ovarian Cancer 
5.1 Introduction 
The targeting, diagnostics and therapeutic capability of the nanocomplexes 
discussed in last chapter can be straightforwardly extended for the detection and 
treatment of other cancer cells. In this chapter, we have explored the theranostic 
capabilities of the nanocomplexes for targeting, multimodal imaging via MRI and FOI, 
and photothermal cancer therapy of HER2 expressing ovarian cancer cells at the cellular 
level. This study provides an important strategy for the diagnosis and treatment of ovary 
cancer which is specifically important due to the aggressiveness of ovarian cancer, lack 
of early detection, chemotherapeutic resistance as well as resistance to many clinically 
relevant drugs. Rizia Bardhan prepared the nanocomplexes, characterized them, and 
contributed in FOI and cancer therapy in vitro. Wenxue Chen performed cell culture, 
FOI, MRI and cancer therapy in vitro. Reproduced with permission from Wenxue Chen*, 
Rizia Bardhan*, Marc Bartels, Carlos Perez-Torres, Robia G. Pautler, Naomi J. Halas, 
and Amit Joshi, Mol. Cancer Therapeutics, 2010, in press (*equal contribution). 
Copyright 2010 American Association for Cancer Research. 
Epithelial ovarian cancer is the most lethal gynecologic malignancy, and is the 
fourth most frequent cause of cancer-related death of women in Western countries. In 
2008, there were 21,650 new cases of ovarian cancer and 15,520 deaths reported in the 
United States. However, the difficulty in detecting ovarian cancer at an early stage, 
aggressiveness, and the lack of effective therapy contribute to high mortality.154 Currently 
recognized prognostic factors in advanced ovarian cancer (AOC) are primarily clinical, 
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including patient performance status and characteristics of tumor volume, stage classified 
by the International Federation of Gynecology and Obstetrics (FIGO), residual tumor size 
after initial surgery, and presence of ascites. However, most prognostic models proposed 
in the literature do not include biological factors.155 In 2004, Camilleri-Broet and 
coworkers studied HER2 overexpression in ovarian cancer by using 
immunohistochemically paraffin-embedded tissues and analyzed the prognostic impact of 
HER2 protein level. They found an independent prediction with both overall and disease-
free survival on multivariate analysis.156 HER2 is frequently overexpressed in ovarian 
cancer patients; the overexpression rate has been reported in a wide range from 8% to 
66%.156-160 The 66% figure was reported by fluorescence in situ hybridization (FISH) 
study in 74 cases;160 53% in 181 cases,159 22% in 23 cases,158 and 16% in 95 cases.156 
Dimova et al.157 analyzed multiple samples applying the highly reliable method of FISH 
on tissue microarray, containing 1006 ovarian tumors and reported 8% HER2 
amplifications in ovarian malignant epithelial tumors. HER2 overexpression is associated 
with a poor prognosis due to acquired chemotherapy resistance. In this work, HER2 
expressing cell line OVCAR3 was chosen because it was isolated from a malignant 
effusion, which is resistant to clinically relevant doses of cyclophosphamide, adriamycin, 
and cisplatin.161' 162 Studies on these cells would hence be particularly promising for 
demonstrating molecularly targeting and photothermal therapy. 
The design and development of novel nanoagents that synergistically incorporate 
multiple functionalities, including targeting, imaging and therapy, all within the same 
nanoprobe is emerging rapidly as an impending alternative to traditional therapeutic 
drugs and imaging agents. This promising new paradigm is hence termed as 
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"Theranostic" which entails the efficient integration of therapeutic and diagnostic 
moieties into a single nanoagent. Nanoparticles in the size range of 5-250 nm are 
effective interventional agents for cancer because of their unique size, which allows 
passive accumulation in tumors, and because of their ability to carry multiple diagnostic 
and therapeutic payloads. The majority of clinical trials involving nanoparticles focus on 
targeted chemotherapy delivery, because despite the emerging molecular medicine 
based shift towards cancer-specific cytostatic agents, cytotoxic chemotherapy is still 
considered more effective against broad patient populations. While nanocarrier-based 
chemotherapy can minimize traditional side effects, it is not externally controlled and in 
the case of liposomes, which have been approved since the 1990s, the inability to 
guarantee intracellular drug delivery often results in treatment failure. 
Recently, some theranostic nanoprobes have been synthesized with complex 
geometries164"168 however, their capability has been mostly limited to a single imaging 
modality such as either MRI or optical imaging. We have designed and utilized a 
multifunctional Au nanoshell-based theranostic complex (nanocomplex) to actively 
target, image via MRI and FOI, and induce photothermal tumor ablation in breast cancer 
cells with NIR illumination1. In this study, we demonstrate the efficacy of these 
nanocomplexes for simultaneous diagnosis and therapy of ovarian cancer cells in vitro 
and further demonstrate the non-toxicity of NIR therapy and the nanocomplexes. The 
nanocomplex consist of a Au nanoshell encapsulated in a Si02 shell, which is doped with 
Fe304 nanoparticles and a NIR emitting fluorophore ICG. Au nanoshells are optically 
1 9 tunable nanoparticles consisting of a Si02 core surrounded by a thin Au shell. Based on 
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the relative dimensions of the shell thickness and core radius, nanoshells can be designed 
to scatter and/or absorb light over a broad spectral range, including the NIR. The NIR 
wavelength region provides maximal penetration of light through soft tissue, including 
hypoxic regions in tumors, and irradiation of tumors with NIR laser light can lead to 
thermal ablation.15 ICG molecules, with a quantum yield of ~ 1.3% in aqueous media, 
when incorporated into the oxide layer just outside the gold shell, the nanoshell enhances 
the fluorescence quantum yield by nominally 4500%, resulting in a very bright NIR 
fluorescent probe.105 The Fe3C>4 nanoparticle layer concurrently provides a high MR 
contrast thus enabling multimodal imaging with the same agent. Accumulation of 
nanoshells in tumor cells can be achieved via passive extravasation based on the EPR of 
1 
small particles associated with the leaky tumor vasculature. However, when targeted 
using antibodies against oncoproteins overexpressed on cell surfaces, a higher 
concentration of nanoshells can be selectively bound to cell surfaces and enable extended 
periods of imaging as well as therapy. 
The photothermal properties of nanoshells are attributed to their ability to absorb 
NIR light at their plasmon resonant wavelength, due to their large absorption cross 
section, efficiently converting the light energy to heat. The heat generated by the 
nanoshells raises the local temperature in their direct vicinity, resulting in the thermal 
ablation of cancer cells.17, 169 In particular, targeted nanoshells will accumulate at the 
specific tumor site, enabling photothermal therapy of cancer cells only, and greatly 
minimizing damage to adjacent healthy cells. In this study, we have demonstrated that 
NIR laser irradiation at low power densities, as well as nanoshells by themselves, are 
non-toxic and do not induce cytotoxicity. These molecularly targeted nanocomplexes are 
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highly promising and clinically relevant for providing molecule-specific diagnostic 
information that will enable the detection and treatment of cancer long before phenotypic 
changes occur. In practice, this will provide an efficient tool for the detection of tumors at 
an early stage and provide a benign therapeutic strategy for cancer treatment. 
5.2 Experimental Methods 
Anti-Her2 conjugated Nanocomplexes: Au nanoshells (NS) [ri, r2] = [60, 74] nm were 
fabricated as described in chapter 1. The nanocomplexes were developed as described 
previously in chapter 4. Anti-HER2 (c-erbB-2) / HER-2 / neu epitope specific rabbit 
antibody 200 |J.g/mL, Thermo Scientific) was conjugated to the nanocomplexes similarly 
as described in chapter 4. The number of antibodies was quantified by ELISA. 
In Vitro Fluorescence Optical Imaging: OVCAR3 Ovarian Adenocarcinoma Human 
(Homo sapiens) cells, and the control cell line, MDA-MB-231 Breast Adenocarcinoma 
Human (Homo sapiens) cells were grown in MEM/F-12 50/50 I* (Dulbecco's Mod. of 
Eagle's Medium/Ham's F-12 50/50 mix with L-glutamine), 1 % antibiotics and 10 % 
fetal bovine serum (FBS). Cells were incubated at 37 °C in a 5 % C02 environment and 
were detached from culture with trypsin (0.05 %) and EDTA (0.02 %) and resuspended 
in media for passaging to wells. 3><105 cells of OVCAR3 and MDA-MB-231 were plated 
in each well of 4 well plates respectively, and allowed to incubate. Subsequently, cells 
were washed with lxPBS twice and fixed with PFA (3.7 % paraformaldehyde in PBS). 
Cells were then quenched with Lysine-periodate and permeabilized with 0.2 % triton, 
following which they were washed twice with PBS. 10 % Normal Goat Serum(NGS) 
solution was added to each well plate and incubated for 15 min, following which excess 
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NGS was removed and the cells were incubated with nanocomplex-anti-HER2 conjugates 
and unconjugated nanocomplexes at particle concentration 2x 109 particles/mL for 2 h at 4 
°C. After 2 h, the cells were washed with PBS to remove unbound nanocomplexes, 
following which the secondary antibody, Goat Anti-Rabbit IgG-Alexa Fluor 488 
(Invitrogen) was added to the wells and incubated for 1 h at 4 °C. The cells were again 
washed with PBS while protected from light for excess secondary antibody removal. The 
cell plates were then mounted on slides with mounting media containing DAPI 
(Invitrogen) and prepared for FOI. 
In Vitro MRI: 1*1Q6 cells of OVCAR3 and MDA-MB-231 were plated in each well of 
60x15 mm Style cell culture dishes respectively, and allowed to incubate. A similar 
procedure was followed as described in section III. After 2 h incubation with the 
nanocomplexes, the cells were washed with PBS, followed by scraping the cells from the 
bottom of the petri dish, dispersed in 500 p,L PBS, and centrifuged at 1100 rpm for 5 min. 
The supernatant was then removed leaving -100 p.L cells containing nanocomplex-anti-
HER2 conjugates, and unconjugated nanocomplexes in the Eppendorf tubes respectively. 
500 (iL of 0.5 % agarose gel was added to each tube and the samples were left at 4 °C for 
10 min to allow the agarose to solidify. The tubes containing the solidified agarose gel 
with OVCAR3 and MDA-MB-231 cells, with the nanocomplexes suspended within the 
gel were directly utilized for MR Imaging. 
In Vitro Photothermal Therapy and Cytotoxicity: OVCAR3 and MDA-MB-231 cells 
were grown in 6 wells plate and incubated with either nanocomplex-anti-HER2 
conjugates or unconjugated nanocomplexes, which were already suspended in media 
appropriate for the cell line at a concentration of 2x109 particles/mL. Cells were 
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incubated with nanocomplexes for 2 h and then washed with PBS. Laser ablation was 
performed using an NIR laser at 808 nm (L808P200, Thorlabs Inc.) for 10 min at a power 
density of 5.81 W/cm2 and spot size of ~0.8 mm diameter. After irradiation, cells were 
rinsed gently with PBS and incubated with media for 4 h. Cell viability was assessed 
using Calcein to stain live cells and propidium iodide (PI) to stain dead cells. A dye 
solution mixture containing 3 |iM PI and 2 (iM Calcein was prepared and 150 |iL was 
added to each well with nanocomplexes which were photothermally ablated. For 
cytotoxicity studies, cells were incubated with nanocomplexes-anti-HER2 conjugates, 
unconjugated nanocomplexes, and no nanocomplexes. These cells were not illuminated 
with the NIR laser. After incubating the cells with Calcein/PI mixture for 30 min at 37 
°C, a cover slip was mounted and imaged. In this stain, calcein AM enters the cells and is 
cleaved by esterases in the live cells to yield cytoplasmic green fluorescence. Dead cells 
are determined by plasma membrane integrity. This can be assessed in two ways: The 
ability of a cell to prevent a fluorescent dye from entering it and the ability of a cell to 
retain a fluorescent dye within it. As a cell dies, its plasma membrane becomes permeable 
enabling fluorescent dyes enter the cell. This allows PI to enter and bind to nucleic acids 
generating red fluorescence. PI is membrane impermeant and excluded from viable cells. 
Instrumentation: MRI experiments were performed on a Bruker Avance Biospec, 9.4 T 
spectrometer, 21 cm bore horizontal imaging system (Bruker Biospin, Billerica, MA) 
with a 35 mm volume resonator. Extinction spectra were obtained using a Cary 5000 
UV/Vis/NIR spectrophotometer. The ICP-OES analysis were done using a Perkin Elmer 
inductively coupled plasma optical emission spectrometer the spectral range of 165-800 
nm. Fluorescence emission spectra were obtained using Jobin Yvon Fluorolog 3 and the 
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samples were excited at 780 nm. To acquire the fluorescence images we used a Leica 
fluorescence microscope (DM6000 B; Leica Microsystems GmbH) with a 100 W xenon 
lamp and specific filters. The images were obtained using cutoff filters with appropriate 
excitation and emission wavelengths (chapter 4). 
5.3 Properties of Nanocomplexes 
' Anti-HER2 ^ ^ s t r e p t a v i d i n # Iron oxide 
, Biotin indocyanine Green Sil ica^old nanoshells 850 900 950 
Wavelength [nm] 
Figure 5.1. (A) Schematic representation of anti-HER2 conjugated nanoshell contrast 
agents. (B) Extinction spectra of nanoshells (blue) resonant in the NIR at 777 nm, 
nanoshells after coating with Fe3C>4 (red) resonant at 821 nm, and after encapsulating in a 
silica SiC>2 epilayer (green) resonant at 842 nm. (C) Fluorescence spectrum of ICG doped 
in the silica layer of the nanoshells at 833 nm. 
A schematic illustration of the nanocomplexes conjugated with antibody is 
depicted in Figure 5.1 A. Au Nanoshells (NS) were surrounded with thin 10 - 15 nm) 
epilayers of Si02 doped with the fluorophore, ICG, and Fe3C>4 nanoparticles. This was 
followed by streptavidin binding and biotinylated anti-HER conjugation of the 
nanocomplex. Normalized extinction spectra of the NIR resonant nanoshells, nanoshells 
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after coating with Fe304 and after encapsulating in a silica epilayer, are shown in Figure 
5. IB. Fluorescence spectra of ICG doped in the silica layer of the nanocomplexes at 833 
nm is shown in Figure 5.1C. These nanocomplex spectral characteristics provide a better 
understanding of their functions as imaging probes as well as a therapeutic agent. 
5.4 In vitro Fluorescence Optical Imaging 
The efficacy of the targeted nanocomplexes-anti-HER2 conjugates to provide image 
contrast for tumor cells in vitro was established by fluorescence optical imaging. 
Fluorescence images of OVCAR3 cells and MDA-MB-231 cells incubated with 
nanocomplex-anti-HER2 conjugates and unconjugated nanocomplexes were obtained. 
MDA-MB-231 Breast Adenocarcinoma Human (Homo sapiens) cells were chosen as a 
control due to the low levels of HER2 expression present in this cell line.170' 171 Low 
levels of HER2 expression were used to assign the cell lines into previously clinically 
defined subtypes, which can be used to guide clinical trial design.172-174 The fluorescence 
optical images of HER2 positive OVCAR3 cells with nanocomplex-anti-HER2 
conjugates are shown in Figure 5.2A where (i) depicts nuclei stained with DAPI (blue), 
(ii) cytoplasm stained with Alexa Fluor 488 conjugated secondary antibody Goat Anti-
Rabbit IgG (green), (iii) NIR fluorescence from ICG doped in silica layer of 
nanocomplexes (red), and (iv) i, ii, iii merged together showing the nanocomplexes 
binding outside the cells membrane. 
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Figure 5.2. (A) Fluorescence optical images of HER2 overexpressing OVCAR3 cells 
with nanocomplex-anti-HER2 conjugates showing (i) nuclei stained with DAPI (blue) (ii) 
cytoplasm stained with secondary antibody-Alexa-fluor 488 (green), (iii) NIR 
fluorescence from ICG doped in silica layer of nanocomplexes (red), and (iv) i, ii, iii 
merged together showing the nanocomplex-anti-HER2 conjugates binding outside the 
cells membrane. (B) Fluorescence optical images of OVCAR3 cells with the control, 
unconjugated nanocomplexes. Fluorescence optical images of HER2 low expressing 
MDA-MB-231 cells with (C) nanocomplex-anti-HER2 conjugates and (D) control. 
Original magnification is x400 and the scale bar is 10 pm for all panels. 
After 2 hr incubation with OYCAR3 cells, the nanocomplex-anti-HER2 
conjugates show specific binding to the cell membrane. Figure 5.2B shows the 
fluorescence images of OVCAR3 cells incubated with the control, unconjugated 
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nanocomplexes (without antibodies). Due to the absence of the primary antibody (anti-
HER2), the secondary antibody did not bind and no signal was observed from the Alexa 
Fluor 488. Fluorescence images of low HER2 expressing MDA-MB-231 cells with 
nanocomplex-anti-HER2 conjugates and with the control are shown in Figure 5.2C and 
5.2D. The nanocomplex-anti-HER2 conjugates showed minimal non-specific binding to 
the extracellular matrix of MDA-MB-231 cells, resulting in a very weak NIR signal from 
the ICG. Similarly, without the primary antibody, the secondary antibody did not bind as 
well leading to low fluorescence from Alexa Fluor. The unconjugated nanocomplex 
incubated with MDA-MB-231 cells also did not bind to the cell membrane. This 
sequence of experiments demonstrate that the nanocomplex-anti-HER2 conjugates 
significantly target HER2-overexpressing OVCAR3 cells membrane in comparison with 
MDA-MB-231 cells, which express low levels of HER2. 
5.5 In vitro Magnetic Resonance Imaging 
The nanocomplex-anti-HER2 conjugates and unconjugated nanocomplexes were 
incubated with OVCAR3 cells and MDA-MB-231 cells at a concentration of 2x109 
particles/mL, containing 0.215 mM Fe nanoparticles (determined by ICP-OES). The 
schematic representation of sample preparation for in vitro MRI studies is shown in 
Figure 5.3Ai. Briefly, cells are incubated with nanocomplexes suspended in media for 2 
hrs and subsequently centrifuged and redispersed in 0.5% agarose. Optical image of 
OVCAR3 cells bound to nanocomplex-anti-HER2 conjugates suspended in agarose, and 
OVCAR3 cells suspended with unconjugated nanocomplexes in agarose are shown in 
Figure 5.3Aii and 5.3Aiii. 
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Figure 5.3. (A) (i) Schematic representation of sample preparation for in vitro MRI 
studies. Magnetic nanocomplexes are incubated with cells, washed after 2 h, centrifuged 
and suspended in 0.5 % agarose. Optical image of (ii) cells with nanocomplex-anti-HER2 
conjugates suspended in agarose, and (iii) cells with control, unconjugated 
nanocomplexes suspended in agarose. MR image of OYCAR3 cells suspended in 0.5 % 
agarose with (B) nanocomplex-anti-HER2 conjugates and (C) control, unconjugated 
nanocomplexes. MR images of MDA-MB-231 cells suspended in 0.5 % agarose with (D) 
nanocomplex-anti-HER2 conjugates, and (E) control. Maximum intensity projection of 
128x128x64 pixel threshold T2 maps of the images corresponding to part B-E. (F) 
OVCAR3 cells with nanocomplex-anti-HER2 conjugates and (G) control, (H) MDA-
MB-231 cells with nanocomplex-anti-HER2 conjugates and (I) control. 
In Figure 5.3B, MR images of OVCAR3 cells suspended in agarose with nanocomplex-
anti-HER2 conjugates are shown. In vitro imaging of cells suspended in agarose was 
done using a 3D RARE (rapid acquisition with relaxation enhancement) sequence with a 
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TR/TE equal to 2000/20 ms with a RARE factor of 8 leading to an effective TE of 60 ms. 
FOV was 25.6x25.6x12.8 mm with an acquisition matrix of 128x128x64 yielding an 
isotropic 200 (am resolution. The cells labeled with nanocomplexes appear as hypointense 
signal (dark spots) or higher contrast, suggesting that the nanocomplex-anti-HER2 
conjugates were bound to OVCAR3 cells. OVCAR3 cells incubated with unconjugated 
nanocomplexes (fig 5.3C) show a few hypointense signals, indicating minimal 
nonspecific binding. MR images of MDA-MB-231 cells suspended in agarose with 
nanocomplex-anti-HER2 conjugates (fig 5.3D) clearly show less binding in comparison 
to OVCAR3 cells. Additionally, MDA-MB-231 cells incubated with the control (fig 
5.3E) also demonstrate nominal nonspecific binding. 
The maximum intensity projections (MIP) of 128x128x64 pixel threshold T2 
maps, where each pixel represents the cubic volume of 156x156x156 |im, are shown in 
Figure 5.3F-I. The MIP were created from the 3D MRI data using a threshold 
segmentation approach as described in section VI. The hypointense pixels (brown spots) 
represent the nanocomplex-labeled cells and the surrounding normointense pixels (blue) 
agarose. The OVCAR3 cells labeled with nanocomplex-anti-HER2 conjugates are shown 
in Figure 5.3F and the control, unconjugated nanocomplexes, are shown in Figure 5.3G. 
MDA-MB-231 cells labeled with nanocomplex-anti-HER2 conjugates are shown 
in Figure 5.3H and the control is shown in Figure 5.31. Each hypointense pixel 
represented here contains a cluster of labeled cells since the scan resolution is insufficient 
to identify individual cells. The number of hypointense pixels was quantified to 
determine the specificity and selectivity of the nanocomplex-anti-HER2 conjugates in 
targeting HER2 expressing cells. Both the MDA-MB-231 and OVCAR3 cells that had 
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been incubated with the unconjugated nanocomplexes showed approximately equal 
counts of hypointense pixels, which are nonspecific binding. The MDA-MB-231 cells 
incubated with nanocomplex-anti-HER2 had 2.3 times the number of hypointense pixels 
relative to the cell samples incubated with unconjugated nanocomplexes. On the contrary, 
OVCAR3 cells incubated with nanocomplex-anti-HER2 conjugates had 9.0 times the 
number of hypointense pixels relative to OVCAR3 cells incubated with the unconjugated 
nanocomplexes. OVCAR3 cells incubated with nanocomplex-anti-HER2 conjugates also 
had 3.1 times the number of hypointense pixels as the MDA-MB-231 cells incubated 
with the nanocomplex-anti-HER2 conjugates. 
5.6 In vitro Photothermal Therapy and Cytotoxicity Studies 
The photothermal ablation of OVCAR3 cells incubated with nanocomplex-anti-HER2 
conjugates allowing targeted destruction is shown in Fig. 5.4. Both OVCAR3 and MDA-
MB-231 cells incubated with the nanocomplexes-anti-HER2 conjugates and 
unconjugated nanocomplexes were illuminated with NIR laser light at 808 nm for 10 min 
at a power density of 5.81W/cm2 and a spot size of -0.8 mm diameter. Following 
photothermal therapy, cells were stained with the Calcein/PI mixture. Live cells appeared 
green due to the calcein stain and dead cells appeared red due to the PI stain (Fig. 5.4). 
The nanocomplex-anti-HER2 conjugates, which were bound to the OVCAR3 cell 
membrane, produced hyperthermia upon laser irradiation, resulting in cell death (Fig. 
5.4A). The increased PI uptake by the dead cells within the laser spot is clearly 
observable. 
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Figure 5.4. Photothermal ablation and live/dead stain of OVCAR3 cells incubated with 
(A) nanocomplex-anti-HER2 conjugates and (B) control, unconjugated nanocomplexes 
and treated with NIR laser at 808 nm for 10 min at a power density of 5.81 W/cm2 and 
spot size of ~0.8 mm diameter. Live cells are stained green with calcein and dead cells 
are stained red with propidium iodide. Similar staining procedure for MDA-MB-231 cells 
incubated with (C) nanocomplex-anti-HER2 conjugates and (D) control, and treated with 
NIR laser as well. Original magnification is xlOO and scale bar is 250 (j.m for all panels. 
MDA-MB-231 cells incubated with nanocomplex-anti-HER2 conjugates were also 
exposed to the same NIR laser treatment, and showed minimal cell death (Fig. 5.4C). A 
small amount of the unconjugated nanocomplexes was nonspecifically bound to both the 
OVCAR3 cells and the MDA-MB-231 cells, and resulted in some cell death after laser 
treatment (Fig. 5.4B and D). Irradiation of OVCAR3 cells incubated with nanocomplex-
anti-HER2 conjugates with NIR laser resulted in selective destruction of these cells. In 
contrast, MDA-MB-231 cells incubated with nanocomplex-anti-HER2 conjugates 
showed no observable effects on cell viability. 
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Figure 5.5. Cytotoxicity studies of OVCAR3 cells incubated with (A) nanocomplex-anti-
HER2 conjugates, (B) unconjugated nanocomplexes, and (C) control, no nanocomplexes. 
Cytotoxicity studies of MDA-MB-231 cells incubated with (D) nanocomplex-anti-HER2 
conjugates, (E) unconjugated nanocomplexes, and (F) control, no nanocomplexes. Live 
cells are stained green with calcein and dead cells are stained red with propidium iodide. 
Original magnification is x200 and the scale bar is 100 pm for all panels. 
Nanocomplexes by themselves, without photothermal ablation, were observed to be 
innocuous to cells, and nominal cell cytotoxicity was observed. OVCAR3 cells and 
MDA-MB-231 cells were incubated with nanocomplex-anti-HER2 conjugates and the 
unconjugated nanocomplexes for 2 h, followed by staining with Calcein/PI dye mixture. 
Cytotoxicity studies of OVCAR3 cells incubated with nanoshell-anti-HER2 conjugates, 
unconjugated nanoshells, and control, no nanocomplexes are shown in Fig. 5.5A-C. 
Similarly, cytotoxicity studies of MDA-MB-231 cells incubated with nanocomplex-anti-
HER2 conjugates, unconjugated nanocomplexes, and control are shown in Fig. 5.5D-F. 
The results for both cell lines are comparable and minimal differences in cell viability 
and cell death were observed. 
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5.7 Discussion 
Currently, the majority of ovarian cancer diagnoses are for rather advanced stages 
of the disease due to the lack of availability of early detection and treatment strategies. 
The standard protocols for the treatment of ovarian cancer have included conventional 
surgical approaches followed by chemotherapy or radiation therapy. These standard care 
treatments often require invasive surgical procedures or other therapies associated with 
significant side effects, high cost, and poor clinical outcome. Since HER2 receptor 
amplification occurs in ovarian cancers and is associated short survival time and short 
time to relapse,43' 156"160' 175 it can be targeted with alternative nanoparticle based 
therapies. Furthermore, HER2 positive cell line OVCAR3 have also been found to be 
resistant to clinically relevant drugs including adriamycin, melphalan, and cisplatin, with 
survival rates of 43%, 45%, and 77%, respectively relative to untreated controls in 
vitro.161 The drug resistance of ovary cancer cells can be effectively addressed by image 
guided photothermal therapies. 
The nanocomplexes utilized here provide a unique platform with targeting, 
diagnostic and therapeutic capabilities all within the same agent. There are several 
advantages offered by these nanoscale agents. First, the nanocomplexes effectively 
assimilate two imaging modalities, MRI and fluorescence imaging, which are non-
invasive, safe, clinically relevant, and complementary techniques. While MRI has the 
advantage of 3D resolution and visualization of overall anatomical background, it lacks 
sensitivity. Optical imaging methods such as fluorescence provide high target sensitivity, 
although they lack 3D resolution. Hence combining these two imaging modalities 
synergistically integrates the advantages of the two techniques and overcomes the 
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disadvantages simultaneously. Second, antibody targeting allows nanocomplex-anti-
HER2 conjugates to specifically bind to HER2-overexpressing cell surface receptors. 
Here, both immunofluorescence staining and MRI successfully demonstrate that 
nanocomplex-anti-HER2 conjugates bind to HER2-overexpressing OVCAR3 cells in 
contrast to MDA-MB-231 cells, which have low HER2 expression. Some nonspecific 
binding was observed for the unconjugated nanocomplexes. This could be attributed to 
the overall negative charge on the outer surface of the silica layer of the nanocomplex, as 
a consequence of the fabrication procedure, which interacts electrostatically with the 
proteins present in the cells. However, the non-specific binding can be reduced with 
improvised chemical modification of the nanocomplexes in future studies. Third, due to 
the unique plasmonic properties of the nanocomplexes and tunability in the NIR they can 
absorb resonant light; effectively convert light to heat, followed by photothermal 
therapeutic actuation resulting in tumor ablation with near 100% remission rates.17 
Fourth, the nanocomplexes have low cytotoxicity and a particle size conducive to passive 
extravasation from the tumor vasculature.46' 47 This will allow future studies in animal 
models as these nanocomplexes will accumulate in the tumor enabling simultaneous 
comprehensive imaging and therapy. 
5.8 Conclusions 
In conclusion, this is the first demonstration of a successful integration of dual modal 
bioimaging with photothermal cancer therapy for the treatment of ovarian cancer cells, 
using a molecularly targeted gold nanoshell-based theranostic probe. Unlike conventional 
cancer therapy approaches such as radiation- or chemotherapy, which can have fatal side 
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effects, nanoshell-based photothermal ablation therapy is benign and safe. Moreover, due 
to their selective accumulation at cancer cells expressing the HER2 cell receptor, only 
cells retaining the nanoshells will heat up and ablate when illuminated with NIR laser, 
while neighboring healthy cells will not experience plasmonic heating. These 
nanocomplexes can potentially be used as a tool for evaluating transmembrane receptor 
number, cell viability and real-time monitoring of cell status. As cancer predominantly 
spreads through the blood and lymphatic system, the potential ability to molecularly 
image cancer cells in metastatic carcinoma without incision and with microdose amounts 
of safe, non-toxic, multifunctional nanoparticles will have a significant impact on the 
standard of diagnosis and therapy for many cancers. The low cytotoxicity of these 
nanocomplexes and their therapeutic efficacy could be potentially beneficial in the study 
of deep organ metastatic carcinoma in animal models. 
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Chapter 6: In Vivo Multimodal Imaging of Breast Cancer with 
Magneto-Fluorescent Gold Nanoshells 
6.1 Introduction 
In the previous two chapters, chapter 4 and 5, the multifunctional nanocomplexes were 
explored for dual modal imaging and photothermal therapy in vitro. In this chapter we 
target and diagnose breast cancer cells in vivo by multimodal imaging modalities, MRI 
and FOI, with the nanocomplexes conjugated with antibodies. We studied biodistribution 
in animal models 72h post-injection of nanocomplexes. We also examined 
nanocomplexes structural integrity in vivo by analyzing tumor sections with TEM. Rizia 
Bardhan fabricated the nanocomplexes, characterized them, performed ICP-MS to 
analyze gold concentration in tissues, and assisted in tissue analysis by TEM and FOI in 
vivo. Wenxue Chen performed cell culture, xenografts, injected nanocomplexes in mice, 
sacrificed mice and collected organs 72h post-injection, assisted in TEM sample 
preparation and FOI in vivo. Manuscript in preparation: Wenxue Chen*, Rizia Bardhan*, 
Marc Bartels, Carlos Perez-Torres, Maria F. Botero, Robin Ward-McAninch, Rachel 
Schiff, Robia G. Pautler, Naomi J. Halas, Amit Joshi (*equal contribution). 
The estrogen receptor (ER) and the HER (c-erbB) signaling pathways are the 
dominant drivers of cell proliferation and survival in the majority of human breast 
cancers and provide an ideal target for breast cancer theranostics. Targeting these 
pathways will, thus, provide the most effective therapies in appropriately selected 
patients. Endocrine therapy to target ER and trastuzumab to target HER2 provide 
prominent benefits in the adjuvant setting when micrometastatic disease is present (50% 
reductions in recurrence).176' 177 These treatments, while capable of inducing tumor 
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regression, are much less effective in patients with macroscopic metastatic tumor, 
indicating that other survival pathways must also be operative in this setting. The HER 
signaling pathway has been described in systems biology terms as a robust network with 
complex input signals (4 receptors, 11 ligands), a core processing unit (phosphorylation 
signaling cascade), a variety of output signals (transcription factors), and complicated 
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system controls (+ve and -ve feedback circuits). ' These features provide redundancy 
that allow the cell to respond to "network damage" (targeted therapies) by evolving and 
switching to alternative pathways in order to maintain survival signals, resulting in 
clinical drug resistance.180 Therefore, de novo and acquired resistance remain major 
obstacles necessitating new therapeutic strategies for successful treatment. 
Alternative cancer therapeutics based on the photothermal response of gold 
nanostructures designed to absorb NIR, tissue-penetrating light has exhibited near 100% 
efficacy in the remission of tumors, and stands as one of the most promising new 
technologies to emerge from nanoscience research in the past decade. Following the 
initially demonstrated therapeutic success of gold nanoshells, other gold nanoparticles 
such as gold nanorods, hollow gold nanospheres, and gold nanocages have also been used 
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to demonstrate similar, highly promising therapeutic responses. ' ' ' Gold-based 
nanostructures show particular promise as theranostic agents, based on their 
straightforward adaptability to integrate targeting, diagnostic, and therapeutic 
functionalities into a single hybrid multifunctional nanoscale complex.13' 183 Gold 
nanoshells resonant in the NIR effectively absorb NIR light and generate hyperthermia 
for externally controlled tumor cell death.13 '15 '17 '183 Conventionally gold nanoshells and 
other gold nanostructures such as nanorods/cages are typically imaged optically by 
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exploiting their high absorption and scattering cross-section via microscopic methods and 
optical coherence tomography.14' 183-185 This has limited their visualization to tissue 
depths of ~ 1 mm. For imaging nanoshell distributions in tissue depths relevant to whole 
body imaging in nude mice, or for clinical applications, additional modalities need to be 
integrated, as native absorption/scattering contrast of nanoshells is not sufficient for 
sensitive photon migration measurements over multiple centimeters. Plasmon enhanced 
fluorescence of water-soluble and biocompatible NIR organic dyes can provide a 
potentially promising and sensitive optical detection route at centimeter scale tissue 
depths.105 
Highly sensitive, noninvasive NIR fluorescence optical imaging (FOI) is 
constrained by limited photon penetration in tissue and cases like breast cancer metastasis 
in deep axillary lymph nodes, and distant organs like lungs, liver, skeleton and brain.34'35 
While MRI does not have tissue depth constraints, SPIO particles require heavy tumor 
loading for imaging and therapy, and in case of surgery, they do not provide any 
• 1 
intraoperative guidance for tumor margin determination. The complimentary 
capabilities of FOI and MRI imaging provide the motivation for combining NIR light and 
magnetic field based imaging and therapy in one nanoparticle. Gold nanostructures 
integrated with NIR emitters iron oxide nanoparticles can provide FOI and MRI 
enhancement and hence serve as simultaneous theranostic reporter-actuators.187 With 
antibody or peptide conjugation, these theranostic hybrid nanoparticles can be delivered 
to specific cells or tissues for therapy, with reporter functionalities providing tracking 
capabilities before, during and after treatment. This multimodality structure is ideal for 
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the next critical phase of cancer nanotechnology research: transitioning this potentially 
revolutionary technology into clinical practice. 
Recently, we illustrated the design and theranostic capabilities of magneto-
fluorescent gold nanoshells (nanocomplexes) for diagnosis and photothermal therapy of 
breast cancer cells in vitro.187 In this study, the efficacy of the nanocomplexes have been 
demonstrated in vivo for specifically targeting and diagnosing HER2 overexpressing 
breast cancer cells via MRI and FOI. The nanocomplexes were fabricated by 
encapsulating Au nanoshells in a Si02 epilayer which was doped with Fe304 
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nanoparticles and NIR fluorophore ICG similar to that described in chapter 4. ' The 
plasmon response of nanoshells can be straightforwardly tuned to the NIR "water 
i o 
window" (670-900 nm), where hemoglobin, water and blood are minimally absorptive, 
by simply altering the dimensions of the core and shell.12 Gold nanoshells, due to their 
tunability in the NIR, the high intensity electromagnetic field on their surface, and strong 
absorption/scattering characteristics, have already been successfully demonstrated in a 
wide range of biomedical applications. " ' ' These plasmonic properties of 
nanoshells also contribute towards dramatic emission enhancements of weak NIR 
fluorophores in their vicinity.105'130 We have shown that nanoshells enhance fluorescence 
of ICG molecules from a mere 1.3 % in aqueous media to nearly 80 % when positioned at 
an appropriate distance from the nanoshell surface.105' 187 To our best knowledge, this 
study is the first demonstration that exemplifies the difference between HER2 expression 
levels of two breast cancer cell xenografts via combined NIR fluorescence and MR 
imaging with gold nanoshell based agents. 
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6.2 Experimental methods 
I. Nanocomplexes Fabrication: The nanocomplexes were fabricated similar to that 
described in chapter 4 and 5. The anti-HER2-biotin conjugate was mixed with the 
streptavidin attached nanocomplexes and gently stirred for 8 h at 4 °C. An additional step 
was included for the in vivo studies, 50 fiM PEG-biotin (Nanocs, MW-5000) was finally 
added to block nonspecific adsorption sites and increase circulation time. Finally 
nanocomplexes were redispersed in phosphate buffer at pH 7.5. 
II. Live animal studies: The protocols were approved by the Institutional Animal Care 
and Use Committee (IACUC) of Baylor College of Medicine. 
III. BT474AZ xenografts: The estrogen-dependent BT474AZ/ATCC breast carcinoma 
Human (in which HER2 is naturally amplified) cells were grown in RPMI 1640 medium, 
1% Penicillin-Streptomycin and 10% fetal bovine serum (FBS). Cells were incubated at 
37 °C in a 5% CO2 environment and were detached from culture with trypsin (0.05%) 
and EDTA (0.02%) and resuspended in media for passaging to wells. Athymic Nude-
Foxnlnu female mice (4-6wk of age, 20±3g, Harlan) were implanted s.c. with E2 pellets 
(0.2mg, 60d release; Innovative Research of America) on the dorsal flank. The next day, 
mice were injected s.c. on the right flank near 4th mammary gland with 1 x 107 
BT474AZ/ATCC cells suspended in serum-free medium mixed with Matrigel (BD 
Biosciences) at 1:4 ratio as described.188 Tumors were allowed to grow to about 8 -10 
mm in diameter before nanocomplexes injection and imaging. 
IV. MDA-MB-231 xenografts: The estrogen-independent human breast adenocarcinoma 
(Homo sapiens) cell line MDA-MB-231 (which expresses basal levels of HER2 receptor) 
were grown in DMEM medium, 1% Penicillin-Streptomycin and 10% FBS. Cells were 
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incubated at 37 °C in a 5% CO2 environment and were detached from culture with trypsin 
(0.05%) and EDTA (0.02%) and resuspended in medium for passaging to wells. Athymic 
Nude-Foxnlnu female mice (4-6wk of age, 20±3 g, Harlan) were injected s.c. on the right 
flank near 4th mammary gland with 3><106 cells/mouse, the cells suspended in serum-free 
medium. Tumors were allowed to grow to about 8-10 mm in diameter before 
nanocomplexes injection and imaging. 
V. FOI Methodology: Tumor bearing mice were each placed on a dark platform and 
isoflurane was delivered in concentrations of 1-3% in oxygen (up to 5% for initial 
induction), using a precision vaporizer and ventilation. The body temperature of mice 
was maintained at 37 °C during anesthesia by employing a heating pad and temperature 
controller (FHC Bowdoin, ME, USA). The in vivo images were acquired using an optical 
imaging system in continuous wave (CW) mode with a charged-coupled device (CCD) 
camera (PhotonMax 512, Princeton Instruments) and a 28 mm Nikkor (Nikon) lense. 
Camera was custom-controlled by MatLab (The Math Works, Inc.) software. Excitation 
light is generated with a 100 mW near infrared (NIR) diode at 785 nm (Thorlabs, Inc.) 
and diffused with the combination of an aspheric lense and a diffuser (both Thorlabs, 
Inc.). The excitation light was captured by using a neutral density filter with optical 
density (OD) 3 (Andover Corporation). The emission light was collected using a 
fluorescence band pass filter at (830 ± 20) nm (Andover Corporation) and a holographic 
notch filter (OD 6) at 785 nm (Kaiser Optical Systems, Inc.) while rejecting excitation 
1 80 
leakage, as suggested by Hwang et. al. 
VI. MRI Methodology: MR Imaging experiments were performed on a Bruker Avance 
Biospec, 9.4 T spectrometer, 21 cm bore horizontal imaging system (Bruker Biospin, 
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Billerica, MA) with a 35 mm volume resonator. Animals were initially anesthetized with 
gaseous isoflurane at 2-3% in oxygen (up to 5% for initial induction), and placed into a 
mouse holder within the magnet where they were subsequently maintained at 2% 
isoflurane in oxygen. During the imaging, the animal body temperature was maintained at 
37 °C continually monitored with a rectal probe using an animal warmed air heating 
system (SA Instruments, Stony Brook, NY). Imaging was performed with a multislice 
RARE (rapid acquisition with relaxation enhancement) sequence with a repetition time 
(TR) of 2805 msec, an echo time (TE) of 20 msec (TR/TE equal to 2805/20 ms) with a 
RARE factor of 6 leading to an effective TE of 60 ms. the imaging sequence included a 
5ms fat suppression pulse. FOV was 30><30 mm with 20 slices at 1mm thickness. The 
acquisition matrix of 256x256 yielded an in-plane isotropic 117 |im resolution. 
VII. Sample Preparation for ICP-MS: The mice were sacrificed 72 h post-injection, 
tissues were collected and immediately frozen at -80 °C. The organs were lysed in trace-
metal grade aqua regia, boiled to evaporate excess aqua regia and finally dispersed in 1% 
aqua regia. Gold standards were prepared in 1% aqua regia. The samples were measured 
on Perkin-Elmer Elan9000 inductively coupled plasma mass spectrometer. 
VIII. Cell Preparation for TEM: After 72 h organs were collected and a small portion of 
BT474AZ tumor was immediately fixed in 2.5% glutaraldehyde and 2 mM CaCl2 in 0.1 
M cacodylate buffer (PH 7.39). Tissue was cut into 1 mm cube keeping them immersed 
in fixative solution. Specimens were stained for 1 hour in saturated uranyl acetate + 50% 
ethanol, then counter-stained for 4 minutes in Reynold's lead citrate. Sections were then 
cut at 70-75 nm (silver sections) on an RMC MT-6000XL ultramicrotome and used for 
TEM. A Hitachi H-7500 TEM at accelerating voltage 80 kv was used. 
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6.3 Properties of dual modal nanocomplexes 
The multifunctional nanocomplexes were fabricated as described in chapter 4 and 5. The 
scanning electron microscope (SEM) image of nanocomplexes (Fig. 6.1 A) and 
corresponding high resolution transmission electron microscope (TEM) image (Fig. 
6.IB) demonstrates that these particles are nearly 185 nm in diameter. Since SPIO 
nanoparticles and SiC>2 epilayer have significantly less contrast than Au in TEM, the 
difference in the two layers may be difficult to visualize. However, the texture and 
surface roughness indicates the presence of these multiple layers. The extinction spectra 
of the nanocomplexes were tuned to the NIR demonstrating plasmon maximum at 825 
nm in aqueous media (Fig. 6.1C). The nanocomplexes plasmon peak is tuned to match 
the emission wavelength of ICG molecules doped within the silica layer to maximize 
fluorescence enhancement.105 Nearly 650 nM of ICG is doped in a particle concentration 
of ~9xl09 particles/mL. The emission maximum is observed at 830 nm in aqueous media 
(Fig. 6. ID). NIR optical image of a syringe containing nanocomplexes prior to injection 
is also shown in Fig. 6.ID inset. 
The silica epilayer encapsulating the SPIO coated nanoshells serve multiple 
functions simultaneously: (i) it provides an effective spacer between the Au nanoshell 
surface and ICG molecules which maximizes fluorescence enhancement as demonstrated 
previously,105' 130 (ii) the doped ICG molecules in the silica layer are less prone to 
photobleaching due to interaction with aqueous media and tissue,90 (iii) the porous silica 
layer increases the molecular motion of H2O within the pores enhancing H 2 0 interaction 
with SPIO nanoparticles. This improves the proton relaxation rate and provides high T2 
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relaxivity, 390 mM^sec"1, and significant MR contrast144'187 and (iv) the silica surface is 
available for binding antibodies and PEG molecules via simple conjugation chemistry. 
600 800 1000 1200 800 825 850 875 900 
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Figure 6.1. Characterization of the magneto-fluorescent nanocomplexes: (A) SEM image 
of several nanocomplexes with an overall radius of r = 92.5 ± 4 nm. (B) High resolution 
TEM image of nanocomplexes clearly showing SPIO and silica layer on the surface. (C) 
Extinction spectra of nanocomplexes, plasmon maximum A.max= 825 nm. (D) 
Fluorescence spectra of nanocomplexes, emission maximum A,max— 830 nm. Fluorescence 
image of nanocomplexes in a syringe before injection is provided as inset. 
6.4 Fluorescence optical imaging in vivo 
The diagnostic capabilities of the nanocomplexes were visualized in vivo by targeting 
HER2 expressing breast cancer tumors in animal models. Molecular targeting was 
achieved by assembling anti-HER2 antibodies on silica surface via streptavidin-biotin 
binding procedure similar to that reported previously.187 This conjugation protocol yields 
~ 300-350 antibodies per nanocomplex as quantified by enzyme-linked immunosorbent 
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assay. PEG-biotin molecules were then conjugated to nanocomplexes to block 
nonspecific streptavidin adsorption sites, provide steric stability, improve circulation time 
in the body, reduce immunogenicity and in combination with antibodies increase 
nanoparticle accumulation in tumor.190 PEG, a nontoxic FDA approved biopolymer, is 
known to promote solubility in aqueous media, provide steric repulsion between colloidal 
nanoparticles reducing aggregation in tissue.191 For in vivo experiments, 9xl09 
particles/mL of nanocomplexes were injected systemically via the tail vein into nude 
mice (20±3 g), 12.5 pL/g body weight. The nude mice have HER2 overexpressing human 
breast cancer tumor, BT474AZ, and control, HER2 basal expressing MDAMB231 
tumors on the right flank. NIR fluorescence images of mice with MDAMB231 xenografts 
(top) and BT474AZ xenografts (bottom) are shown (Fig. 6.2A) at 0.3 h, 2 h, 4 h, 24 h, 48 
h and 72 h post-injection of nanocomplexes. The NIR images were obtained using a 100 
mW, 785 nm diode laser focused uniformly over the entire mouse body. The fluorescence 
intensity of the tumor-to-body ratio of BT474AZ xenografts (n=6) and MDAMB231 
xenografts (n=3) analyzed at different time points demonstrate maximum contrast at 4 h 
post injection (Fig. 6.2B). 
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Figure 6.2. NIR fluorescence images of mice with HER2 basal expressing MDAMB231 
xenografts (top) and HER2 overexpressing BT474AZ xenografts (bottom) at 0.3 h, 2 h, 4 
h, 24 h, 48 h and 72 h post-injection of nanocomplexes. (B) Fluorescence (Fl) intensity of 
tumor-to-body ratio at different time points of mice with BT474AZ xenografts (n=6) and 
MDAMB231 xenografts (n=3) showing maximum fluorescence at 4 h. (C) Fluorescence 
intensity comparison between tumors only of BT474AZ (n=6) and MDAMB231 (n=3) 
showing 71.5% increase in signal at 4 h in BT474AZ compared to MDAMB231 tumors. 
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Fluorescence intensities determined as tumor-to-body ratio represents the normalized 
signals and accounts for the total nanocomplexes distributed in the body relative to the 
tumor. Significant statistical variation as returned by unbalanced two-way ANOVA 
across tumor types, P value 0.007, and across time points, P value 3e~10, was observed 
suggesting high fluorescence contrast in tumor. Within 72 h nanocomplexes are cleared 
from the body indicated by the diminishing florescence intensity. Due to the higher 
binding affinity of the anti-HER2 conjugated nanocomplexes to the BT474AZ 
xenografts, more nanocomplexes are accumulated and retained in the BT474AZ tumors. 
A portion of the nanocomplexes are cleared by mononuclear phagocytes of the 
reticuloendothelial system comprising of the macrophages of liver and spleen. Over time 
some nanocomplexes are excreted via the kidneys which explain the noticeable 
fluorescence signal observed from the body of BT474AZ mice in the region of liver, 
spleen and kidneys. 
While tumor-to-body ratio provides normalized signal intensities, to verify the 
specificity and sensitivity of nanocomplex-antibody conjugates in targeting HER2 
overexpressing xenografts, fluorescence measurements of tumors only is needed. A 
comparison of the fluorescence intensities of tumors only at different time points (Fig. 
6.2C) demonstrates a 71.5% increase in the BT474AZ tumor signal at 4 h compared to 
MDAMB231 tumors. This significant variation, P value 0.003 across tumor types and P 
value le~" across time points, indicates that the antiHER2-nanocomplex conjugates 
accumulate in the tumor by specifically targeting the cell surface markers on the tumor in 
addition to the enhanced permeability and retention (EPR) effect.45 
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6.5 Magnetic resonance imaging in vivo 
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Figure 6.3. T2-weighted MR images of mice with BT474AZ xenografts (top) and 
MDAMB231 xenografts (bottom) pre-injection 0 h, and 4 h, 24 h, 48 h, and 72 h post-
injection of nanocomplexes. The tumor is shown in red circle. (B) MR image intensity of 
tumor-to-body ratio at different time points of mice with MDAMB231 xenografts (n=3) 
and BT474AZ xenografts (n=3) showing T2-weighted contrast for BT474AZ even at 72 
h. (C) MR image intensity comparison between tumors only of BT474AZ (n=3) and 
MDAMB231 (n=3) showing 50.5% decrease in MR contrast at 24 h in BT474AZ tumors 
compared to MDAMB231 tumors. 
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The SPIO nanoparticles incorporated within the porous silica epilayer of 
nanocomplexes provide significant MR contrast enabling tumor diagnosis at considerable 
depths. The T2-weighted MR images of mice with BT474AZ xenografts (Fig. 6.3A top) 
and MDAMB231 xenografts (Fig. 6.3A bottom) pre-injection, 0 h, and 4 h, 24 h, 48 h, 72 
h post-injection of nanocomplexes are represented. The tumor area is shown in red circle. 
As the nanocomplexes accumulate in the tumor, the intensity of the tumor decreases 
(darker), as expected for T2 contrast agents, and by 72 h the tumor intensity increases 
(brighter). The decrease in MR contrast over time was evaluated by analyzing the T2 
values of tumor-to-body ratio. This accounts for variation in the performance of the MRI 
instrument over time as well as distribution of nanocomplexes in the tumor relative to the 
body. The MR image intensity of tumor-to-body ratio at different time points of mice 
with BT474AZ xenografts (n=3) and MDAMB231 xenografts (n=3) (Fig. 6.3B) shows 
T2-weighted contrast for BT474AZ tumors even at 72 h. The discrepancy between MR 
contrast and fluorescence in vivo is primarily attributed to the surface weighted 
characteristics of optical imaging, where as in MRI sections of the tumor core are 
visualized. It is not surprising that nanocomplexes take longer to distribute within the 
tumor core compared to accumulation in peripheral vasculature. Statistical analysis show 
significant variations only across tumor type, P value 0.002, but not across time points, P 
value 0.360. The low sensitivity of MRI and low signal-to-noise ratio can explain the 
high P value across time points which also contribute towards the discrepancy between 
MRI and FOI analysis. 
Analogous to FOI analysis, comparison of the MR intensities of tumors only at 
different time points (Fig.6.3C) validates the specificity of the nanocomplexes in 
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targeting HER2 overexpressing breast cancer xenografts compared to HER2 basal 
expressing MDAMB231 xenografts. The comparison shows -50.5% decrease in the 
BT474AZ tumor signal at 24 h compared to MDAMB231 tumors. Significant variation is 
observed among tumor types, P value 0.038, but not across time points, P value 0.118. 
The discrepancy in the results between the two diagnostic modalities, MRI and FOI, 
signifies the intrinsic differences between the two techniques. While MRI provides high 
spatial resolution and capability to achieve anatomical background information at 
significant depths, but it lacks sensitivity, FOI offers exceptional detection sensitivity but 
is limited by penetration depth and hence not suitable for deep tissue imaging. The 
integration of these complementary imaging techniques in a single functional contrast 
agent, nanocomplexes, is hence advantageous and allows their use in clinical procedures 
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for pre- and post-operative MRI and then intra-operative FOI. ' 
6.6 Nanocomplex Biodistribution 
Fluorescence and MR images in vivo provide significant information regarding time 
required for nanocomplexes to accumulate and retain in tumor, efficacy of 
nanocomplexes and their specificity in targeting breast cancer tumors. However, to 
determine the distribution of these nanocomplexes in different organs and clearance from 
the body, the individual tissues need to be analyzed. NIR fluorescence images of 
individual tissues, (Fig. 6.4A) retrieved from MDAMB231 (n=3) and BT474AZ (n=5) 
mice sacrificed 72 h post-injection of nanocomplexes, clearly demonstrate maximum 
accumulation in tumor compared to other tissues. Since a higher concentration of 
nanocomplexes were accumulated in the tumor of BT474AZ mice at all times points 135 
measured (Fig. 6.2 and Fig. 6.3), consequently, more nanocomplexes are cleared from the 
body into liver, spleen and kidneys. This explains the higher fluorescence intensity 
observed in these organs of BT474AZ compared to MDAMB231 (Fig. 6.4A). A surface 
averaged fluorescence intensity analysis, where the fluorescence intensity was divided by 
the surface area of each tissue (Fig. 6.4B) demonstrate that tumors have maximum 
nanocomplex uptake, for both tumor types, followed by liver, kidneys, spleen, lungs, 
heart and brain. Significant variation, P value 0.005, is observed in fluorescence intensity 
across tumor types. Some nanocomplex accumulation observed in MDAMB231 
xenografts may be due to basal HER2 expression in this cell line as well as the EPR 
effect. In the case of BT474AZ, it is surprising that kidneys and liver have similar surface 
averaged fluorescence intensity. This may be attributed to the surface weighted 
characteristics of optical images, and since liver is larger, nanocomplexes buried deeper 
into liver may not be observable by fluorescence. While FOI is an effective technique, a 
method that analyzes the atomic Au content accurately is required to verify the 
nanocomplex distribution in all organs. The Au content in each tissue was measured 
using inductively coupled plasma-mass spectrometry (ICP-MS). 
Au distribution (ng) per mass of tissue (g) for each tissue type, for both BT474AZ 
and MDAMB231 mice, (Fig. 6.4C) corresponds well with the measured fluorescence 
intensities (Fig. 6.4B) with minor differences. In both tumor types, the tumors have 
maximum Au content followed by liver, kidneys, spleen, lungs, heart and brain. Tissues 
of BT474AZ have higher nanocomplex accumulation compared to MDAMB231 and it is 
also notable that BT474AZ mice livers have higher gold distribution than kidneys, as 
expected. The measured Au levels in lungs and heart may be due to residual blood left 
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behind in these highly perfused tissues. Both fluorescence and ICP-MS measurements 
show low Au concentration in brain, indicating that the nanocomplexes have low 
permeation through the blood-brain barrier. Statistically significant variation is observed 
across tumor types, P value 0.019. 
After in vivo administration of nanoparticles, their biodistribution are largely 
based on the particle size and surface properties such as surface charge, hydrophobicity, 
and moieties bound to the surface.193 The mononuclear phagocytes of the 
reticuloendothelial system are known to rapidly scavenge nanoparticles from the blood 
stream, accumulate in these organs and subsequently eliminate via kidneys.194 However, 
PEG conjugated nanoparticles have been shown to minimize the recognition by the 
reticuloendothelial system, therefore prolonging blood circulation time.195'196 The stealth 
character of PEG grafted surfaces can be attributed to the low interfacial free energy of 
PEG in aqueous media and steric repulsion arising from a loss of conformational entropy 
of PEG chains in close proximity to foreign materials.191 While PEG mediated passive 
targeting is effective for nanoparticle accumulation in the tumor by EPR effect, active 
targeting via antibodies have been shown to have higher specificity due to the direct 
recognition of the cell surface receptors.54'197 The nanocomplexes utilized in this study 
simultaneously promote active and passive targeting via the attached PEG-biotin chains 
and the anti-HER2 antibodies. The high targeting capability of the nanocomplexes is 
attributable to their maximum accumulation in tumor and low uptake in liver and spleen. 
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Figure 6.4. (A) NIR fluoresce images of mice organs harvested from MDAMB231 (left) 
and BT474AZ (right) 72 h post-injection of nanocomplexes. (B) Surface averaged 
fluorescence intensity analysis of mice organs of BT474AZ (n=5) and MDAMB231 
(n=3) showing maximum fluorescence in tumors. (C) Gold distribution per mass of tissue 
obtained from ICP-MS in various mice organs of BT474AZ (n=5) and MDAMB231 
(n=3) showing maximum Au content in tumors. 
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6.7 TEM analysis of nanocomplexes in tumor sections 
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Figure 6.5. TEM images of BT474AZ tumor sections retrieved from mice 72 h post-
injection. (A) Low resolution image showing nanocomplex bound to the cell surface (red) 
and nanocomplexes internalized in the cytoplasm (black). (B) High resolution image of 
the nanocomplex shown within red box in part A. (C) High resolution image of the 
nanocomplexes shown within black box in part A. (D) Low resolution image of a 
different area of the tumor section showing nanocomplex in cytoplasm. High resolution 
image of the nanocomplex provided as inset. 
Tumor sections retrieved from BT474AZ mice 72 h post-injection of 
nanocomplexes were examined with TEM to verify the structural integrity of the 
nanocomplexes in vivo and tumor internalization (Fig. 6.5). Low resolution image (Fig. 
6.5A) and corresponding high resolution image shows a nanocomplex bound to the cell 
surface (Fig. 6.5B) and nanocomplexes internalized in the cell (Fig. 6.5C). In Figure 
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6.5C, a few nanocomplexes are embedded in different planes of the tumor section 
appearing as dark gray spots in the image. A different area of the tumor section shows 
another nanocomplex internalized in the cell (Fig. 6.5D). Although, the Si02 epilayer and 
the tissue background have similar contrast in TEM, the high resolution images (Fig. 
6.5B, 6.5C and 6.5D inset) clearly show the intact SiC>2 layer encapsulating the darker Au 
shell. This indicates that the nanocomplexes retained their topology and structural 
integrity in vivo. 
6.8 Conclusions 
In summary, we have designed and developed non-toxic multifunctional 
nanocomplexes with enhanced fluorescence and MR contrast for effective diagnosis of 
breast carcinoma cells in vivo. Additionally, we have demonstrated biodistribution 72 h 
post-injection showing nanocomplexes accumulation primarily in the tumor and verified 
their structural integrity in vivo. For effective clinical translation, nanoparticle based 
diagnostic and therapeutic agents should essentially (i) be composed of well 
characterized non-toxic materials, (ii) be hydrophilic, (iii) have long blood circulation 
time, (iv) exhibit high targeting and uptake efficiency in diseased cells, (v) be less prone 
to aggregation in vivo and retain the structural integrity for increased therapeutic benefits 
and (vi) have surface properties, which can maximize tumor accumulation evading the 
macrophages of the reticuloendothelial system.54, 126' 198 The nanocomplexes utilized in 
this study efficiently integrate all these capabilities demonstrating their potential use as a 
theranostic agent for simultaneous detection and treatment of tumors. Ultimately these 
nanocomplexes will provide far more advantages than single modality conventional 
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imaging probes. Gold nanoshells have successfully demonstrated efficient light to heat 
conversion inducing hyperthermia and subsequent tumor remission.15' 27 As nanoshell-
based photothermal cancer therapy transitions from bench to bedside,27 the application of 
these magneto-fluorescent nanoshells in clinical settings as theranostic agents is 
impending. Following exhaustive biodistribution studies and photothermal therapy in 
vivo these nanocomplexes could potentially revolutionize early diagnosis of cancer 
followed with rapid treatment bringing us closer to an era of personalized medicine. 
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Chapter 7: Nanosphere-in-a-Nanoshell: A Simple 
Nanomatryushka 
7.1 Introduction 
Nanoshells have proven extremely effective as theranostic complexes for diagnosis 
and therapy of cancer, as described in the last 3 chapters. However, for treatment of 
specific types of cancer, for example brain cancer, development of smaller nanoparticles 
in the sub-100 nm size regime is essential for effective delivery into the brain. This 
chapter describes a simple strategy for designing sub-100 nm nanoshells resonant in the 
NIR by simply introducing a gold nanoparticle core inside a SiCVAu nanoshell. 
Multilayered Au/SiCVAu nanoshells resonant in the NIR have been fabricated in the sub-
150 and sub-100 nm size regime to potentially expand the therapeutic capabilities of 
nanoshells. The nanostructures were fabricated, characterized and optical studies were 
performed by Rizia Bardhan. Shaunak Mukherjee contributed towards theoretical 
analysis and discussion. Reproduced with permission from Rizia Bardhan*, Shaunak 
Mukherjee*, Nikolay A. Mirin, Stephen D. Levit, Peter Nordlander, and Naomi J. Halas, 
J.Phys.Chem.C, 2009, in press (*equal contribution). Copyright 2009 American 
Chemical Society. 
Metallodielectric layered nanoparticles and nanostructures form a unique and 
important class of nanomaterials linked by their ability to manipulate light in similar 
ways. Their optical properties arise from the surface plasmons supported at their metal-
dielectric interfaces. Surface plasmons, whether on closely adjacent nanoparticles199 or on 
21 200 • . . . different metal-dielectric interfaces ' of the same nanoparticle, mix and hybridize in 
direct analogy with simple quantum systems. These nanostructures form a class of 
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plasmonic "artificial molecules" with hybridized plasmons that are highly dependent on 
nanoscale geometry.101 As nanostructures of this type are synthesized with increasingly 
complex geometries, this paradigm becomes even more important, providing a qualitative 
understanding of the optical resonances of the nanostructure prior to actual synthesis. The 
ability to control both near and far field properties from the dipole up has made this 
c o . . 27 201 
family of nanostructures interesting for a broad range of spectroscopic, " biomedical ' 
1^ 0 909 
and photonic applications. ' 
Multilayered metallodielectric nanostructures, or "nanomatryushkas", where 
nanoscale dielectric spacer layers separate concentric metallic layers, are of particular 
interest. Here the coupling between the surface plasmons is determined by the thickness 
• 21 203 
of the dielectric spacer layers, which can be controlled in the nanoparticle synthesis. ' 
A theoretical model of a silver core/shell multilayered nanostructure has shown that large 
local field enhancements are characteristic of the void between the central metal core and 
the adjacent, innermost metal shell.204 Such multilayered shells can act as a collection of 
optical condensers that focus light toward the center of the structure multiplicatively, 
resulting in an exponential increase in the near-field enhancements as the number of 
metal shells increases.204 This structure is the spherical analog of the plasmonic 
"snowman", a self-similar chain of adjacent nanoparticles of decreasing size, where the 
maximum near field focusing occurs not at the tip of the chain but in the junction 90S 907 
between the smallest, terminal nanoparticle and its next-nearest, larger neighbor. " In 
addition to these distinctive near-field properties, the far-field properties of concentric 
nanostructures are also controlled largely by the thickness of the intermediate dielectric 908 900 layer. ' This geometric "tunability" of the plasmon resonances of the nanoparticle 
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into the NIR region of the spectrum is highly beneficial for light-based biomedical 
diagnostics and therapeutics. 
Gold nanoshells, consisting of a silica nanoparticle core surrounded by a thin Au 
shell, have generated significant interest due to their applications in biotechnology and 
biomedicine. In therapeutic applications, tuning the nanoshell plasmon to the NIR "water 
window" of 700-1200 nm allows them to be strong optical absorbers or scatterers in a 
-30 
wavelength region where light penetrates several centimeters into the human body. In 
this regime, nanoshells can be used as contrast agents for enhancing optical imaging, as 
1c 1n jn 
photothermal heat sources for cancer therapy, ' ' converting the light they absorb to 
heat for tumor ablation with near 100% remission rates, and as gene therapy vectors, 
where resonant light can release genetic cargo bound to their surfaces. Multiple 
diagnostic and therapeutic functions can even be designed into the same plasmonic 
nanoparticle theranostic complex.187 While many of these tasks can be achieved with 
nanoshell complexes in the 150 nm diameter size range, there are important reasons to 
develop nanocomplexes that maintain similar optical functionality in smaller size 
regimes. For the detection and treatment of specific types of tumors, such as brain 
tumors, nanoparticles in the sub-100 nm size regime are expected to have higher 
photothermal therapeutic efficacy since they can surpass the blood-brain barrier (BBB), 
allowing higher nanoparticle concentrations to accumulate in tumors. The BBB is a 
physical barrier in the form of tight junctions between epithelial cells which impede the 9 10 
transfer of injected agents in the bloodstream into brain tissue. Development of NIR 
resonant plasmonic nanostructures in the sub-100 nm size range will ultimately extend 
these powerful functionalities to this critical, and largely inaccessible, zone of treatment. 
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In this study we demonstrate the fabrication of sub-100 nm and sub-150 nm 
concentric nanostructures consisting of a solid Au nanoparticle immediately surrounded 
by a silica dielectric layer and then an outer Au shell. We show that the plasmon 
resonances of this nanoparticle result from the interaction between the essentially fixed-
frequency plasmon response of the central nanosphere with the bonding and antibonding 
plasmons of the surrounding nanoshell. The coupling of nanosphere and nanoshell 
plasmons in this nanomatryushka particle provides even greater spectral tunability than 
for an individual Au nanoshell. We relate the optical spectra of the synthesized 
nanoparticles directly to the plasmon hybridization model of the nanoparticle. For larger 
nanomatryushkas of this geometry, we observe an additional quadrupolar mode due to 
phase retardation. 
7.2 Experimental Methods 
Materials Required: HAUCI4.3H2O (99%, Sigma), potassium carbonate ( K 2 C O 3 , 
anhydrous, Fisher), CO gas (Matheson), tetraethyl orthosilicate (TEOS, Sigma), 30% 
N H 4 O H (Fisher), 200 proof ethanol (Decon Labs Inc.), N-n-butyl-aza-2,2-
dimethoxysilacyclopentane (Gelest, SIB 1932.4), tetrakis(hydroxymethyl)phosphonium 
chloride (THPC, Sigma), lMNaOH (Fisher). 
Fabrication of Au Nanoparticles: Au nanoparticles were fabricated by reducing Au from 
a 1% HAuC14-K2C03 solution with CO(g). Briefly, 25 mg K2C03 was added to 100 mL 
H 2 0 in an amber glass bottle, and subsequently 1.5 mL 1% HAuCU was added and the 
solution was allowed to age at room temperature, in the dark, for 24-72 hours. The 1% 
HAuCU was aged for 14 days prior to adding to the K 2 C O 3 solution. The 30 nm diameter 
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Au nanoparticles were fabricated by aging the 1 % H A U C 1 4 - K 2 C O 3 solution for 24 hours 
and bubbling CO(g) through the solution for 3 minutes under vigorous stirring. The 40 
nm and 50 nm diameter Au nanoparticles were fabricated similarly, except the 1% 
HAuCU- K 2 C O 3 solution was aged for 48 hours. The 80 nm diameter Au nanoparticles 
were also synthesized similarly, except the 1% HAuCL- K 2 C O 3 solution was aged for 72 
hours. The nanoparticles were centrifuged twice, 30 minutes each time, and redispersed 
in H2O. The centrifuge speeds are mentioned below. 
Fabrication of Nanoparticles coated with Silica: The 80 nm diameter Au nanoparticles 
were coated with silica following a similar procedure as reported previously.105 Briefly, 7 
mL of a concentrated Au nanoparticle solution (-1010 particles/mL) was mixed with 40 
mL of 200 proof fresh ethanol and 400 pL 30 % N H 4 O H , and subsequently 4 pL 
tetraethyl orthosilicate (TEOS) was quickly added. The reaction was allowed to proceed 
for 45 minutes at room temperature under vigorous stirring and then stored in the 
refrigerator at 4 °C for 24 hours. The following day, the Au/Si02 nanoparticles are 
centrifuged and resuspended in 10 mL ethanol. 
The 30, 40, and 50 nm diameter Au nanoparticles were coated with silica by 
following a slightly different procedure. Concentrated TEOS and NH4OH (30%, pH~12) 
result in aggregation of the smaller nanoparticles due to charge destabilization at high pH 
and excess silane coupling agent. Hence, 2 mL of the smaller nanoparticle aqueous 
solution (5xl010 particles/mL) were mixed with 10 mL of 200 proof fresh ethanol and 70 
pL of 0.4 % N H 4 O H (pH - 8.5), and subsequently 50 -100 pL 10 mM ethanolic TEOS 
solution (11 pL TEOS in 5 mL ethanol) was quickly added to the reaction mixture. The 
reaction was allowed to proceed for 45 minutes at room temperature under vigorous 
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stirring and then stored in the refrigerator at 4 °C for 24 hours. The smaller nanoparticles 
were not centrifuged but directly used for silane functionalization. 
Cyclic Silane Functionalization of Nanoparticles: The smaller Au/Si02 nanoparticles (30, 
40, and 50 nm diameter) were functionalized with 200-400 |j.L of 1 mM ethanolic 
solution of cyclic silane (4 (iL silane to 20 mL ethanol) for 24 hours. The 80 nm diameter 
Au/Si02 nanoparticles were functionalized with 1 mL of 1 mM ethanolic solution of 
cyclic silane for 24 hours. The silane-functionalized, silica-coated nanoparticles were 
used directly for the next step without further centrifugation. Excessive centrifugation 
resulted in aggregation of nanoparticles. 
Fabrication of Au/SiO?/Au nanoshells: The metal core nanoshells were fabricated by seed 
mediated electroless plating of Au onto the silica coated nanoparticles as previously 
1 8 
reported. The precursor particles were prepared by decorating the silica coated 
nanoparticles with small gold colloid (2-3 nm) fabricated by the method reported by Duff 
90 
et al. Briefly, 10 mL of the silane functionalized silica coated nanoparticles were mixed 
with 40 mL of Duff gold colloid and 2 mL NaCl (1 M). The precursor particles were left 
unperturbed for 24 hours at room temperature, following which they were centrifuged 
and redispersed in 5 mL H2O. The 1% HAuCU- K 2 C O 3 solution previously prepared was 
used as the plating solution. A continuous gold shell was grown around the Au/SiC>2 
nanoparticles by mixing 3 mL of the plating solution with different aliquots of the 
precursor particles and bubbling CO(g) for 10 seconds.28 The reaction was scaled up to 
obtain appropriate volume, centrifuged and finally redispersed in H2O. 
Instrumentation and Modeling: Scanning electron microscope (SEM) images were 
obtained using a FEI Quanta 400 environmental SEM at an accelerating voltage of 25 
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kV. Extinction spectra were obtained using a Cary 5000 UV/Vis/NIR spectrophotometer. 
Simulated surface charge plots were performed using the RF module of the commercial 
Finite Element Method software (COMSOL Multiphysics 3.5a) using three-dimensional 
scattered harmonic propagation. 
Centrifuge Speeds for Nanoparticles of Different Sizes: The following speeds were used: 
Diameter Au nanoparticles Au/Si02 precursor Au/Si02/Au nanoshells 
80 nm 1500 rcf 390 rcf 150 rcf 
50 nm 1600 rcf 700 rcf 250 rcf 
40 nm 1700 rcf 800 rcf 300 rcf 
30 nm 1850 rcf 920 rcf 370 rcf 
7.3 Plasmon Hybridization of Au/SiO/Au Nanoshells 
Plasmon Hybridization is a useful tool for interpreting the plasmon modes of 
21 
complex metallic nanostructures. This approach has been used to explain the resonant 
modes of a nanomatryushka, where the plasmon modes of the inner and outer metallic 
shells hybridize, giving rise to symmetric and antisymmetric plasmon modes. The 
fabricated Au/Si02/Au nanoshell is a simple example of a nanomatryushka, where the 
inner solid gold nanosphere can be viewed as a gold nanoshell of zero aspect ratio. The 
response of this system can be interpreted as the interaction between the primitive 
plasmon mode of a solid Au sphere and the plasmon modes of the nanoshell. 
For a nanomatryushka in the quasistatic regime, [ri, r2, rj] = [5, 7, 9] nm (Fig. 
7.1 A), where ri is the radius of the gold core, r2 the radius of the silica-coated core, and r3 
the total nanoparticle radius, three dipolar plasmon modes are obtained. Two modes 
correspond to the hybridization of the low-energy bonding nanoshell plasmon with the 
nanosphere plasmon, giving rise to a low energy antisymmetric bonding mode 
(I >(i)M,_Mp) a n d a symmetric antibonding mode (| o/_
 MP). 
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Figure 7.1. Theoretical analysis of Au/Si02/Au nanoshells showing (A) an energy level 
diagram describing the interaction between the Au nanoparticle and Au nanoshell 
plasmon resonances resulting in three hybridized energy levels in the quasistatic regime 
[ f j , r2, r3] = [5, 7, 9] nm in n =1 media in the dipole limit. (B) Surface charge 
distributions on the Au core, inner and outer Au shell interfaces qualitatively 
corresponding to the three energy eigenmodes. (C) Simulated far field extinction 
spectrum of the quasistatic Au/SiCVAu nanoshell using the Johnson & Christy dielectric 
function for gold; with plasmon peaks assigned as (a) hybridized bonding and (b) 
hybridized antibonding modes. (D) Energy level diagram describing plasmon modes of 
Au/SiCVAu nanoshell having dimensions [r/, r2, rj] = [40, 55, 65] nm showing the 
hybridized energy level for I =1 dipole (bottom) and / =2 quadrupole (top). (E) Simulated 
far field extinction spectrum of this larger Au/SiCVAu nanoshell using Johnson & 
Christy dielectric function for gold with appropriate peak assignments. 
Because the interaction between the higher-energy antibonding nanoshell plasmon mode 
and the nanosphere plasmon is extremely weak, we designate this third mode 
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(| CQ+_ > (I )nb) as a non-bonding mode. This mode is essentially dark, since it has a very 
small dipole moment due to its appreciable antibonding character. To determine the 
nature of the modes that couple to the incident plane wave, Finite Element Method based 
simulations were performed for this small quasistatic Au/SiCVAu nanoshell. The induced 
surface charge distribution (Fig. 7.IB) was calculated on Au core, inner and outer Au 
shell interfaces. These charge plots fully confirm the hybridization picture. The dipolar 
bonding | co~_ >(I)ns_np mode is identified by its distinct regions of positive and negative 
charge density. The higher energy dipolar antibonding | co+_ >(i)NS_NP mode is recognized 
by the similar induced charges residing on each of the interfaces, and the higher energy 
nonbonding mode | co+_ >(1)nb possesses an alternating charge distribution for each 
successive interface of the nanoparticle. 
The calculated far field extinction spectrum (Fig. 7.1C) shows two distinct 
plasmon peaks situated at 750 nm and 515 nm (labeled as ' a ' and '6') which corresponds 
to hybridized bonding | o)~_ >(1) ^ a n d antibonding | > ( I ) n s _ n p modes. This 
calculation was performed in vacuum (£"=1) using the experimentally obtained Johnson 
and Christy dielectric function for gold115 and a constant dielectric value (s = 2.04) for 
silica. The symmetric antibonding mode has a larger dipole moment relative to the 
antisymmetric bonding mode, which results in a strong coupling to the incident light. 
However, its overlap with the interband transitions of Au results in significant linewidth 
broadening and therefore a decrease in the peak amplitude. 
The plasmon modes for a larger size Au/SiCVAu nanoshell [r/, r2, r?] = [40, 55, 
65] nm were calculated in the same manner and the modes are identified using the 
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plasmon hybridization model. (Fig. 7.ID). As for the small quasistatic shell in Figs. 
7.1A-C, the same three dipolar hybridized modes are formed. The simulated far field 
extinction spectrum of this larger Au/SiCVAu nanoshell exhibit three peaks, positioned at 
920 nm, 650 nm and 535 nm (labeled as a (1 = 1), a (I = 2) and b (I = 1) in Fig. 7.1E). 
The peak at 920 nm is the dipolar bonding mode (| af_ >(i)NS_NP) and the peak at 535 nm 
is the dipolar antibonding mode (| a>+_ >(i)NS_NP)- The relative intensity of the antibonding 
mode is higher than for the small quasistatic nanoshell because here it is shifted further 
away from the interband transition threshold. The additional mode that appears as a weak 
shoulder at 650 nm is a quadrupolar bonding mode (| af_ > ( 2 ) n s _ n p ), which can be excited 
because of phase retardation. 
7.4 Fabrication and Characterization of Au/SiO2/Au Nanoshells 
The Au/SiCVAu nanoshells were experimentally fabricated as shown 
schematically in Figure 7.2A. The synthesis technique developed here is originally 
• 211 • • 
adapted and modified from one reported previously. Au nanoparticles of various sizes 
are initially coated with an epilayer of amorphous Si02 by the condensation of tetraethyl 
orthosilicate in an alkaline medium. Typically N H 4 O H (pH 8-12) is used to initiate this 
base-catalyzed reaction. The Au/Si02 nanoparticles were then functionalized with a 
cyclic silane (N-n-butyl-aza-2,2-dimethoxysilacyclopentane). The use of cyclic 
azasilanes has several advantages compared to the use of alkyl trialkoxy silane coupling 
agents such as 3-aminoproplytriethoxysilane (APTES) and 3-
mercaptoproplytriethoxysilane (MPTES). Alkyl trialkoxy silanes undergo stepwise 
hydrolysis in alkaline aqueous media to form the corresponding silanol and subsequent 
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condensation to siloxanes.212 The hydrolysis is relatively rapid than the condensation 
reaction. During the condensation reaction, depending on the amount of H2O present, 
polymerization of silanes may occur,212 which often results in nanoparticle 
agglomeration. 
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Figure 7.2. (A) Schematic representation of the fabrication procedure of Au/SiCVAu 
nanoshells. SEM images showing (B) Au nanoparticles of radius, ri = 40 ± 4 nm, (C) Au 
nanoparticles coated with 15 ± 2 nm SiC>2 epilayer, (D) Au/SiCh nanoparticles decorated 
with 2 nm Au colloid, (E) Au/SiCVAu nanoshells with dimensions [n, r2, r3] = [40, 55, 
65] nm. The scale bar is 200 nm. 
Cyclic azasilanes, alternatively, are particularly useful in surface modification of 
hydroxyl-containing nanoparticles, since they cause significantly less nanoparticle 
flocculation. Under basic conditions, cyclic azasilanes undergo ring opening by 
hydrolytic cleavage of the C-N bond which has a lower bond energy (320 kJmole"1) than 
the Si-0 bond (450 kJmole"1).213 Due to this ring-opening mechanism, cyclic azasilanes 
relieve the ring strain and consequently hydrolyze faster. Therefore, unlike APTES and 
MPTES, cyclic azasilanes do not require water as a catalyst for hydrolysis, resulting in no 
reaction byproducts. Therefore self-polymerization of the silane is substantially reduced, 
resulting in less nanoparticle aggregation.213 Subsequent to silanization, small Au colloids 
(2-3 nm diameter) were attached to the silane functionalized Au/SiC>2 nanoparticles, 
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which serve as nucleation sites for the electroless plating of the outer Au shell layer onto 
the nanoparticle surface. A complete outer Au layer is formed by reducing Au from a 1% 
12 18 
HAuCU aqueous solution in the presence of gaseous CO as the reducing agent. ' This 
synthesis technique allows the fabrication of relatively monodisperse nanostructures with 
a complete and homogeneous outer Au layer. Scanning electron microscope (SEM) 
images of the nanostructures at various stages of the fabrication procedure are shown in 
Figure 7.2B-E. Au nanoparticles of radius 40 ± 4 nm (Fig. 7.2B) coated with 15 ± 2 nm 
layer of silica (Fig. 7.2C) were fimctionalized with silane and decorated with 2-3 nm 
diameter Au colloid (Fig. 7.2D). Completed Au/Si02/Au nanoshells with dimensions [rj, 
f2, r^] = [40, 55, 65] nm are shown in Figure 7.2E. 
7.5 Optical properties of Au/SiO2/Au Nanoshells 
The experimentally observed plasmon resonances of the Au/Si02/Au nanoshell solutions 
of varying dimensions, dispersed in aqueous media, are shown in Figure 7.3A. The 
extinction spectra of the core Au nanoparticles of radius ~ 40 nm and the Au/Si02 
nanoparticles of radius ~ 55 nm are shown in Figure 7.3A i-ii. For these nanoparticles, 
the plasmon resonance of the core nanosphere redshifts from 550 nm (in aqueous 
solution) to 562 nm after coating with Si02, due to the higher refractive index of Si02 (n 
= 1.46) compared to H2O (n = 1.33). Extinction spectra of Au/Si02/Au nanoshells with 
the same inner nanosphere radius and spacer layer but with increasing thickness of the 
outer core are shown in Figure 7.3A iii-vi. The observed optical spectra of these 
structures are dramatically different than those of the Au/Si02 nanoparticles. A new 
dipolar bonding resonance is observed in the NIR, which blueshifts across the 1000-800 
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nm wavelength range with increasing shell thickness. Specifically, as the outer Au shell 
thickness increases from 10 nm to 13 nm, 18 nm and 31 nm, the dipolar bonding 
resonance blueshifits from 990 nm to 930, 885, and 800 nm, respectively. In addition, a 
new broad resonance appears at 620 nm when the metallic shell is present (Fig. 7.3A iii), 
also shifting to shorter wavelengths with increasing shell thickness (Fig. 7.3A iv-vi). 
The theoretical extinction spectra corresponding to the Au/SiCVAu nanoshells are 
shown in Figure 7.3B. The calculated optical spectra were obtained using Mie theory, 
assuming a symmetric nanostructure with a spherical Au core, and a spherically 
symmetric SiC>2 layer and outer Au shell using Johnson and Christy gold permittivity 115 
was used in these calculations. The maxima in each calculated extinction spectrum 
correspond well to those observed in the experimental spectra. The blueshifting 
resonances are the hybridized dipole bonding, | a>~_ >CI>NS—NT> ' an<^ dipole antibonding, 
| col >(])ns np modes of the Au/SiCVAu nanoshells, (Fig. 7.ID). For increasing shell 
thickness, the interaction between the cavity and sphere plasmons in the nanoshell 
decreases, resulting in a blue shift of the bonding nanoshell plasmon resonance (Fig. 
7.3B). The smaller narrow resonant feature observed in the theoretical spectra, which 
blue shifts from 685 nm to 600 nm as the outer Au shell thickness increases is the 
quadrupole bonding mode, (| af_ >(2) ) indicated in Fig. 7.IE. 
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Figure 7.3. (A) Experimental extinction spectra of (i) Au nanoparticles of radius ri = 40 
nm, (ii) Au/SiC>2 nanoparticles, r2 = 55 nm, and Au/Si02/Au nanoshells where (iii) r3 = 65 
nm, (iv) r3 = 68 nm, (v) r3 = 73 nm, and (vi) r3 = 86 nm. (B) Theoretical spectra 
corresponding to the experimental spectra from part A. The spectra are color coordinated 
and offset for clarity. (C) SEM images of Au/SiCVAu nanoshells corresponding to the 
spectra from part A. (i) r3 = 65 nm, (ii) r3 = 68 nm, (iii) r3 = 73 nm, and (iv) r3 = 86 nm. 
The scale bar is 100 nm. 
Experimentally, this spectral feature is observed as a lineshape modulation, and in fact 
appears both broader and stronger in the experimental spectra than in the theoretical 
calculations. The broad linewidth of this feature is due to the inhomogeneous broadening 
characteristic of the optical spectroscopy of nanoparticle ensembles. The fact that this 
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feature is more clearly observable in the experimental spectra than in our calculated 
spectra we attribute to the reduced symmetry of the nanoparticles themselves, in other 
words, the irregularities of the synthesized nanoparticles. For structural defects that break 
the spherical symmetry of the system, such as for instance an outer shell of nonuniform 
thickness or a nonconcentric alignment of the shells, quadrupole modes will hybridize 
with dipolar modes, thus strongly enhancing their brightness..214 Scanning electron 
microscope (SEM) images of the Au/Si02/Au nanoshells corresponding to the 
experimentally observed optical spectra are shown in Figure 7.3C i-iv, in the order of 
increasing Au shell thickness. 
The optical extinction spectra of several Au/SiCVAu nanoshells in the sub-100 nm 
diameter regime, and their corresponding SEM images, are shown in Figure 7.4. The 
optical spectra shown in Figure 7.4Ai-ii represent Au/SiCVAu nanoshells equivalent in 
overall dimensions, but as the size of the Au core increases from r j = 15 nm to 20 nm, the 
intermediate SiC>2 layer thickness is decreased. This results in a redshift of the 
I co~_ >(i)NS_NP plasmon resonance from 660 nm to 730 nm due to an increase in the 
interaction between the plasmons supported by the Au nanosphere core and the Au outer 
shell layer. The spectra in Fig. 7.4Aiii-iv shows redshifits of the | of_ >(I)ns NP mode from 
755 nm to 790 nm as the outer Au layer thickness decreases while all other dimensions 
remain constant. Theoretical Mie extinction spectra of the sub-100 nm Au/SiC^/Au 
nanoshells (Fig. 7.4B) quantitatively reproduce the experimental data (Fig. 7.4A). SEM 
images of Au nanoparticles of radius 25 ± 3 nm, and those coated with a homogeneous 
12 ± 2 nm layer of SiC>2 are shown (Fig. 7.4C, D). The SEM images of the sub-100 nm 
Au/Si02/Au nanoshells corresponding to the experimental extinction spectra are also 
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shown (Fig. 7.4E-H). The inner Au core is clearly visible when the silica layer thickness 
and outer Au shell layer are on the order of ~ 10 nm. 
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Figure 7.4. (A) Experimental extinction spectra of sub 100 nm Au/SiCVAu nanoshells 
with different dimensions (i) [ri, r2, r3] = [15, 30, 42] nm (ii) [ri, r2, r3] = [20, 30, 42] nm 
(iii) [ri, r2, r3] = [25, 37, 51] nm (iv) [ri, r2, r3] = [25, 37, 47] nm (B) Theoretical spectra 
corresponding to the experimental spectra in (A). The spectra are color coordinated and 
offset for clarity. SEM images of (C) Au nanoparticles of radius, ri = 25 ± 3 nm, (D) and 
coated with 12 ± 2 nm Si02 epilayer. Sub 100 nm Au/Si02/Au nanoshells corresponding 
to the spectra from part A. (E) [ri, r2, r?] = [15, 30, 42] nm (F) [ri, r2, r3] = [20, 30, 42] nm 
(G) [n, r2, r3] = [25, 37, 51] nm (H) [n, r2, r3] = [25, 37, 47] nm. The scale bar is 100 nm. 
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7.6 Calculated Far-Field Properties of Au/SiO/Au Nanoshells 
Upon illumination with resonant light, metallic nanoparticles will preferentially scatter or 
absorb light, or some combination of the two.26 In applications, scattering is useful for 
contrast enhancement in bioimaging. Absorption, and its subsequent photothermal 
heating, which occurs due to nonradiative plasmon decay, results in the therapeutic 
actuation of hyperthermic cell death or oligonucleotide release. For simple nanoparticles, 
the absorption and scattering efficiencies are mainly a function of nanoparticle size: for 
layered nanoparticles this relationship becomes more complex and geometry dependent. 
For multilayered nanomatryushkas, their relative absorption and scattering efficiencies 
can be modified, for a fixed nanoparticle size, by varying the internal geometry. The 
calculated absorption and scattering profiles of the sub-100 nm Au/Si02/Au nanoshells 
fabricated here are shown in Figure 7.5. For fixed nanoparticle size, an increase in the 
radius of the Au core and a decrease in the silica layer increase the coupling between the 
core and shell plasmons and results in an increase in absorption efficiency. As seen here, 
this dependence can be quite significant: by increasing core radius and reducing silica 
spacer layer thickness each by only 5 nm, the relative absorption efficiency increases 
from 46% to 63% for the same overall size nanoparticle (Fig. 7.5 A, B). This suggests that 
for bioimaging applications, where a larger scattering cross section is preferable, 
Au/SiCVAu nanoshells with a thicker intermediate silica layer (>10 nm) would be more 
efficient, while for therapeutic-actuation applications, where a larger absorption cross 
section is desired, a geometry with thinner silica layers (< 10 nm) would be preferred. 
The relative absorption and scattering efficiencies can also be modified by altering the 
outer Au shell thickness. A nanomatrushka with a thicker Au shell (> 10 nm) has greater 
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scattering efficiency, while the thinner Au shell (< 10 nm) has a greater absorption 
efficiency (Fig. 7.5C-D). Again, the higher absorption efficiency corresponds to the case 
where the constituent plasmons of the nanoparticle layers couple most strongly. 
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Figure 7.5. Calculated absorption (red) and scattering (black) efficiencies of Au/Si02/Au 
nanoshells of different sizes. (A) [ri, r2, r3] = [15, 30, 42] nm (B) [ri, r2, r3] = [20, 30, 42] 
nm (C) [r,, r2, r3] = [25, 37, 51] nm (D) [r,, r2, r3] = [25, 37, 47] nm. 
7.7 Conclusions 
The Au/Si02/Au nanoshells fabricated in this study are simple examples of 
nanomatryushkas and provide a high degree of plasmonic tunability. Their small size 
makes them extremely versatile and promising for a wide array of optical and biomedical 
159 
applications. The induced charges at the gold-dielectric interfaces govern both the near-
field and far-field properties of the structure. The relative absorption and scattering 
efficiencies can be controlled by tuning the internal geometry for a fixed outer 
nanoparticle diameter. The plasmon hybridization model reveals that the spectral modes 
of this nanoparticle arise due to the coupling between the inner Au core and outer Au 
shell plasmon modes. Understanding precisely the plasmon response of concentric 
symmetric nanostructures is fundamentally interesting and may provide routes to a 
variety of technological applications, ranging from novel optical devices to biomedical 
imaging and the treatment of deadly diseases. 
160 
Chapter 8: Metallic Nanoshells with Semiconductor Cores: 
core media modification of absorption and scattering response 
8.1 Introduction 
In the previous chapter, we discussed a unique route to tuning the plasmon 
resonance of nanoshells to the NIR in sub-100 nm size regime by simply introducing Au 
nanoparticle core inside a SiCVAu nanoshell. In this chapter we investigate another 
approach for achieving sub-150 nm and sub-100 nm nanoshells resonant in the NIR, by 
changing the core material to a higher permittivity semiconductor oxide such as cuprous 
oxide (e ~ 7.8). The high permittivity of the CU2O core induces a dramatic increase in 
absorption efficiency, a significant redshift of the plasmon energy, and a reduced 
plasmon linewidth, relative to nanoshells with lower permittivity dielectric cores. The 
CU2O core also results in a strong enhancement of the electromagnetic field inside the 
core, an important property which may enable new optical applications. Rizia Bardhan 
fabricated and characterized the CU2O/AU nanoshells, performed optical studies and 
calculated far field properties. Nathaniel Grady contributed in analysis and discussion. 
Manuscript in preparation: Rizia Bardhan, Nathaniel K. Grady, Tamer Ali, Naomi Halas. 
Nanoshells, nanoparticles with dielectric cores and metallic shells, have elicited 
increasing scientific and technological interest due to their ability to manipulate light in 
unique ways. Their optical properties are governed primarily by the surface plasmons 
supported by this structure, whose resonance frequencies are tuned by varying the 
internal nanoparticle geometry. The surface plasmons give rise to intense local 
electromagnetic fields at the nanoshell surface, which have been harnessed for several 
215 216 217 218 27 187 photonic, ' spectroscopic ' and biomedical ' applications. At the plasmon 
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resonance, these nanoparticles also exhibit large far field scattering and absorption cross 
sections. Nanoshell plasmons have also been shown to dramatically affect radiative 
transitions in materials adjacent or inside of a metallic nanostructure.5'130'219 Analogous 
to the Purcell effect in cavities and waveguides, emission from an adjacent excited atom, 
molecule, or semiconductor can decay directly into a resonant plasmon, modifying the 
available photon density of states and changing its radiative decay rate.220 The plasmon 
then radiates the emission to the far field. This is essentially a nanoantenna effect, where 
the nanoparticle serves to couple the emission of the adjacent fluorescent medium to the 
far field. The scattering cross section of the nanoshell is critically important to the 
efficiency of this process. 
The plasmon resonance frequencies of nanoshells is a function of the dimensions 
and permittivity of the core, the shell and the embedding medium.23'25 In addition to 
tuning the resonance energy, the core and shell properties also dramatically influence 
nanoshell absorption and scattering efficiencies. For simpler nanoparticles like 
nanospheres or nanorods, the amount of light absorbed or scattered by the nanoparticle is 
a function of nanoparticle size. While smaller nanoparticles are predominantly 
absorptive, the absorption to scattering ratio decreases with increasing nanoparticle size, 
where ultimately larger particles are better light scatterers than light absorbers. With the 
layered nanoshell geometry, however, this relationship is more complex. Recently we 
showed that the absorption and scattering efficiencies of gold-silica-gold layered 
nanostructures can be modified, for a fixed nanostructure size, by tailoring the thickness 
99 i 
of the intermediate dielectric layer. In this study we show that by changing the core 
material to a higher permittivity semiconductor cuprous oxide (CU2O), the absorption and 
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scattering cross sections of the nanoshell can be significantly altered. The unique ability 
to manipulate the optical properties of this nanoparticle by varying either internal 
geometry or material makes nanoshells extremely attractive for a wide variety of 
applications. 
CU2O, a semiconductor with a bandgap of 2.17 eV, is an ideal material for 
studying exciton physics. In bulk CU2O, the lowest-energy "yellow" exciton series is a 
prototypical example of Wannier excitons, with energy levels following a simple 
999 99^ 994 
hydro genie model for n > 2 ' and oscillator strengths for n > 3. The Is state is 
distinct because its excitonic Bohr radius (0.53 nm) is comparable to the lattice constant 
(0.43 nm), resulting in several interesting properties. Electron-hole exchange interactions 
split the Is exciton into a triply degenerate orthoexciton with total orbital angular 
momentum J = 1, and a paraexciton 12 meV below the orthoexciton with a total orbital 99^  99A 
angular momentum J = 0. " Due to the inversion symmetry of CU2O, direct creation 
of Is excitons by one-photon optical transitions is only quadrupole allowed for the 
orthoexcitons and completely forbidden for the paraexcitons. In contrast, two-photon 
absorption processes may provide a route to populating these states. The small Bohr 
radius also results in a large binding energy, approximately 150 meV for the paraexciton 
and 140 meV for the orthoexciton, attributable to the lack of Coulomb screening by the 
lattice. Because these excitons are strongly bound, they retain their bosonic character up 
to a relatively high temperature and density, providing a promising system for the study 
994 997 
of excitonic Bose-Einstein condensation (BEC). ' In addition to BEC, these excitons 
have also been well studied for numerous physical effects. The nearly ideal excitonic 
structure allows detailed studies of the manipulation of the band structure with magnetic, 
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electrical and optical fields. This can be exploited to populate and probe optically 
99 fi 9"in 
forbidden exciton states, and has led to the observation of dynamical Stark shifts in 
the exciton spectrum.231 Exciton physics is not the only area in which CU2O has attracted 
significant interest. CU2O is also a promising material for third harmonic generation in the 
near- and mid-IR due to its significant non-resonant third order susceptibility (x(3)) 
combined with a lack of competing second order processes and minimal absorption of the 
generated light. 
By encapsulating Cu20 in a nanoscale Au shell, the nanoshell plasmons generated 
at the CU2O/AU interface can be used to effectively control the coupling of these excitons 
to light. This can be achieved both by dramatically enhancing the excitation field in the 
semiconductor, particularly important for two-photon absorption, and by tuning the 
radiative decay rate. More directly, coupling between plasmons and excitons can lead to 
the formation of hybrid plasmon-excition, or plexciton, states. This has been previously 
observed for Frenkel excitons in J-aggregates adsorbed to the surface of a nanoshell. 
The optically bright nanoshell plasmon modes can couple to the optically dark 
paraexcitons of CU2O, providing a simple and feasible route for detecting these optically 
forbidden exciton states. The nanoshell plasmon resonance also results in strong field 
enhancements which can dramatically increase the nonlinear response of the CU2O core. 
In this study, we experimentally fabricate nanoshells consisting of a CU2O core 
coated with a thin Au shell, (CU2O/AU) and, in conjunction with theoretical models, 
investigate the unique plasmonic properties of these nanoshells. The nanoshells were 
fabricated in the sub-100 nm and sub-150 nm size regime and have'tunable plasmon 
resonances from the visible to the NIR region of the spectrum. Due to the high 
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permittivity of C 1 1 2 O , the plasmon resonance of CU2O/AU nanoshells were observed to 
red shift by -100-130 nm compared to nanoshells with a lower permittivity core material, 
such as SiC>2 core (e~2.04) Au shell (SiCVAu) nanoshells of equivalent dimensions. 
Theoretical analysis reveals that the larger dielectric constant of CU2O results in a 
nanoshell with high absorption efficiency compared to dielectric core materials such as 
SiC>2. The presence of the CU2O core material results in a strong enhancement of the 
electromagnetic field inside the nanoparticle. Due to their compact size, tunability in the 
NIR and larger absorption cress-sections, CU2O/AU nanoshells should also be highly 
efficient nanoparticles for photothermal heating applications in biomedicine, where 
efficient conversion of absorbed light to heat is required. 
8.2 Experimental Methods 
CutO nanoparticle synthesis: All materials were purchased from Sigma Aldrich and used 
without further purification. The CU2O nanoparticles were synthesized by adapting and 
modifying a protocol previously reported.234 Briefly, 4 ml of 0.01 M aqueous CUSO4 
solution were mixed with 16 mL of PEG dithiol (MW 1530) at various concentrations 
under vigorous stirring at room temperature. Subsequently, 13 mL of 0.115 M NaOH and 
10.5 mL of 0.005 M Ascorbic acid were mixed together in a separate vessel and quickly 
added to the CUSO4 - PEG dithiol solution mixture. The reaction was proceeded for an 
additional 2 minutes under vigorous stirring following which it was quenched by blowing 
an inert gas (N2 or Ar) into the reaction mixture for 20 minutes. Depending on the 
particle size, the solution turns from colorless to bright yellow (for smaller CU2O 
nanoparticles) or orange (for larger CU2O nanoparticles) in color. The nanoparticles were 
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purified by centrifuging the nanoparticles between 5500-7000 rpm depending on particle 
size. All reaction conditions are provided in Table 8.1. 
CuyO/Au nanoshells synthesis: The CU2O/AU nanoshells were fabricated by seed 
mediated electroless plating of Au onto CU2O nanoparticles. Briefly, monodisperse CU2O 
nanoparticles were decorated with small gold colloid (2- 3 nm) prepared by the method 
90 
reported by Duff et al. A continuous gold shell was grown around the CU2O 
nanoparticles by reducing gold from an Au+ plating solution onto the attached small 19 18 
colloid in the presence of CO(g). ' The plating solution was prepared by mixing 50 mg 
of potassium carbonate with 200 mL of H2O and 3 mL of a 1 % HAuCU solution and 
allowed to age for 24 hours before using. The fabricated CU2O/AU nanoshells were 
centrifuged several times and finally redispersed in aqueous media to form desired 
particle concentrations. 
Formation of Cu?Q nanoparticle arrays: CU2O nanoparticle arrays were formed by 
applying droplets of nanoparticle solution to a silicon or quartz substrate and allowing the 
solvent to evaporate under ambient conditions. The silicon and quartz substrate were 
thoroughly rinsed with acetone and dried in a stream of N2 before applying the droplet of 
nanoparticle solution. The solvent evaporation resulted in the nanoparticle monolayer to 
self-assemble into ordered arrays. The pattern morphologies of the nanoparticle arrays 
were dependent on the particle concentration of the CU2O nanoparticle solutions. At very 
low particle concentrations, only isolated small monolayer domains of arrays with short-
range order could be formed on the substrates. Increasing the particle concentration 
resulted in an increase in the domain size as the initially separated domains began to 
coalesce with each other to form continuous long-range-ordered monolayers. 
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Characterization: The nanoparticles were characterized by obtaining SEM images using 
a FEI Quanta 400 field emission SEM at an acceleration voltage of 25 kV, XRD patterns 
by using a Rigaku Ultima II vertical 0 - 0 powder diffractometer (Cu Ka, X,= l.5418 A) 
and absorption measurements using a Varian Cary 5000 UV-Vis-NIR spectrophotometer. 
8.3 Fabrication and Optical Properties of Cu20 nanoparticles 
Figure 8.1. SEM images of CU2O nanoparticles of different sizes. The radii of the 
nanoparticles are (A) 15 ± 0.5 nm, (B) 30 ± 1 nm, (C) 50 ± 2 nm, (D) 100 ± 5 nm, (E) 
250 ± 30 nm, and (F) 350 ± 50 nm. 
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The C 1 1 2 O M . U nanoshells were fabricated by a stepwise procedure by first 
synthesizing CU2O nanoparticles in the size range of 15 ± 0.5 nm to 350 ± 1 5 0 nm in 
radius in aqueous media at ambient temperature. The synthesis technique developed here 
is originally adapted and modified from one reported previously. The nanoparticles 
were fabricated by reducing copper (II) salts with ascorbic acid in the presence of sodium 
hydroxide and poly (ethylene) glycol dithiol (HS-PEG-SH). All the reaction conditions 
are provided in Table 8.1. Representative scanning electron microscope (SEM) images of 
the CU2O nanoparticles verify their morphology and dimensions (Fig. 8.1). X-ray powder 
diffraction spectra confirming the composition of the CU2O nanoparticles are shown in 
Figure 8.2. By simply varying the concentration of HS-PEG-SH, which acts as a 
stabilizing polymer, while keeping the concentration of the other reagents constant, the 
size of the CU2O nanoparticles were straightforwardly tuned. It is noticeable that the 
polydispersity is as low as ~ 3% for the nanoparticle sizes < 200 nm; however, for the 
larger nanoparticles polydispersity increases beyond 10%. This observation indicates that 
at higher HS-PEG-SH concentrations, more nucleation sites are initiated leading to a 
higher rate of growth kinetics resulting in a larger size distribution. As the size of the 
nanoparticle increases, particularly for sizes > 200 nm, more particles exhibit truncated 
cubic rather than near-spherical shapes (Fig. 8.1). The preferential adsorption of ions in a 
solution to different crystalline faces directs the development of nanoparticles into 
unusual shapes by controlling the growth kinetics along the different crystal axes. For 
CU2O, cubic shape is known to form when the crystalline growth is along the (111) 
plane.234 The observed shapes imply that a fraction of the PEG-dithiol molecules may be 
adsorbing on the (111) plane and hence assisting in the morphological development of 
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the CU2O nanoparticles along the <111> direction. In addition, the HS-PEG-SH 
molecules also terminate the CU2O nanoparticles with thiol groups which can attach to 
Au without the need of further functionalization for Au coating. 
Figure 8.2. XRD patterns of CU2O nanoparticles of different sizes. The diameter of the 
nanoparticles corresponding to each pattern is provided on the right. The amorphous 
background observed on the lower two patterns is due to the glass substrate used for 
sample preparation. 
Table 8.1. Experimental parameters for synthesizing CU2O nanoparticles of various sizes. 
CuS04 PEG-dithiol Ascorbic Acid NaOH Particle Size 
(4 mL) (16 mL) (10.5 mL) (13 mL) (nm) 
0.01 M 0.005 M 0.005 M 0.115 M 700± 100 
0.01 M 0.003 M 0.005 M 0.115 M 500 ± 60 
0.01 M 0.0025 M 0.005 M 0.115 M 200 ± 10 
0.01 M 0.0015 M 0.005 M 0.115 M 100 ± 4 
0.01 M 0.0008 M 0.005 M 0.115 M 60 ± 2 
0.01 M 0.0003 M 0.005 M 0.115 M 30 ± 1 
The experimental and theoretical optical properties of the CU2O nanoparticles 
demonstrate the shape dependent optical response of these nanoparticles (Fig. 8.3). 
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Optical images (Fig. 8.3A) of the CU2O nanoparticles dispersed in aqueous media clearly 
shows as the nanoparticle sizes increase the solution changes from bright yellow to 
orange, similar to that reported previously for CU2O nanostructures.234 Experimental 
extinction spectra of the CU2O nanoparticles of different sizes dispersed in aqueous media 
demonstrate the different peaks that arise as the size of the nanoparticles increase (Fig. 
8.3B). The radius of the nanoparticles corresponding to each optical spectrum is indicated 
on the right. The extinction spectra of the smaller nanoparticles (< 100 nm) exhibit strong 
Rayleigh scattering and a small peak at 440 nm. As the nanoparticle sizes increase to 200 
nm, new peaks are observed in the visible near 530 nm and in the near-infrared near 700 
nm. With increasing size of the Cu20 nanoparticles, the peaks in the visible and the near-
infrared red shifts and additional features are observed in the near and mid-infrared. 
These additional extinction peaks observed for the larger nanocrystals are due to 
scattering at the well known Mie resonances of dielectric particles.26'235 
The theoretical extinction spectra of the CU2O nanoparticles (Fig. 8.3C) were 
obtained utilizing Mie theory assuming a spherical geometry with diameters matching the 
experimentally obtained nanoparticle sizes. The calculated extinction spectra correspond 
well to the measured spectra for all the nanoparticle sizes. Small disparities between 
calculated and experimental spectra are plausibly due to polydispersity, the combination 
of spherical and truncated cubic shapes in the nanoparticle solutions, and small variations 
in the dielectric function of the fabricated particles from the values for bulk CU2O 
obtained from literature.236 Nanoparticles have been reported to have higher band gap 
energy compared to the bulk material which is attributed to impurities and defects in 
crystal structure.237 The CU2O nanoparticles also form self-assembled ordered arrays 
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when a droplet of the nanoparticle solution is allowed to dry in ambient air at room 
temperature on a silicon or quartz substrate as represented in the SEM images (Fig. 8.4). 
400 600 800 1000 1200 
Wavelength (nm) 
Figure 8.3. (A) Optical image of CU2O nanoparticles dispersed in aqueous media of 
increasing sizes (indicated by arrow). (B) Experimental absorption spectra of the CU2O 
nanoparticles dispersed in aqueous media. The radius of the nanoparticles corresponding 
to the spectra is indicated on the right. Spectra are offset for clarity. (C) Calculated 
absorption spectra of the CU2O nanoparticles in aqueous media (n = 1.33). The spectra 
are color coordinated with part (B) and offset for clarity. 
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Figure 8.4. Self-assembled arrays of C112O nanoparticles of increasing diameter (A) 30 
nm, (B) 60 nm, (C) 100 nm and (D) 200 nm. The scale bar in (A) - (D) is 500 nm. (E) 
Low resolution SEM image of 100 nm diameter CU2O nanoparticle arrays. 
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8.4 Fabrication and Optical Properties of Cu20/Au Nanoshells 
Figure 8.5. SEM images of Cu20/Au-NS of different sizes. (A) [r,, r2] = [15, 32] nm, (B) 
[rh r2] = [30, 46] nm, (C) [n, r2] = [40, 54] nm, (D) [n, r2] = [50, 65] nm. The scale bar is 
200 nm. 
CU20/AU nanoshells are fabricated by seed mediated electroless plating of Au 
onto the thiol terminated Cu20 nanoparticles.12' 18 Small Au nanoparticles 2 nm in 
diameter) are immobilized onto the surface of the Cu20 cores. The immobilized Au 
nanoparticles act as nucleation sites for electroless plating of Au onto the surface of core 
particles, which gradually results in the formation of a continuous and complete metal 
shell layer upon reduction. Further metal deposition onto the nanostructure increases the 
thickness of the Au layer. SEM images of Cu20/Au nanoshells fabricated on cores 
ranging in size from a radius of 15 nm to 50 nm are shown in Figure 8.5. While Cu20 
nanoparticles can be synthesized in different shapes, ' the growth of a uniform Au 
layer on the nanoparticles modifies the overall shape.. The Au shell grows as a 
polycrystal on the Cu20 nanoparticle cores and hence results in a spherical morphology 
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with minor surface roughness. This facile synthesis route allows the fabrication of 
uniform, monodisperse, and non-flocculated core-shell nanostructures in sub-150 nm and 
sub-100 nm size regimes. The Au coating also allows dispersiblity in aqueous media and 
provides a biocompatible surface, which can be straightforwardly conjugated with 
functional molecules. 
The experimental and calculated optical properties of the CU2O/AU nanoshells are 
represent the morphological development of the CU2O after Au shell growth (Fig. 8.6). 
The optical images of CU2O/AU nanoshells dispersed in aqueous media (Fig. 8.6A) 
indicates a change in the solution color from purple to blue as the size of the CU2O/AU 
nanoshells increases. The experimentally observed extinction spectra of the CU2O/AU 
nanoshells dispersed in aqueous media with different core/shell ratios corresponding to 
the SEM images (Fig. 8.5) are illustrated in Figure 8.6B. The extinction spectra spans 
from the visible to the NIR region of the optical spectrum with the smallest size [ri, r2] = 
[15, 32] nm showing a plasmon resonance at 610 nm. With increasing nanoshell sizes, 
the plasmon resonance red shifts to 705 nm, 780nm, and 830 nm respectively (Fig. 8.6A). 
In the quasistatic limit, where the size of the nanoshell is much smaller than the spatial 
wavelength of light corresponding to its plasmon resonance, the plasmon energies of a 
OQ 
nanoshell depend on their aspect ratio ri/r2. As the aspect ratio increases the plasmon 
resonance shifts to longer wavelengths, which explains the redshifted plasmon resonance 
as the size of the Cu20/Au nanoshells increases. This behavior can be explained 
straightforwardly in terms of plasmon hybridization, an analytical tool useful for 
21 
understanding the resonant modes of complex metal nanostructures. 
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Figure 8.6. (A) Optical image of C112O/AU-NS of different sizes, (i) [ri, r2] = [15, 32] nm, 
(ii) [n, r2] = [30, 46] nm, (iii) [n, r2] = [40, 54] nm, and (iv) [n, r2] = [50, 65] nm (B) 
Experimental extinction spectra of Cu20/Au-NS dispersed in aqueous media of different 
sizes: (i) [rj, r2] = [15, 32] nm, Xm^ = 610 nm, (ii) [ri, r2] = [30, 46] nm, = 705 nm 
(iii) [r]? r2] = [40, 54] nm, Xm^ = 780 nm and (iv) [ri, r2] = [50, 65] nm, A,max = 830 nm. 
Spectra are offset for clarity. (C) Calculated extinction spectra of the Cu20/Au-NS in 
aqueous media. The spectra are color coordinated with part (B) and offset for clarity. The 
calculations were performed assuming spherical core and shell geometry. 
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For a spherical nanoshell where the dielectric constant of the core sc < 8, the low 
energy bonding nanoshell plasmon is optically active and is primarily observed in the 
99 9^ 0 
extinction spectra. ' For increasing shell thickness, the interaction between the cavity 
and sphere plasmons decreases, resulting in a blueshift of the bonding mode and a 
redshift of the antibonding mode. In addition, the plasmon resonance shifts to longer 
wavelengths with increasing overall size due to phase retardation effects.24' 25 The 
calculated extinction spectra of the CU2O/AU nanoshells corresponding to those observed 
experimentally were obtained using Mie theory assuming a spherical core and spherical 
shell geometry (Fig. 8.6C). The calculated spectra and peak positions correspond well 
with the experimental extinction spectra suggesting that CU2O nanoparticles < 100 nm are 
mostly spherical and the small fraction of truncated cubic shapes present do not affect the 
ensemble plasmon line shape or peak position. For the smallest fabricated CU2O/AU 
nanoshells, with [rj, r2] = [15, 32] nm, the observed plasmon line width is larger than 
those obtained theoretically, probably due to inhomogeneities in the Au layer thickness 
and some aggregation of the nanoshells after the growth of the Au layer. 
The tunability of the plasmon resonance was also observed experimentally by 
varying the Au shell thickness for a fixed core size. The experimental extinction spectra 
of CU2O/AU nanoshells with the same core radius 40 ± 2 nm and varying the shell 
thicknesses for a total outer radius of 54 ± 5 nm, 57 ± 5 nm, 60 ± 7 nm, and 63 ± 11 nm 
are shown in Figure 8.7A. Spectra calculated using Mie theory corresponds well to the 
experimental extinction spectra (Fig. 8.7B). With increasing Au shell thickness the aspect 
ratio ri/r2 increases similar to that observed in Figure 8.6, the plasmon resonance peak 
blue shifts to shorter wavelengths from 780 nm to 710 nm. 
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Figure 8.7. (A) Experimental extinction spectra of Cu20/Au-NS for core radius ri = 40 ± 
2 nm with varying Au shell thicknesses: (i) r2 = 54 ± 5 nm, (ii) 57 ± 5 nm, (iii) 60 ± 7 nm 
and (iv) 63 ± 11 nm. (B) Calculated extinction spectra of Cu20/Au-NS of similar sizes as 
observed experimentally. The calculations were performed assuming a spherical core and 
shell geometry. 
8.5 Far-field properties of Cu2OZAu vs. SiC>2/Au nanoshells 
Changing the core dielectric allows another important aspect of the optical 
response to be controlled: the relative contribution of absorption and scattering to the 
overall extinction cross section. The theoretical extinction, absorption, and scattering 
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spectra of CU2O/A nanoshells (solid) compared with Si02/Au nanoshells (dashed) of 
equivalent aspect ratios (ri/r2) demonstrates a significant difference in the optical 
response between the two materials (Fig. 8.8). The optical properties of 4 different sizes 
are examined here: [n, r2] = [30, 42] nm, [40, 52] nm, [50, 62] nm, and [60, 72] nm. The 
extinction spectra of the Cu20/Au nanoshells are ~ 100-130 nm red shifted compared to 
the Si02/Au nanoshells of equivalent dimensions for all the sizes calculated here due to 
the high dielectric constant of Cu20. The overall scattering efficiency of Si02/Au 
nanoshells is higher than Cu20/Au nanoshells for similar dimensions, despite the 
extinction being only slightly weaker. This is due to the high permittivity of the Cu20 
nanoparticle core which screens the induced charges more efficiently than the Si02 core. 
The line width is also reduced slightly in the case of Cu20/Au nanoshells. Scattering is 
essentially radiative decay of the plasmon; a reduction of the scattering cross section 
therefore corresponds to a reduction of the damping of the plasmon. Consequently, the 
corresponding plasmon line widths are significantly narrower for the Cu20/Au 
nanoshells. While the finite imaginary component of the Cu20 dielectric function causes 
some additional damping, ohmic losses in the Au and radiation dominate the damping 
and the field in the core is fairly weak such that this is a minor effect. 
The high absorption efficiencies of Cu20/Au nanoshells compared to Si02/Au 
nanoshells can be attributed to three possible reasons: (i) charge difference between the 
inner and outer surface of the Au shell, (ii) plasmon hybridization between the sphere and 
cavity plasmons and (iii) finite conductance of the Cu20 cores which is absent for the 
Si02 cores. Due to the higher permittivity of the Cu20 core, it polarizes more strongly 
reducing the charge on the inner surface of the Au shell. The increased imbalance of 
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charge between the inside and outside surfaces of the shell generates a larger field across 
the metal. Since the metal is highly absorptive, this results in higher absorption 
efficiencies. The stronger absorption can also be understood in terms of plasmon 
hybridization. The high permittivity core shifts the plasmon resonance of the cavity-like 
mode to lower energy resulting in an increase in the admixture of the cavity plasmons in 
the bonding mode since the energy of the sphere and cavity modes are closer. Hence, 
despite this mode maintaining a strong dipole moment due to interaction with the cavity 
plasmons, the energy primarily is lost to absorption because the cavity mode does not 
radiate effectively. This effect also occurs for the antibonding plasmon mode. Due to the 
larger admixture of sphere-like plasmon, the dipole moment increases allowing it to 
interact with light. This is particularly noticeable in Fig. 8.8L, where the scattering in 
CU2O/AU nanoshell exhibits peaks at wavelengths shorter than 600 nm, due to the 
increased admixture of the sphere-like plasmon in the anti-bonding modes. As the total 
size of the nanoshells increase, scattering dominates due to retardation effects and 
consequently the absorption cross-section decreases. 
Thus far, the semiconducting nature of the core has been neglected. The plasmon 
response of semiconductor/Au nanoshells can be further understood by evaluating the 
wavelength dependence of the semiconductor dielectric function and examining plasmon-
exciton coupling by overlap of plasmon wavelength with the semiconductor bandgap 
energy. In the case of CU2O, the real part of the dielectric function (Fig. 8.9) is ~8 in the 
near-infrared region of the spectrum and increases to ~ 9.5 near the band gap energy. 
Due to the conductance of CU2O, the imaginary part of the permittivity is finite and 
decreases monotonously to nearly 0 at long wavelengths. 
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Wavelength (nm) Wavelength (nm) Wavelength (nm) 
Figure 8.8. Calculated extinction, absorption, and scattering efficiency spectra of 
CU2O/AU-NS (solid) compared with Si02/Au-NS (dash) nanostructures of different sizes. 
(A-C) [n, r2] = [30, 42] nm, (D-F) [n, r2] = [40, 52] nm, (G-I) [n, r2] = [50, 62] nm, (J-L) 
[ri, r2] = [60, 72] nm. The calculations are performed assuming a spherical core 
encapsulated in a spherical shell. 
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Figure 8.9. Dielectric function of CU2O obtained from ref. 236. 
Wavelength (nm) Wavelength (nm) 
Figure 8.10. Calculated extinction (blue), absorption (red) and scattering (black) spectra 
of CU2O/AU nanoshells of different sizes. Calculations were performed using Mie theory 
assuming a spherical core and shell with a constant permittivity of 8 for the cores. 
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Interestingly, neither the imaginary part of the dielectric function of CU2O nor the 
wavelength dependence of the dielectric function affects the nanoshell properties 
significantly. Calculated extinction, scattering and absorption efficiencies of CU2O/AU 
nanoshells using constant permittivity of 8 for the cores demonstrates that for similar 
sizes, the absorption and scattering efficiencies are comparable for both the constant 
dielectric (Fig. 8.10) and the frequency dependent dielectric function (Fig. 8.8). This 
observation is not surprising as below the bandgap of the semiconductor core the residual 
imaginary dielectric is not strong enough to affect the nanoshell properties. This is 
especially true for the CU2O/AU nanoshells fabricated here, since the observed plasmon 
resonances are at longer wavelengths beyond the CU2O bandgap energy. 
Theoretically, the cases where the semiconductor band-gap is at the plasmon 
energy or at much lower energy than the plasmon resonance, can be investigated by 
considering Cadmium Telluride-core/Au-shell (CdTe/Au) nanoshells and Lead Sulfide 
core/Au-shell (PbS/Au) nanoshells, respectively. The band gap energy of CdTe is 1.49 
eV and that of PbS is 0.37 eV. Calculated extinction, absorption and scattering spectra of 
CU2O/AU nanoshells are compared with CdTe/Au nanoshells and PbS/Au nanoshells of 
similar sizes (Fig. 8.11). In both cases, shifts in the plasmon resonance are essentially due 
to the increased dielectric constant rather than the frequency dependence or absorption in 
the core, similar to those discussed previously. Unlike the case of CU2O, where the 
damping due to the imaginary part of the dielectric function is trivial, significant damping 
occurs due to the electronic transitions in the semiconductor core when the bandgap 
energy is at or below the plasmon resonance energy. 
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Wavelength (nm) 
Figure 8.11. Calculated extinction (blue), absorption (red) and scattering (black) spectra 
of various semiconductor cores/Au shell nanoshells of size [ri, r2] = [40, 54] nm. (A) 
Cu20 core/Au shell (B) CdTe core/Au shell, (C) PbS core/Au shell. 
Nonetheless, no plasmon-exciton coupling effects are observable. It may be 
surprising that the frequency dependence of the dielectric function of the core material 
has such a small effect. For most common semiconductors at room temperature, the 
excitons are sufficiently broad that they appear as fairly weak peaks over a strong 
polarizibility due to the one electron transitions. For quantum dots at room temperature or 
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bulk semiconductors at low temperature this may not be the case; however, a detailed 
discussion of plasmon-exciton coupling in these cases is beyond the scope of this paper. 
8.6 Conclusions 
In conclusion, we have engineered a plasmonic nanostructure, by utilizing 
straightforward fabrication technique, consisting of a high permittivity semiconductor 
core encapsulated in a thin Au shell. The plasmon resonance of the CU2O/AU nanoshells 
can be tuned from the visible to the NIR by simply modifying the core and shell 
dimensions. Compared to a dielectric core material such as SiC>2, the optical response of 
CU2O/AU nanoshells can be tuned farther into the NIR for equivalent nanoshell 
dimensions. This suggests that CU2O/AU nanoshells would span a broader range of the 
spectrum compared to SiCVAu nanoshells for smaller nanoparticle sizes. This property 
could be potentially useful in biomedical applications where smaller nanoparticle sizes 
resonant in the NIR are necessary. Altering the permittivity of the core material also 
allows optimization of the far field properties for specific applications. For photothermal 
applications such as cancer therapy and gene therapy CU2O/AU nanoshells with their 
enhanced absorption efficiency would be more practical. On the contrary, for 
photoemission applications such as bioimaging and biological sensing Si02/Au 
nanoshells with their high scattering efficiency would be more useful. In addition, the 
near field properties of CU2O/AU nanoshells may tremendously impact non-linear optical 
studies as well as BEC studies of CU2O. For CU2O, low temperature measurements are 
likely necessary to observe plasmon-exciton effects because the excitonic structure in 
CU2O is not observable at room temperature due to thermal broadening. 
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Chapter 9: Au Nanorice Assemble Electrolytically into Mesostars 
9.1 Introduction 
The assembly of materials and structures from constituent nanoparticles is 
currently an important topic of fundamental research, stimulated by the growth of 
numerous applications such as new optical devices,240, 241 chemical sensing,216' 242 
composite materials,243 catalysis,244 and biomedicine.245'246 The design and synthesis of 
novel nanoparticles has been an important starting point, since nanoscale size, shape, and 
morphology determine the properties of larger materials assembled from nanoscale 
substituents. The hierarchical self-assembly of nanoscale building blocks can lead to the 
formation of complex supramolecular assemblies, frequently in striking similarity to 
structure formation in biological systems. In this chapter we report a surprising 
observation of the formation of mesoscale star-shaped particles with a hierarchical 
substructure when an aqueous suspension of nanorice particles247 are subjected to 
electrolysis. Rizia Bardhan performed nanorice fabrication, mesostar development, 
characterization, growth mechanism and optical studies. Oara Neumann contributed in 
electrolytic cell set-up, mesostar development, optical studies and discussion. 
Reproduced with permission from Rizia Bardhan, Oara Neumann, Nikolay Mirin, Hui 
Wang and Naomi J. Halas, ACS Nano, 2009, 3, 266-272. Copyright 2009 American 
Chemical Society. 
The unusual electrolytically assisted assembly reported here is distinct from other 
electrochemically driven processes, such as the electrochemical synthesis of metal or 
metal oxide structures.248' 249 In this case, electrolysis transforms both the shape and 
185 
composition of the nanorice particles. The nanorice particles consist of a prolate iron 
oxide (hematite, a-Fe203) core coated with a thin Au shell, whereas the hyperbranched 
mesostars were composed of Au, iron oxide, and iron oxyhydroxide (goethite, a-
FeOOH). To the best of our knowledge, the process of electrolyzing an aqueous 
suspension to transform nanoparticles into mesoscale structures has not been previously 
reported. This discovery may provide a new approach for the development of new 
structures and materials from nanoscale constituents. 
9.2 Mesostar Formation 
Materials Utilized: Ferric chloride (FeCl3.6H20), (3-aminopropyl) triethoxysilane 
(APTES, 99%), tetrachloroauric acid (HAUC14.3H20), tetrakis hydroxymethyl 
phosphonium chloride (THPC), polyvinyl pyridine (PVP) were purchased from Sigma-
Aldrich (St. Louis, MO). 37% formaldehyde, sulfuric acid (H2S04, 100%), hydrogen 
peroxide (H2O2, 30%), potassium dihydrogen phosphate (KH2P04) and 200-proof ethanol 
were obtained from Fisher Scientific (Hampton, NH). All the chemicals were used as 
received without further purification. Platinum electrodes and platinum wire were 
purchased from Alfa Aesar. DC Power supply was purchased from Hewlett-Packard. 
Quartz slides were purchased from Technical Glass. 
Nanorice fabrication: Monodisperse spindle-shaped a-Fe203 nanoparticles and nanorice 
947 9^ 0 
particles were fabricated as previously reported. ' Briefly, a-Fe203 particles with an 
aspect ratio of 6.3 (340 nm x 54 nm) were prepared by forced hydrolysis of ferric 
chloride solutions by reacting 100 mL of an aqueous mixture containing 2.0 x 10 M FeCl3 and 4.0 x 10"4 M KH2P04 at 100 °C for 72 hours. The resulting precipitate was 
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centrifuged and washed several times with water and ethanol and finally redispersed in 
20 mL ethanol. The surface of the a-Fe203 particles was functionalized with organosilane 
molecules (APTES) to generate an amine terminated surface. This was achieved by 
mixing 500 |iL of APTES with 5 mL of ethanolic solution of hematite particles for 12 
hours under vigorous stirring. The resulting particles were centrifuged and redispersed in 
ethanol several times to remove excess APTES. These functionalized nanoparticles were 
decorated with small gold colloid (2- 3 nm) prepared by the method reported by Duff et 
20 
al. Nanorice particles were fabricated via seed-mediated reduction of AuCLf ions onto 
the attached small colloid in the presence of formaldehyde. 
Mesostar Formation: The electrolytic cell used to form the mesostars is shown (Scheme 
9.1). Platinum electrodes 0.020 mm wide were placed 0.014 m apart in an aqueous 
suspension of nanorice particles (109 particles/mL) and connected to a DC power supply. 
DC Power 
Supply 
Scheme 9.1. Schematic representation of experimental set-up showing a DC power 
supply connected between two Pt electrodes (gray bars), separated by 0.014 m, immersed 
in aqueous Au nanorice solution. 
The nanorice particles utilized in these experiments consisted of prolate hematite cores 
with a longitudinal diameter of 340 ± 25 nm and a transverse diameter of 54 ± 6 nm, 
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coated with a 22 ± 3 nm Au shell. At ambient temperature and pressure, a potential 
difference of 5 V was applied to the cell, and the particles self-assembled to form 
mesostars within 24 hours. 
Nanoparticle films for optical measurements: Nanoparticle films were obtained by 
immobilizing them on PVP functionalized quartz slides. Briefly, quartz slides were 
cleaned in piranha solution (H2SO4 (100%): H2O2 (30%) = 3:1) for 2 hours, rinsed with 
H2O and 200 proof-ethanol and dried in a stream of N2 gas. The slides were then 
immersed in a 1 wt% solution of PVP in ethanol for 24 hours, followed by rinsing 
thoroughly in ethanol and drying with N2 gas. The PVP functionalized slides were 
immersed in aqueous solutions of nanorice, mesostars, hematite nanoparticles and 
pyramidal mesostructures for 1 hour. Upon removal from the individual solutions, the 
slides were rinsed with ethanol and dried with N2 gas. This resulted in a monolayer of 
randomly oriented nanoparticles on the PVP functionalized slides. 
9.3 Mesostar Characterization 
The mesostars were characterized using several analytical techniques to elucidate their 
formation mechanism including TEM using a JEOL JEM-2010 TEM operated at 200 kV, 
SEM using a FEI Quanta 400 field emission SEM at an acceleration voltage of 20 kV, 
XRD by using a Rigaku Ultima II vertical 0 - 0 powder diffractometer (Cu Ka, 1=1.5418 
A) and absorption measurements using a Varian Cary 5000 UV-Vis-NIR 
spectrophotometer. 
The mesostars were typically 650 ± 80 nm in length and width and -380 ± 30 nm in 
height, as shown in the scanning electron microscope (SEM) image in Figure 9.1 A. All 
the mesostars observed in solution had similar shape and morphology but varied in size 
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distribution. Powder X-ray diffraction (XRD) studies (Fig. 9.IB) revealed a surprising 
transformation in the composition, and crystal structure of the mesostars relative to the 
nanorice particles. XRD spectrum of a-Fe203 particles, which served as the core material 
of the nanorice is shown in Figure 9.1B-i. 
20 (deg.) 
Figure 9.1. Electron microscopy and crystallographic studies of mesostars prepared at 
5V. (A) SEM image of Mesostars. (B) XRD spectra of (i) a-Fe2C>3 cores, (ii) nanorice 
(showing Au peaks), and (iii) mesostars. The spectra are offset for clarity. 
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These particles show a highly crystalline, hexagonal phase of a-Fe203 with cell 
parameters a = 5.035 A and c = 13.747 A and space group R3c (167) (JCPDS card no. 
98-000-0240). The XRD peak intensities correlate well with those from the powder 
diffraction intensity profile of a-Fe203. However, a preferential orientation of the a-
Fe2C>3 core particles is observed, a common feature among single crystalline 
nanoparticles. The XRD spectrum of nanorice (Fig. 9. lB-ii) clearly demonstrates the 
presence of a crystalline Au shell covering the a-Fe203 cores. The crystal structure of the 
Au shell corresponds to the cubic phase of Au with cell parameters a = 4.078 A and space 
group Fm3m (225) (JCPDS card no. 98-000-0230). The Au shell on the a-Fe203 cores 
grows non-epitaxially as a polycrystal, which explains the absence of preferential 
orientation in the XRD spectrum of nanorice. The XRD spectrum of mesostars (Fig. 
9.1B-iii) reveals a mixture of peaks corresponding to a-FeOOH, a-Fe203, and Au. The a-
FeOOH peaks suggest a partial transformation of a-Fe203 into a-FeOOH, which has an 
orthorhombic phase with lattice parameters a = 4.937 A, b = 4.432 A, and c = 2.994 A, 
and space group P21nm (31) (JCPDS card no. 00-026-0792). The strongest peak 
corresponding to the a-FeOOH (101) plane indicates that the mesostars are mostly 
composed of goethite, and also specifies a preferential orientation of the goethite 
crystalline domains. 
The observed alteration in structure and composition of nanorice particles to form 
mesostars was further studied using transmission electron microscopy (TEM) and 
electron diffraction (ED). TEM images with corresponding ED and selected area electron 
diffraction (SAED) patterns of mesostars are shown in Figure 9.2. A smaller star-shaped 
structure obtained within 6 hours of electrolysis (Fig. 9.2A) was observed to be 
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polycrystalline as suggested by the ED ring pattern. The TEM micrograph and 
corresponding SAED pattern of a mesostar formed after 24 hours of electrolysis (Fig. 
9.2B) demonstrates an orthorhombic single crystalline area that is oriented toward the 
(200) plane and corresponds to a-FeOOH. In addition to the mesostars, a-FeOOH 
nanocrystals were also observed in the solution mixture (Fig. 9.2C). These nanocrystals 
demonstrated the orthorhombic phase of a-FeOOH that is preferentially oriented towards 
the [001] direction. The tips of the mesostars (Fig. 9.2D) also consisted of single 
crystalline domains of a-FeOOH oriented along the (200) plane. Dark-field TEM, an 
effective tool in observing lattice defects, grain boundaries, and ordered domain 
structures, was utilized to image the mesostar tip as shown in Figure 9.2E. The highly 
crystalline a-FeOOH domains are clearly demarcated by the lighter areas in Figure 9.2E. 
The darker central area indicates that this region is relatively dense and does not allow 
the electron beam to penetrate through. The TEM micrographs and SAED patterns in 
Figure 9.2 (A-E) undoubtedly show that these mesostars have many crystalline domains 
of a-FeOOH, which explains the a-FeOOH peaks observed in the XRD spectrum of 
mesostars (Fig. 9.1B-iii). The chemical composition of the observed mesostars was 
generally identical, composed mostly of a-FeOOH crystalline domains. However, the 
mesostars are also composed of Au as indicated by the XRD spectrum. The ED pattern of 
a single mesostar (Fig. 9.2F, top inset) illustrates polycrystallinity, however, its SAED 
pattern (bottom inset) shows a face-centered cubic single crystalline domain of Au 
oriented along the (220) plane. Since these mesostructures were polycrystalline, 
individual crystallographic domains of Au, a-FeOOH, and a-Fe203 are difficult to 
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determine for each particle, however these representative TEM images confirm their 
composition. 
Figure 9.2. TEM micrographs of a (A) star-shaped structure obtained after 6 hours of 
electrolysis and ED pattern showing polycrystalline rings provided as inset, (B) mesostar 
formed after 24 hours of electrolysis and corresponding SAED pattern representing 
orthorhombic a-FeOOH single crystalline domain, (C) a-FeOOH nanocrystals observed 
in solution and SAED pattern showing orthorhombic a-FeOOH single crystalline domain, 
(D) tip of a mesostar and corresponding SAED pattern representing orthorhombic a-
FeOOH single crystalline area, (E) dark field image of mesostar tip corresponding to (D), 
and (F) mesostar obtained after 24 hours of electrolysis, ED pattern showing 
polycrystalline rings provided as top inset, and SAED pattern representing cubic Au 
single crystalline area provided as bottom inset. The selected area corresponding to the 
SAED patterns in (B), (C), (D) and (F) are shown in circle. 
The phase transformation of a-FeOOH to a-Fe203 is known to occur via heat 
treatment by loss of H2O molecules, 251 or by liquid phase transformation.252 However, at 
present the reverse mechanism of a-Fe2C>3 conversion to a-FeOOH is not well 
understood. The formation of a-FeOOH nanocrystals is strongly influenced by the 
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presence of anions in solution, the temperature of the reaction mixture, the pH, and the 
oxidizing agents.253, 254 The shape and size of a-FeOOH nanocrystals influence many of 
their physical properties, which consequently determine the morphological development 
of larger-ordered structures. The formation mechanism discussed below explains the 
morphological modification as well as the alteration in the composition of a-Fe203 -Au 
nanorice particles to form mesostars composed of a-Fe2C>3, Au and a-FeOOH. 
Figure 9.3. (A) Schematic representation of mesostar formation mechanism. (B) SEM 
images supporting the mesostar formation mechanism starting with (i) nanorice, (ii) 2 hrs 
of electrolysis, (iii) 4 hrs, (iv) 6 hrs, (v) 8 hrs, (vi) 10 hrs, (vii) 12 hrs, and (viii) 24 hrs. 
9.4 Formation Mechanism 
A systematic and controlled study of mesostar formation revealed electrolysis-induced 
complex assembly of nanorice particles to form these hierarchical structures. A schematic 
representation of the mesostar formation mechanism (Fig. 9.3A) and representative SEM 
images taken after 0, 2, 4, 6, 8, 10, 12, and 24 hours of electrolysis (Fig. 9.3B) support 
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the proposed mesostar growth mechanism. Additional images showing an overview of 
the entire system at a given time period is shown in Figure 9.4. During electrolysis, the 
Au shell of nanorice particles (Fig. 9.3B-i) is etched away, leaving residual Au islands 
and small Au colloid in the reaction mixture (Fig. 3B-ii). The etching process of the Au 
shell may result from two plausible mechanisms. First, active O2 is produced during 
electrolysis (eq. 2) which has been shown to etch Au. Second, active hydroxyl groups, 
which are also produced during electrolysis (eq. 1), may react with the hematite core, 
altering its crystal structure. The subsequent re-crystallization of the hematite core may 
then induce strain on the Au shell, causing it to partially etch. 
Cathode: 2H20 a) + 2e~ H2 (g) + 20H" (aq) Ered = 0.00 V (1) 
Anode: 40H~
 (aq) 0 2 (g) + 2H20 (D + 4e~ Eox = -1.23 V. (2) 
Active hydroxyl anions produced during electrolysis could also be incorporated into the 
hematite crystal lattice as hydroxyl defects, forming a metastable phase termed 
"hydrohematite" (Fe203.H20).257' 258 a-Fe203 possibly converts to a-FeOOH from the 
hydrohematite phase by replacement of oxygen atoms with hydroxyl ions: 
2Fe203 H 2 0 + 20H" + 2H+ —» 4FeOOH + 0 2 + 2H2. (3) 
In addition to partial removal of the Au shell, the electrolysis process partially 
disintegrates the a-Fe2C>3 particles, converting them into a-FeOOH nanocrystals (see 
Figure 9.2C). Subsequent to Au shell disintegration, the partially etched nanorice 
particles were completely coated with a-FeOOH nanocrystals and colloidal Au particles. 
These structures then preferentially aligned along their centers to form a cross-shaped 
structure (Figure 9.3B-iii). In some cases, end-to-end assembly occurred and formed long 
chains, but these were produced in relatively low yield, Figure 9.5. After 4 hours of 
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electrolysis, a-FeOOH nanocrystals assembled on the central axis of the cross structures, 
which was possibly the most convenient polarizable axis in the DC-field. This 
transformed the cross structures into star-shaped structures (Figure 9.3B iv-v). These star-
shaped mesostructures continued to grow and after 24 hours of electrolysis yielded 
hierarchical crystalline mesostars (Figure 9.3B vi-viii). The mesostars were formed in the 
bulk of solution, and were not observed on the electrodes. Representative SEM image of 
the cathode utilized in the electrolytic cell is shown in Figure 9.6 and high resolution 
image is provided as inset, a -FeOOH nanocrystals, which were also observed in the bulk 
solution, were present on the cathode, but mesostars were not observed. The anode is not 
shown as we did not observe any structures or particles on it. This suggests that mesostars 
were likely formed in the bulk of solution rather than on the electrodes. Colloidal Au 
particles that initially disintegrated from nanorice particles were also incorporated into 
these complex mesostructures. The conversion yield from nanorice particles to mesostars 
was ~ 50 %. Since these mesostructures are larger in size than the nanorice, and the 
formation of mesostars is distinct from solution phase synthesis or seeded growth 
method, a lower conversion yield is expected. 
These observations elucidate the a-Fe2C>3 and Au peaks observed in the XRD 
spectra of mesostars (Figure 9.1B-iii) as well as the Au SAED pattern shown in Figure 
9.2F. The Au peaks in the XRD spectra could also be due to the residual colloidal Au 
colloidal particles in solution which disintegrated from the nanorice. These observations 
also explain the polycrystalline rings in the ED patterns (Fig. 9.2A, 9.2F), which could be 
a consequence of self-assembly and oriented attachment of many a-FeOOH nanoparticles 
to form the mesostars. 
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Figure 9.4. Additional SEM images supporting the mesostar formation mechanism 
starting with (A) 2 hrs of electrolysis, (B) 4 hrs, (C) 6 hrs, (D) 8 hrs, (E) 12 hrs, and (F) 
24 hrs. The scale bar is 500 nm. 
Figure 9.5. SEM image of long chain branched structures obtained both at 5 V and 10 V 
in addition to the mesostars. 
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Figure 9.6. SEM image of one electrode utilized in the electrolytic cell is shown. High 
resolution SEM image is provided as an inset, the scale bar is 100 nm. 
The formation of the mesostars as a result of the specific oriented assembly of the 
a-FeOOH nanoparticles on the central axis of the cross structures could be due to defects 
• 258 
in the a-FeOOH crystal structure and resulting magnetization in individual particles. ' 
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 This magnetization results in weak interparticle magnetic interactions. Magnetism in 
a-FeOOH nanocrystals depends on several factors including the crystallinity of the 9^ 4 9SQ 
particles, particle size, temperature, and surface defects. Bocquet et al. ' ' proposed 
that as the size of a-FeOOH particles decreases, the number of crystal defects increases 
facilitating magnetic cluster ordering and reduced Neel temperature (TN). The TN of bulk 
a-FeOOH is ~ 398 K. The saturation magnetization values found in nanoscale materials 
are usually smaller than the corresponding bulk phases, provided that no change in ionic 
configurations occurs. Bocquet et al.259 have reported a TN as low as ~ 261 K for a-
FeOOH nanocrystals, which indicates they have a net magnetic moment at ambient 
temperature. Structural defects in a-FeOOH nanocrystals, such as iron and hydrogen 
vacancies, results in unpaired chains at the surface, which also contributes to a net 
increase in magnetization. ' Thus, the formation of mesostars could have occurred 
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due to the assembly of a-FeOOH nanocrystals along the most convenient polarizable axis 
in the DC-field as well as the weak interparticle magnetic interaction between the a-
FeOOH nanocrystals. 
The formation mechanism of these hierarchical mesostructures was further 
established by studying the electrolysis-assisted assembly of nanorice particles as a 
function of voltage. The voltage between the electrodes was varied between 0.5 V and 10 
V, while the reaction time (24 hours) and the distance between the electrodes (0.014 m) 
remained constant. At both 0.5 V and 1 V, only aggregated nanorice particles were 
obtained, but mesostars were not observed (Figure 9.7A). This strongly indicates that 
below 1.23 V, the redox potential for H2O electrolysis, mesostar formation is not 
initiated. At 2 V, very few micron-sized star-shaped structures were observed, while most 
of the nanorice particles remained in solution (Figure 9.7B). These were large fractal 
structures, measuring ~ 4 ± 0.2 jam in length and width, and 1.1 ±0.2 jxm in height. The 
small yield probably occurred because fewer nucleation sites for mesostar formation were 
initiated at lower voltage. This resulted in slower growth kinetics, which usually favors 
Ostwald ripening in order to minimize the overall surface free energy, resulting in the 
formation of larger but fewer stars. At 3 V, slightly smaller star-shaped structures with a 
length and width of 3.1 ± 0.7 (xm and a height of 0.8 ± 0.3 fim were obtained. As the 
voltage was raised to 5 V, a higher yield of mesostars with a length and width of 650 ± 80 
nm and a height of 380 ± 30 nm was observed. As the voltage was further increased to 10 
V, a high yield of incomplete and deformed stars 450 ±150 nm in length were obtained. 
These observations indicate that at higher voltage more nucleation sites are initiated 
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leading to a higher rate of growth kinetics. This also results in the formation of distorted 
star-shaped morphologies with an overall decrease in size, and a larger size distribution. 
Figure 9.7. SEM images of mesostructures obtained by varying the voltage while 
keeping electrolysis time constant at 24 hrs. (A) Aggregated nanorice formed at 0.5 V 
and 1 V and high resolution image provided as inset, (B) stars ~ 4 ± 0.2 |xm in length and 
width, and 1.1 ±0.2 pm in height formed at 2 V, (C) stars ~ 3.1 ± 0.7 pm in length and 
width, and 0.8 ± 0.3 Jim in height obtained at 3 V, (D) mesostars 650 ± 80 nm in length 
and width, and 380 ± 30 nm in height observed at 5 V and, (E) distorted stars 450 ± 150 
nm in length obtained at 10 V. 
In addition to electrolysis, the resulting crystal structure of these hierarchical self-
assembled mesostructures can also be interpreted in the context of nucleation, oriented 
attachment, and Ostwald ripening. Nucleation in the reaction mixture results in small 
199 
crystalline a-FeOOH primary particles which aggregate via oriented attachment to form 
secondary particles. Oriented attachment involves self-organization of adjoining particles 
such that a regular crystallographic orientation is achieved followed by the joining of 
these particles at a planar interface. Oriented assembly usually results in single crystals, 
which could explain the single crystalline domains found in the mesostars (ED and 
SAED patterns shown in Fig. 9.2). Several single crystalline domains then aggregate 
forming polycrystalline structures. The kinetics of crystal growth and coarsening strongly 
depend on various factors including the structure of the material, the surface chemistry of 
the particles resulting from the ions in the solution, and the interface between the crystals 
and surrounding solution.262"264 With increasing time, Ostwald ripening controls the 
crystal growth by the diffusion of ions along the matrix-particle boundary resulting in 
larger particle sizes.265'266 The observed morphology of the mesostars could be due to the 
simultaneous occurrence of adjacent particles in solution epitaxially assembling during 
the electrolysis process along the most convenient polarizable axis for DC-field as well as 
Ostwald ripening. 
9.5 Optical Properties 
Since the optical properties of materials are governed by shape, size, and chemical 
composition, the extinction spectra of the a-Fe203 cores, Au-nanorice, and mesostars 
were compared using UV-Vis spectroscopy (Fig. 9.8). The extinction spectra were 
obtained by immobilizing the particles on quartz slides. The a-Fe203 cores showed an 
absorption maximum at ~ 390 nm, while nanorice demonstrated two separate peaks at 
650 nm and 1100 nm. The strong plasmon resonance feature at 1100 nm was due to the 
longitudinal plasmon mode of the nanorice while the weaker plasmon resonance at 650 
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nm was due to the transverse plasmon mode of the nanorice particles. The optical 
spectrum of the mesostars is strikingly different from nanorice and revealed a broad peak 
with absorption maximum at 430 nm, which was attributable to the presence of a-Fe203, 
a-FeOOH, and Au. In the control experiment, the optical properties of the pyramidal 
mesostructures obtained with the hematite cores did not show any well defined peak (see 
below) which additionally signifies the contribution of Au colloidal particles in the 
observed optical spectra of the mesostars. 
Figure 9.8. Extinction spectra of (i) a-Fe203 cores with A,max~390 nm, (ii) nanorice 
particles with longitudinal plasmon X,max - 1 1 0 0 nm and transverse plasmon Xmax~ 650 
nm, and (iii) mesostars with X,max~ 430 nm. The samples measured are monolayers of 
nanoparticles immobilized on PVP-glass slides. The spectra are offset for clarity. 
9.6 Control Experiment 
A control experiment with the a-Fe203 cores without any Au shell was performed 
resulting in an alteration of the composition and morphology of the a-Fe203 
nanoparticles. Very few pyramidal mesostructures were obtained, but mesostars were not 
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observed, as shown in Figure 9.9. The a-Fe203 cores (Fig. 9.9A) assemble in a distinctive 
pattern after 10 hours of electrolysis at 5 V (Fig. 9.9B). After 14 hours of electrolysis, a 
low yield, ~ 5%, of pyramidal mesostructures 500 ± 50 nm in length and width, and 380 
± 30 nm in height (Fig. 9.9C) were observed. These pyramidal structures increased in 
size within 24 hours of electrolysis forming larger pyramidal mesostructures 650 ±100 
nm in length and width, and 370 ± 50 nm in height (Fig. 9.9D). Most of the a-Fe203 core 
particles remained in solution. In addition to the pyramidal structures, a-FeOOH 
nanocrystals were also observed in the reaction mixture. The formation mechanism of 
these structures is not completely understood, since a time-dependent study did not 
clearly reveal a step-by-step growth process. 
Figure 9.9. SEM images of (A) a-Fe203 cores, (B) assembled a-Fe203 cores formed 
after 10 hrs of applying 5 V, (C) pyramidal mesostructures 500 ± 50 nm in length and 
width, and 380 ± 30 nm in height formed after 14 hrs, (D) larger pyramidal 
mesostructures 650 ±100 nm in length and width, and 370 ± 50 nm in height formed 
after 24 hrs. 
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We propose a similar mechanism as the formation of mesostars, including electrolysis of 
H2O leading to phase transformation of a-Fe2C>3 to a-FeOOH. Subsequently, the 
nucleation of a-FeOOH nanoparticles, followed by oriented attachment of primary 
particles along specific crystallographic planes, and Ostwald ripening to form pyramidal 
mesostructures. It is evident that utilizing a-Fe2C>3 particles instead of nanorice particles 
resulted in fewer nucleation sites, which consequently produced a poor yield of the 
pyramidal structures. The low yield of the pyramidal structures and absence of mesostars 
suggests that the Au shell may act as a direct agent in initiating nucleation sites for 
mesostar formation and facilitating shape evolution of these hierarchical mesostructures. 
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Figure 9.10. (A) XRD spectra of (i) a-Fe2(>3 cores, and (ii) pyramidal mesostructures. B) 
Extinction spectra of (i) a-Fe203 cores, ^max - 3 9 0 nm, and (ii) pyramidal mesostructures, 
Xmax < 300 nm. The samples measured are monolayers of nanoparticles immobilized on 
PVP-glass slides. The spectra are offset for clarity. 
203 
The XRD spectra of the a-Fe203 cores and the pyramidal mesostructures (Fig. 
9.1 OA) clearly reveal a crystalline morphology as well as conversion of a-Fe203 to a-
FeOOH to form these structures. The strongest peak corresponding to the a-FeOOH 
(101) plane in the XRD spectra of the pyramidal mesostructures suggest a preferential 
orientation of the goethite crystalline domains. The optical properties of the a-Fe203 
cores and pyramidal mesostructures are represented in Figure 9.1 OB. The a-Fe203 core 
particles show an absorption peak at 390 nm. However, no well defined peak is observed 
in the optical spectra of the pyramidal mesostructures. A weak shoulder is observed 
between ~ 450 - 600 nm which is probably characteristic to the pyramidal 
mesostructures. 
9.7 Conclusions 
In conclusion, we have observed the unusual formation of hierarchical mesostars via 
electrolysis of an aqueous suspension of nanorice particles. The Au-a-Fe203 nanorice 
particles self-assembled into fractal mesostructures composed of a-Fe203, a-FeOOH, and 
Au. The remarkable differences in the geometry, composition, and properties between the 
nanorice particles and mesostars strongly indicate that electrolysis can significantly alter 
the morphology and constituent material of the nanostructures. A further examination of 
this striking assembly process could elucidate the unusual self-assembly processes 
observed in nature and biological systems. Further study of this system may be also 
promising in fundamental applications characteristic to hierarchical mesostructures. 
204 
Chapter 10: Facile Chemical Approach to ZnO Submicrometer 
Particles with Controllable Morphologies 
10.1 Introduction 
Development of semiconductor nanostructures has gained tremendous interest due 
to their technological importance in nanoelectronics, nanophotonics and as sensor 
components into single monolithic devices. In this chapter we report the fabrication, 
characterization, growth mechanism and emission properties of zinc oxide (ZnO) 
mesostructures with interesting geometries, controllable sizes and white light emissive 
properties. Rizia Bardhan fabricated the mesostructures, characterized them, performed 
the optical studies, and analyzed the growth mechanism. Hui Wang contributed in 
discussion and data interpretation and Felica Tam contributed in TEM studies. 
Reproduced with permission from Rizia Bardhan, Hui Wang, Felicia Tam, and Naomi J. 
Halas, Langmuir, 2007, 23, 5843-5847. Copyright 2009 American Chemical Society. 
ZnO is currently one of the most attractive semiconducting materials for optical 
and electronic applications because of its direct wide bandgap (3.37 eV) and high exciton 
Oftl 9/^ 8 binding energy (60 meV). ' ZnO particles have been investigated extensively as 
• • 960 970 
active media for applications such as luminescent light emitters, solar cells, 
971 i^ o 
phosphors, and photocatalysts. A proliferation of ZnO nanostructure morphologies 
have been reported, such as nanobelts, nanowires, ' nanorods, nanotubes, 97f\ 977 97Q 980 97A 981 
nanohelices, tetrapods, " nanosheets, and nanorings. ' The properties of ZnO 
particles are highly dependent upon particle size, shape and surface characteristics. 
Several fabrication techniques have been developed to prepare ZnO structures with well-979 97"} 989 defined shapes, such as vapor-phase evaporation, ' ' metal-organic vapor phase 
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epitaxy, template-based synthesis, and laser ablation. These fabrication procedures 
often require high temperature conditions, prolonged reaction times, and specifically 
designed reactors. The development of wet chemistry approaches to ZnO particles with 
controllable sizes and shapes is ultimately more desirable in terms of simplicity, 
efficiency, and low-cost. 284'286"288 
ZnO is a useful and practical gain medium for solid-state UV lasers due to its 
high-quantum efficiency photoluminescence in the UV spectral region. ZnO particles 
have attracted recent attention as some of the smallest lasers yet reported.272' 289' 290 
Meanwhile certain defects and impurities present in ZnO can also give rise to 
subbandgap states with strongly radiative decay channels. The broadband visible light 
emission reported in such systems has been correlated with specific dopants and defect 
morphologies.267'291-294 The subbandgap emission in ZnO-based materials has long been 
viewed as an adverse property, which can be reduced by various approaches, such as 
annealing or placing metallic films directly adjacent to the ZnO in various device 
structures.271' 295 However, it has been recently realized that this visible light emission 
may be a potentially valuable property, rendering ZnO a promising prospective material 90S 
for solid state lighting applications. 
Here we describe a simple bottom-up approach to the selective fabrication of a 
series of ZnO particles with unique morphologies including rings, bowls, hemispheres, 
and disks of various aspect ratios. The size and morphology of the particles is 
systematically controlled by judiciously adjusting the concentration of the precursor, zinc 
acetate dihydrate, in the presence of NH4OH. The pH of the reaction mixture is also 
found to be critical in the formation of these well-defined shapes. The as-fabricated ZnO 
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particles exhibit very strong broadband visible light emission upon UV excitation, far 
stronger than the interband emission. 
10.2 Fabrication of ZnO Particles 
Materials Utilized: Zinc acetate dihydrate (Zn(CH3CC>2)2.2H20) was purchased from 
Sigma-Aldrich (St. Louis, MO). 28.8% Ammonium hydroxide (NH4OH) and 200-proof 
ethanol were obtained from Fisher Scientific (Hampton, NH). All the chemicals were 
used as received without further purification. Ultrapure water (18.2MD resistivity) was 
obtained from Milli-Q water purification system (Millipore, Billerica, MA). 
Fabrication: ZnO rings were fabricated by heating 50 mL of 200-proof ethanol in a round 
bottom flask connected with a condenser at 60°C. While maintaining a constant 
temperature, 0.005 M Zn(CH3C02)2.2H20 was introduced in the round bottom flask 
under vigorous stirring and allowed to dissolve in the ethanol. An appropriate amount of 
NH4OH (2.8 wt %, pH ~ 8.2) was then added and the reaction was continued for 45 
minutes under vigorous stirring. After completion of the reaction, the solution was cooled 
to room temperature. The resulting precipitate was centrifuged and washed several times 
and finally redispersed in 15 mL ethanol. The other ZnO particle morphologies were 
fabricated by varying the Zn(CH3C02)2.2H20 concentration to 0.01 M, 0.02 M and 0.025 
M to obtain bowls, hemispheres and disks, respectively, while the other experimental 
conditions were kept the same. 
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10.3 Characterization of ZnO Particles 
The ZnO particles were characterized by obtaining scanning electron microscope (SEM) 
images on a Phillips FEI XL-30 environmental SEM at an acceleration voltage of 30 kV. 
Transmission electron microscope (TEM) micrographs were obtained using JEOL JEM-
2010 TEM. Photoluminescence (PL) spectra were obtained using a JOBIN YVON UV-
vis Fluorolog, excited at 360 nm. All the samples prepared for PL were maintained at the 
same concentration using the absorbance at 372 nm with a UV-vis-NIR 
spectrophotometer. Fluorescence images were obtained using Axioplan-2 Imaging-Zeiss 
Fluorescence microscope with a color camera (Hg, HBO 100 watt lamp and excitation 
filter between 340-380 nm). X-ray Diffraction (XRD) patterns were obtained using a 
Rigaku Ultima II vertical 0 - 0 powder diffractometer (Cu Ka, >.=1.5418 A). 
The SEM and TEM images of the different ZnO particles fabricated by this 
approach are shown in Figure 10.1. Different morphologies can be selectively obtained 
by simply varying precursor concentrations within a certain pH range (Table 10.1). When 
the concentration of Zn(CH3C02)2 <0.005 M, irregular ZnO nanoparticles are obtained 
(Fig. 10.2A). At 0.005 M Zn(CH3C02)2, ZnO rings with outer diameters of 460 ± 60 nm 
and inner diameters of 250 ± 80 nm are formed (Fig. 10.1 A, B). A further increase in the 
concentration of the Zn precursor to 0.01 M results in submicrometer bowl shaped 
structures with an average size of 710 ± 80 nm and an inner diameter of 260 ± 5 0 nm 
(Fig. 10.1C, D). The inset of Figure 1C shows striations along the radial direction, 
suggesting the preferential growth along the radius of the ZnO crystals to form this 
unusual structure. Submicrometer hemispheres are formed when the concentration of 
precursor is increased to 0.02 M (Fig. 10.IE, F). 
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Figure 10.1. Low- and high-magnification (inset) SEM micrographs and corresponding 
TEM images of ZnO particles fabricated by varying the concentration of the Zn 
precursor. (A and B) Rings (0.005 M), (C and D) bowls (0.01 M), (E and F) hemispheres 
(0.02 M), and (G and H) disks (0.025 M). The scale bar for all of the high-magnification 
SEM images is 200 nm. 
These particles are 790 ± 85 nm in diameter and clearly display a smooth outer surface 
but coarse inner surface with visible crystalline facets. As the concentration of 
Zn(CH3C02)2 is further increased to 0.025 M, disklike shapes are formed (Fig. 10.1G, 
H). Although increasing the precursor concentration from 0.02 - 0.025M did not radically 
change the morphology of the particles, the hemispheres appeared to increase radially 
resulting in a disk-like shape. These disks (average size ~ 910 ± 70 nm) exhibit a 
209 
quasihexagonal cross section (Fig. 10.1H). At zinc acetate concentrations above 0.03 M, 
larger particles are formed with significant agglomeration and indefinite morphology 
(Fig. 10.2B). Therefore, it appears that only over a limited range of Zn2+ concentration 
are the fabrication conditions appropriate for the formation of ZnO particles with these 
well defined morphologies. 
Figure 10.2. (A) Irregular ZnO nanoparticles obtained at 0.001 M of Zn precursor, and 
(B) agglomerated ZnO particles obtained at 0.04M of Zn precursor. 
Table 10.1. Synthesis parameters and morphology of different ZnO Structures 
Concentration of 
Zn<Ac>, (M) 
pi l ( N 1^0112,8%) 
Initial Final 
Morphology Size 
(nm) 
0.001 4.4 6.4 irregular nanoparticles 
0.005 4.2 5.5 rings 460 ± 60 
0.01 4.2 5.5 bowls 710 ± 8 0 
0.02 4.0 5.5 hemispheres 790 ± 85 
0.025 4.0 5.5 disks 910 ± 7 0 
0.04 4.0 6.2 agglomerated particles 
0,05 3.9 6.2 agglomerated particles 
0.01* 4.3 5.6 inhomogcncous matrix 
0.02* 4.1 5.5 in homogeneous matrix 
* We used KOH instead of MH4OH maintained at similar pH 
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Figure 10.3. Crystallographic studies of the ZnO particles obtained at different 
concentrations of the Zn precursor. (A) XRD patterns of (i) rings (0.005 M), (ii) bowls 
(0.01 M), (iii) hemispheres 0.02 (M), and (iv) disks (0.025 M). (B) TEM image of a 
Submicrometer bowl with the corresponding ED pattern (top inset) and the SAED pattern 
(bottom inset, area shown in circle) characteristic of these structures. (C) TEM image of a 
polycrystalline ring. The SAED patterns (areas shown in circles) illustrate crystalline 
domains along different orientations. 
The crystallinity of the ZnO particles obtained at different concentrations of Zn precursor 
was also investigated. Figure 10.3A shows the XRD patterns of all of the obtained 
morphologies rings, bowls, hemispheres, and disks. The XRD patterns exhibit sharp 
peaks, indicating that the particles possess large crystalline domains as well as a high 
degree of crystallinity. Figure 10.3B shows the TEM image of a submicrometer bowl and 
the corresponding electron diffraction (ED) pattern, revealing that the bowl structures are 
composed of several crystalline domains. Selected-area electron diffraction (SAED) 
(Figure 10.3B, bottom inset, area shown in circle) shows a single-crystalline domain with 
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hexagonal wurtzite structure along the [0001] zone axis in this region. The TEM image 
and corresponding SAED patterns of a submicrometer ring are illustrated in Fig. 10.3C. 
The two selected regions in the ring (areas shown in the circle) have crystalline domains 
with hexagonal wurtzite structure along the [0001] zone axis. However, the crystalline 
domains are oriented differently, verifying the polycrystallinity of the particles. 
10.4 Growth Mechanism of ZnO particles 
The growth mechanism and resulting crystal structure of these ZnO particles can 
be interpreted in the context of supersaturation, nucleation, Ostwald ripening, and 
oriented attachment.296 The kinetics of crystal growth and coarsening strongly depends on 
the structure of the material, the surface chemistry of the particles resulting from ions in 
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the solution, and the interface between the crystals and surrounding solution. At Zn 
precursor concentration lower than 0.005 M, insufficient amount of solute is present to 
yield a supersaturated solution. At 0.005 M of Zn2+, nucleation occurs as a supersaturated 
solution is achieved. The ZnO nuclei further grow by diffusive mechanism forming 
primary particles.296 These small crystalline primary particles subsequently aggregate OAS OQ1 through oriented attachment forming secondary particles. ' ' Oriented attachment 
involves self-organization of adjoining particles such that a regular crystallographic 
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orientation is achieved followed by joining of these particles at a planar interface. 
Oriented attachment usually results in single crystals, which could explain the single 
crystalline domains found in the bowls and rings (Fig 10.3B,C). However orientation 
adopted within one region is dissimilar to that in an adjacent region in the reaction 
mixture. Therefore, following aggregation process, polycrystalline structures composed 
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of several single crystalline domains are obtained. In solution phase synthesis, the 
formation of large polycrystalline particles with complex morphologies is not surprising. 
When the Zn precursor concentration is increased, Ostwald ripening controls the crystal 
growth by diffusion of ions along the matrix-particle boundary and results in larger 
particle sizes.298 The observed differences in morphology with increasing concentration 
of Zn(CH3C02)2 could be due to the simultaneous occurrence of Ostwald ripening as well 
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as oriented attachment during the growth of the crystals. ' While Ostwald ripening 
leads to spherical/hemispherical shapes with smooth edge, oriented attachment forms 
irregular shapes with visible facets. The smooth outer surfaces of the bowls, hemispheres 
and disks with irregularly faceted inner surfaces verify this theory (Fig 10.1C, E, G). 
In addition to the effect of precursor concentration on the particle morphologies, 
the pH of the reaction mixture also influences the shape evolution of the particles (Table 
10.1). Although the exact mechanism of formation of these unique morphologies is OOQ 
debatable, we believe besides Zn(CH3C02)2 concentration, the difference between 
the initial and final pH value of the reaction mixture may control the nucleation and 
growth event.286 Larger differences between the initial and final pH values of the reaction 
mixture results in a higher nucleation rate; consequently, ZnO particles are formed at a 
rapid rate leading to agglomerated particles with indefinite morphology. When the 
variation between initial and final pH values of the reaction mixture is small, the 
nucleation rate is slower, leading to development of well-defined particle shapes with 
different sizes. The ZnO submicron rings, bowls, hemispheres, and disks are formed 
when the difference between the initial and final pH values of the reaction were 1.3 - 1.5. 
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Table 10.2. Concentration of Ammonia and Morphology of ZnO Structures 
NH 4 OH wt % PH of Reaction Morphology 
Initial Final 
1.12 3.9 4.8 distorted bowls 
2.8 4.2 5.5 bowls 
5.6 4.4 6.3 inhomogeneous matrix 
8.4 4.9 7 inhomogeneous matrix 
11.2 5.1 7.2 inhomogeneous matrix 
Figure 10.4. (A) Distorted bowl-like shapes obtained at lower concentration of NH4OH 
(1.12 wt %). (B) Inhomogeneous matrix obtained at 5.6 wt % of NH4OH. (C) Matrix 
obtained at higher concentration of NH4OH (8.4 wt % and 11.2 wt %) 
We have also investigated the precise pH range within which well-defined 
morphologies were obtained by varying the concentration of NH4OH (Table 10.2) while 
maintaining the precursor concentration constant at 0.01 M. While distorted bowl-like 
shapes were observed, (Fig. 10.4A) at lower concentration of NH4OH (1.12 wt %), 
inhomogeneous matrix was obtained at higher concentration of NH4+ (Fig. 10.4B, C). It 
appears that at a final pH value of ~ 4.8, the reaction solution may be excessively acidic, 
forming distorted particles; additionally, at final pH values > 6, the reaction conditions 
were unsuitable to form any distinctive structure. We also observed that at higher 
concentration of NH4OH (5.6 wt % and above), the difference between the initial and 
final pH values of the reaction also increases, which explains the formation of matrices 
with no particular morphology. From these observations, it appears that in addition to the 
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Zn precursor, only a certain pH range is suitable for the formation of ZnO nuclei in 
solution, influencing the crystal growth rate and the resulting morphologies. 
In addition to the precursor concentration and reaction pH, the effects of reaction 
temperature and formation of zinc-ammonia ligand on the particle size and morphologies 
were also investigated to gain a better insight into possible growth mechanisms. The 
particles reported here form only at ~ 60°C. At temperatures below 60°C, only amorphous 
ZnO nanoparticles were formed. At reaction temperatures higher than 60°C (70°C, 80°C), 
the formation of an extended ZnO matrix was observed. It thus appears that only at 
temperatures near 60°C does ZnO nucleate and aggregate into the observed 
morphologies. We also observed that the presence of ammonium cations was essential for 
the formation of the reported particles (rings, bowls, hemispheres and disks). Wang et al. 
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 have reported that NH4+ ions may adsorb onto the surface of ZnO crystals due to the 
high surface energy associated with the nanophase materials, and thus affect crystal 
growth. This may also be occurring in the system reported here, and influence the shape 
of the particle morphologies. Alternatively, NH4+ may participate in the reaction by 
forming zinc-ammonia ligand (Zn(NH3)42+) which would then directly affect the 
morphology of the structures. 
Zn2+ + NH3 -> Zn(NH3)42+ (1) 
Zn(NH3)42+ + OH ZnO (2) 
We confirmed the significance of the NH4+ cations as a structure-directing agent by 
replacing NH4OH with KOH, maintaining a similar pH 8.2) as the original ammonium 
hydroxide reactant solution (Table 10.1). In this case, none of the reported morphologies 
were observed, but instead, large ZnO particles, which subsequently coalesced to form a 
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matrix, were achieved (Fig. 10.5A, B). Certain ligands have been known to exert 
thermodynamic control over chemical systems and influence crystal orientation through 
the metal-ligand bond length, ligand strength and the energy associated with the metal-
ligand bond formation.301 So we infer that in addition to zinc acetate concentration, and 
reaction pH, the presence of NH4+ ion may also guide the structural formation of these 
ZnO sub-micron particles, possibly by forming the Zn(NH3)42+ ligand during the course 
of the reaction. 
Figure 10.5. ZnO matrix obtained at different concentrations of Zn precursor and KOH 
(pH ~ 8.2). (A) 0.01 M, and (B) 0.02 M. 
10.5 Optical Properties of ZnO Particles 
These ZnO particles also possess a large concentration of surface defect states, 
which is directly related to the fabrication route and synthesis conditions. Optical studies 
of these particles reveal the presence of surface defects. The as-fabricated ZnO particles 
exhibit strong photoluminescence upon UV excitation. Photoluminescence (PL) spectra 
were obtained using a JOBIN YVON UV-vis Fluorolog, with excitation at 360 nm. All of 
the samples prepared for PL were maintained at the same concentration using the 
absorbance at 372 nm measured with a UV-vis-NIR spectrophotometer. Fluorescence 
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images were obtained using an Axioplan-2 Imaging Zeiss fluorescence microscope with a 
color camera (Hg, HBO 100 W lamp, and excitation filter between 340 and 380 nm). 
Figure 10.6A shows an image of white-light emission from a film of ZnO hemispheres. 
The rings, bowls, and disks all exhibit extremely similar light-emitting properties (Fig. 
10.6B). The PL spectra of all particles show a weak interband emission at 370-389 nm 
(3.19-3.35 eV) and a broad visible band centered at ~ 558 nm (2.22 eV). The visible band 
spans from ~ 420 to 700 nm for all ZnO particle morphologies reported here. 
Various explanations have been proposed for the white light emission from ZnO, 
based on oxygen or zinc defect states. The broadband visible light emission observed in 
these particles may be attributable to a combination of oxygen interstitial defects (Oj) and 
antisite oxygen defects (Ozn)- ' Oxygen interstitial defects have been reported to be 
responsible for yellow emission while antisite oxygen defects cause green emission as 
illustrated in the energy diagram of ZnO defect levels (Fig. 10.6C). A photogenerated 
hole is trapped at the surface by interstitial oxygen defects or antisite oxygen defects 
which then migrate to deeply trapped levels located above the valence band. A broad 
visible emission occurs when the photogenerated hole trapped in a deep level recombines 
with photogenerated electron trapped in a shallow level (levels 1 and 2). ' Depending 
on the temperature and the presence of oxygen during sample preparation, a mixture of 
oxygen defect states can be created, many of which can produce visible light. The precise 
origin of the broadband emission from these unique particles is still under investigation, 
yet the large ratio of the visible PL intensity to the interband PL intensity in these 
polycrystalline structures indicates the presence of a large number of surface defects. 
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Figure 10.6. (A) Fluorescence image of ZnO hemispheres emitting white light upon UV 
excitation. (B) PL spectra of the observed ZnO particles normalized relative to particle 
concentration: (a) rings, (b) bowls, (c) hemispheres, and (d) disks. Weak interband 
emission is observed at 370-389 nm, and strong visible emission centered at -558 nm. 
The spectra are offset for clarity. (C) Energy diagram of defect states in ZnO. 
10.6 Conclusions 
In summary, by controlling the growth kinetics through precursor concentration, reaction 
temperature, pH, and the concentration of ions present in solution, we have fabricated 
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ZnO submicrometer particles of varying shapes and aspect ratio. The broad emission 
from the ZnO particles covering most of the visible region may be attributable to a 
combination of oxygen defect states resulting from the fabrication conditions. Future 
studies may be useful in advancing our understanding of the growth mechanism of 
hemispherical ZnO particles in comparison to rod like particles. In addition, future 
studies of the properties of these ZnO particles may lead to the development of 
economical, white-light-emitting materials for solid-state lighting applications. 
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11: Summary and Prospects 
In this thesis novel plasmonic and photonic nanostructures are fabricated from 
fundamental building blocks and their optical properties are harnessed for several 
technological applications including plasmon enhanced fluorescence sensing, multimodal 
bioimaging and photothermal cancer therapy. The fluorescence enhancement of weak 
NIR fluorophore ICG, which is FDA approved for biomedical imaging, was examined as 
a function of distance from the surface of Si02-core/Au-shell nanoshells. The distance 
between the fluorophore and the nanoshells was manipulated by controllably growing 
silica epilayers of varying thicknesses. A 50X emission enhancement was obtained at a 
distance of 7 nm from the nanoshell surface and 7X enhancement was achieved at 42 nm 
from nanoshell surface. Due to the spherical symmetry of nanoshells Mie theory was 
utilized to theoretically analyze the electromagnetic interaction of nanoshells with light. 
Theoretical models correlated very well with experimental fluorescence enhancement, 
demonstrating nearly 90% calculated quantum yield for ICG molecules positioned 7 nm 
from the nanoshell surface. 
The fluorescence enhancement of IR800, another clinically relevant NIR 
fluorophore, was then compared between nanoshells and gold nanorods to understand the 
detailed photophysics of plasmon enhanced fluorescence. The fluorescence enhancement 
is attributable to a combination of processes including absorption enhancement, 
scattering enhancement and radiative decay rate enhancement. The contribution of each 
of these processes was systematically investigated by examining the scattering 
efficiencies of the nanostructures both experimentally and theoretically as well as 
experimentally determining the quantum yield and lifetime of the fluorophore when 
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bound to the nanostructures at an appropriate distance. The quantum yield of IR800 was 
enhanced from a mere 7% to 86% when positioned in proximity to nanoshells and 74 % 
near nanorods. The native lifetime of IR800 decreased from 564 ps to 121 ps when 
conjugated to nanorods and 68 ps for nanoshells. The experimental observations 
suggested that nanoshells, due to their larger scattering cross-section, improved the 
quantum yield of IR800 more effectively. 
The plasmonically enhanced fluorescent nanoshells were then synergistically 
integrated with iron oxide nanoparticles enabling dual modal imaging including MRI and 
FOI of breast cancer cells. The multifunctional nanoshells (nanocomplexes) were 
conjugated with antibodies to actively target the cancer cells facilitating a higher 
concentration of nanoshells to accumulate in the tumor. The ability of nanoshells to 
efficiently convert absorbed light to heat allowed thermal ablation of tumor cells upon 
resonant light activation. The nanocomplexes had proven extremely effective in detecting 
and treating breast cancer cells in vitro. The theranostic capabilities of nanocomplexes 
were also extended to diagnosis and therapy of ovary cancer cells in vitro and the results 
were analogous to the breast cancer in vitro study. Cytotoxicity studies showed that 
nanocomplexes were innocuous to cells and only induced cell death when activated with 
a NIR laser. The in vitro studies clearly demonstrated that these versatile nanocomplexes 
could be practically employed for diagnosis and treatment of any type of cancer cells. 
The efficacy of the nanocomplexes was then evaluated in vivo by examining 
breast cancer xenografts via MRI and FOI. Nude mice were injected with anti-HER2 
conjugated nanocomplexes via the tail vein. Significant differences were observed 
between the HER2 overexpressing breast cancer tumors and control, HER2 low 
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expressing tumors. The biodistribution studies demonstrated maximum nanocomplex 
accumulation in the tumor relative to the organs of the reticuloendothelial system (RES) 
of liver and spleen. The nanocomplexes were also conjugated with PEG chains, in 
addition to antibodies, to provide a stealth character, increase circulation time in the body 
and reduce recognition by the macrophages of the RES. 
While nanoshells in the sub-200 nm size regime are effective for cancer detection 
and treatment, for certain types of tumor, for example brain tumor, nanoparticle size must 
be sub-100 nm to effectively accumulate in the brain. Novel Au/SiC^/Au multilayered 
nanoshells were wet-chemically fabricated in the sub-150 and sub-100 nm size regime 
and their plasmonic properties were experimentally and theoretically analyzed. These 
multilayered nanoshells are examples of a rudimentary nanomatryushka, concentric 
nanoshells previously fabricated in the Halas group, and provide a high degree of optical 
tunability. Plasmon hybridization theory was employed to assign the spectral modes 
resulting from the interaction of the Au core and Au shell. These structures are 
specifically interesting since the absorption and scattering properties can be tuned by 
simply altering the thickness of the intermediate silica layer for a fixed nanoparticle size. 
Besides introducing a Au core embedded in a nanoshell geometry, the far field 
properties can also be controlled by modifying the core material to a high permittivity 
semiconductor core. Nanoshells in the sub-150 and sub-100 nm size regime consisting of 
a high permittivity CU2O core encapsulated in a thin Au shell were fabricated with 
tunable optical properties from the visible to the NIR. The high permittivity of CU2O 
resulted in increased polarizability of the core which contributed in higher absorption 
efficiencies and higher near field enhancements. 
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Finally photonic nanostructures of interesting geometries and optical properties 
are reported. Mesostars, composed of Au, a-FeOOH, and a-Fe203, were formed by 
electrolytically induced assembly of an aqueous suspension of nanorice particles. To the 
best of our knowledge, the process of electrolyzing an aqueous suspension to transform 
nanoparticles into mesoscale structures has not been previously reported. ZnO 
mesostructures are wet-chemically fabricated and their shape and size are controlled by 
manipulating the concentration of the Zn precursor molecules reduced in an alkaline 
media. The ZnO mesostructures exhibited broadband visible light emission which is 
attributable to a combination of oxygen interstitial defects and antisite oxygen defects. 
The work described in this thesis has promising future prospects in biomedicine 
as well as in photonic devices. The CU2O/AU nanoshells and Au/Si02/Au nanoshells may 
be incorporated with fluorophores and MRI contrast agents enabling multimodal 
functionalities within a compact sub-100 nm size regime. This will expand the diagnostic 
and therapeutic capabilities of nanoshells to diseases which are largely inaccessible. In 
addition NIR fluorophores may be replaced by radionuclides facilitating dual modal 
positron emission tomography (PET) and MRI, both of which are clinically relevant 
diagnostic techniques. 
Nanoshell based substrates may also be used for luminescence enhancement of 
weak NIR quantum dots, for example PbS, InAs, and utilize these nanoshell-quantum dot 
conjugates in photonic devices. The Au/Si02/Au nanoshells also provide an interesting 
geometry for examining fluorescence enhancement if the intermediate silica layer is 
doped with weak fluorophores of interest. In addition, an array of Au/Si02/Au nanoshells 
may be fabricated which will provide a robust substrate for sensing applications with 
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tunable absorption and scattering properties. These Au/SiCVAu nanoshell arrays can also 
act as a waveguide and could be useful in routing signals on a chip. 
Plasmonic-molecular interface has huge technological importance and provides a 
foundation for several areas of research including biomedicine, molecular sensing, 
environmental remediation, optical interconnects, and energy efficient materials. As the 
need for improvising human health and environmental safety increases, I believe the 
interdisciplinary field of nanophotonics may ultimately provide routes to attaining these 
global objectives. 
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